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Abstract 
Severe malaria as a result of infection with Plasmodiumfalciparum is one of the leading 
causes of mortality and morbidity in the world. It is responsible for the deaths of over one 
million children per year in tropical areas. However the number of children who develop 
severe disease is only a small fraction of the number that are infected, hence the need to 
study virulence factors associated with severe malaria. Rosetting - the binding of 
parasitised red blood cells to uninfected red cells to form "rosettes" has been associated 
with severe disease in many studies in Africa. However a study in Papua New Guinea 
found no association between rosetting and severe disease. It remains unclear whether 
rosetting is a cause or correlate of parasite virulence. 
Rosetting is mediated by the interaction of at least one parasite protein: Plasmodium 
falciparum erythrocyte membrane protein one (PfEMP1) on the infected erythrocyte 
surface and a variety of host red cell surface receptors including complement receptor 
one (CR!). We reasoned that if rosetting were a cause of severe disease we would be able 
to identify protective polymorphisms in the CR! gene. Here we show that CR1 
deficiency is extremely common among individuals from malaria endemic populations in 
Papua New Guinea. This deficiency is associated with previously reported 
polymorphisms in the CR1 gene and, unexpectedly with alpha-thalassaemia, a red cell 
disorder that occurs in up to 90% of Melanesians. We tested the hypothesis that CR1 
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polymorphisms protect against severe malaria by genotyping samples from a case cOntrol 
study for polymorphisms in the CR1. We found that both CR1 deficiency alleles and 
alpha-thalassaemia protect against severe malaria. 
We wished to test the hypothesis that rosetting was not associated with severe disease in 
Papua New Guinea because of widespread CR! deficiency preventing the formation of 
rosettes strong enough to withstand sheer forces in the circulation. Studies on field 
isolates from Papua New Guinea showed that rosetting was unusual in this population, 
rarely mediated by binding to CR1 and not associated with disease severity. This suggests 
that CR! is essential for physiologically significant rosetting associated with severe 
malaria. We have therefore identified a new malaria resistance gene and provided 
compelling evidence that CR1 mediated rosetting is an important virulence phenotype 
and a potential target for drug and vaccine development. 
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Chapter 1: Introduction 
Chapter 1: 
Introduction 
In this introduction I firstly attempt to describe the problem of severe malaria both 
globally and by looking locally at a particular population around Madang, Papua New 
Guinea, that is studied in this thesis. In the remaining sections of the introduction I 
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outline our understanding of disease process in malaria infections such as cytoadhesion 
and rosetting. As one of the major themes of this thesis is malaria resistance genes I also 
look at how our understanding of natural resistance can inform our understanding of 
pathogenesis. Finally I introduce a candidate malaria resistance gene: complement 
receptor 1 (CR1) which is the focus of study for this thesis. 
1.1 The global burden of malaria 
Malaria due to Plasmodiumfalciparum is the most important tropical parasitic disease in 
the world and is responsible for between 1-2 million deaths per year, 90% of them in sub-
Saharan Africa, and 400 - 900 million clinical episodes each year worldwide(Breman et 
al. 2001). Some 90 countries in the world are malarious, half of them in Africa, the 
remainder in South Asia, Central and South America and island Oceania. In these areas 
the mortality from malaria is less, however, morbidity due to the disease is high and the 
economic and social costs considerable. The problem has worsened over the last 30 years 
as the parasite is increasingly resistant to older and cheaper drugs such as chloroquine 
and pyrimethimine leading to the use of more expensive alternatives to which the 
parasites are already rapidly becoming resistant(Wernsdorfer 1994). Moreover political 
instability in many of the worst affected countries has led to the breakdown of control 
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the development of an appropriate vaccine, which may either prevent transmission of the 
parasite or aim to limit the lethal effects of infection or both(Hoffman et al. 1998). 
Figure 1.1 
Figure 1 .1: The global burden of malaria: shaded areas have regions where malaria is 
endemic while unshaded areas indicate regions that never had malaria or countries 
where malaria has been eradicated (image from the Roll Back Malaria website: 
http://www. rbm.who.int/)  
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1.1.1 Lifecycle and biology of P. falciparum 
Malaria in humans is caused by one of four protozoan parasites of the genus Plasmodium: 
P. falciparum, P. vivax, P. malariae and P. ovale. Of these, most severe disease and 
mortality is caused by P. falciparum though P. vivax is a major contributor to morbidity 
in much of the world. The other two species are rarer and while disease due to them may 
be unpleasant it is rarely life threatening. The life cycle is complex (reviewed in(Bamwell 
et al. 1998; Beier et al. 1998; Frevert et al. 1998; Sinden 1998)) and only a brief 
overview is given here (Figure 1.2). The parasites are carried between human hosts by a 
female mosquito vector of the Anopheles genus that takes up haploid gametocytes. 
Within the mosquito midgut the gametocytes become gametes which combine to form 
diploid zygotes. The zygotes undergo meiosis to form ookinetes which penetrate the 
midgut wall, where further asexual divisions occur to form sporozoites. These invade the 
salivary glands of the vector and are injected into the human host where they invade the 
liver. From the liver emerge the blood stage forms (merozoites) that invade red blood 
cells (RBC) reproduce asexually and burst out (schizogony) to reinvade fresh RBC. In 
falciparum malaria the extent of blood infection can increase exponentially even as high 
as 50% of peripheral RBC. From this population of circulating merozoites a number of 
gametocytes develop. The cycle is completed when the gametocytes are taken up by 
feeding Anophelenes and a new round of sexual reproduction begins. 
4 
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Figure 1.2 
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Figure 1.2 The malaria life cycle (image from www.niaid.nih.gov/publications/  
malariallife/htm) 
5 
Chapter 1: Introduction 
1.1.2 Who dies of malaria? 
While the number of children who die from malaria each year is large, it represents a 
small fraction of the total number of clinical malaria infections. The number of clinical 
infections itself is small compared with parasite prevalence across the whole population. 
The graph in figure 1.3 shows two manifestations of malaria: parasitisation and severe 
disease plotted against age, this data is from Kilifi in Kenya(Marsh et al. 1999), though 
the pattern is repeated throughout malaria endemic areas(Molineaux et al. 1980; Cattani 
et al. 1986; Allen et al. 1996). Severe malaria is largely a childhood disease in areas 
endemic for malaria. While parasite prevalence is still rising as severe disease is falling 
away, suggesting that children develop immunity to severe disease while still susceptible 
to parasitism(Marsh et al. 1999). Some evidence for this comes from showing that 
children become immune to severe malaria syndromes (other than cerebral malaria) after 
only 1 or 2 bouts of clinical illness(Gupta et al. 1999). A molecular explanation was 
forwarded by Bull et al. who showed that surprisingly severe malaria seemed to be 
caused by relatively few common parasite variants while less severe disease was the 
result of many rarer variants to which immunity took a long time to acquire(Bull et at. 
1998; Bull et al. 1999). 
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Figure 1.3 
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Figure 1.3 Indices of malaria in endemic areas (after(Marsh etal. 1999)). 
Surprisingly in highly endemic areas parasite prevalence does not increase with increased 
transmission - i.e. increased numbers of infective bites(Marsh et al. 1999). Furthermore 
some studies show that cerebral malaria can be rare in areas of intense malaria 
transmission, perhaps because of the rapid acquisition of immunity(Marsh et al. 1999). In 
areas of much lower transmission (such as Southeast Asia or the south coast of Papua 
New Guinea) the patterns are different with transmission intensity corresponding to the 
burden of disease. Moreover full immunity may never be developed and so adults as well 
as children can be susceptible to severe disease. Often in adults the pattern of severe 
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disease is unlike the classical cerebral malaria and severe anaemia observed in children in 
endemic areas but instead is characterised by multi-organ failure and metabolic 
disturbances(White 1987). 
1.1.3 Syndromes of severe malaria 
Traditionally malaria mortality has been attributed to two major syndromes, cerebral 
malaria and severe malarial anaemia. Cerebral malaria has been the focus of most 
research into disease pathogenesis. Strikingly the median age for cerebral malaria patients 
is typically much older than that for severe anaemia patients: 40 months vs. 22 months in 
Kenya(Marsh et al. 1997) and 45 months vs. 28 months in the Gambia(Greenwood et al. 
1991), suggesting that partial exposure to malaria maybe a risk factor for severe disease. 
Anaemia accounts for a larger proportion of "severe" malaria requiring hospitalisation, 
but has a lower case fatality rate than cerebral malaria. Studies where a whole population 
has been subject to successful malaria control with concomitant reduction in anaemia 
demonstrate that malaria is a cause of anaemia and not a correlate of poor health indices 
in general(Bloland et al. 1993). The causes of anaemia are perhaps even less well 
understood than the causes of cerebral malaria. The proportion of infected red blood cells 
can reach 50% which obviously precipitates major haemolytic anaemia. Nonetheless 
there remains an important group of patients with relatively low parasitaemias (<2%) 
who nonetheless have extremely low haemoglobin (<5g/dl - the arbitrary definition of 
severe anaemia)(Abdalla et al. 1980). Dyserythropoiesis has been associated with this 
pattern of disease in the Gambia(Abdalla et al. 1980), the cause of this may be the 
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stimulation of cytokine production by malaria: TNF-a and IFN-y have been shown to 
suppress haemopoiesis(Young et al. 1994). Other groups have shown that parasites can 
have an effect on the expansion of erythroid progenitor cells (David Roberts, personal 
communication). 
Recently the importance of metabolic disturbances in malaria has been realised, 
especially in cases of respiratory distress(Marsh et al. 1995). This syndrome is rarely 
found on its own. In about 80% of cases it is associated with severe anaemia or cerebral 
malaria and is a major determinant of mortality. Cerebral malaria cases with respiratory 
distress were nearly 4 times more likely to die than those with coma alone. The prognosis 
for anaemia and respiratory distress was almost as poor, with children being over 12 
times more likely to die than their counterparts with just anaemia(Marsh et al. 1995). 
1.1.4 Malaria in Papua New Guinea 
Papua New Guinea (PNG) occupies the eastern half of the island of New Guinea and 
several smaller Island groups around including New Britain, New Ireland, Manus Island 
and Bougainville Island. PNG is an interesting place to study malaria as this relatively 
small country (461,691 square km - roughly 2 times the size of the island of Great 
Britain, with a population of 4.7 million people) contains a variety of different conditions 
for malaria transmission (Figure 1.4). In the highlands there is epidemic malaria with 
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little natural or acquired resistance to disease(Mueller et al. 2002; Mueller et al. 2002). 
The south coast has intermediate malaria transmission (Flint et al. 1986) with a pattern of 
disease similar to that in Southeast Asia(Lalloo et al. 1996). While the north coast and is 
a good example of a high transmission area where severe disease is prevalent and 
individuals develop some degree of protective immunity. The age-dependence of parasite 
prevalence and severe disease is similar in this area to the situation described in figure 
1 .3(Cattani et al. 1986). Thus it is similar in many respects to Africa where most malaria 
mortality occurs. Though there are crucial differences, notably the relatively low 
mortality rates and the prevalence of malaria due to P. vivax. 
The climate is tropical and characterised by year-round rainfall. In lowland areas two 
seasons are defined: a wet season from October to May and a dry season from June to 
September. Malaria transmission is a year round occurrence with only a slight decrease in 
the dry season. Over the last decades much work has been done by the Papua New 
Guinea Institute of Medical Research to describe malariometric indices in defined areas 
in different parts of the country. Outside these study areas information is more patchy. 
The work in this thesis was largely on individuals and populations around Madang, one 
such well-studied area. 
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Figure 1.4 
Ic 
H .IaO 100km 
Figure 1 .4: Malaria endemicities in Papua New Guinea, dark shading represents areas 
of intense malaria transmission with >70% spleen rates, medium shading represents 
area where there is intermediate malaria transmission 50-69 % speen rates, light 
shading represents areas where malaria is sporadic (spleen rates 10-49%) while the 
white areas have at worst epidemics of malaria with a spleen rate <10 %) (after Flint et 
al. 1986(Flint etal. 1986)) 
1.1.5 Epidemiology of malaria in Papua New Guinea 
Madang is a town of around 20,000 people on the North Coast of Papua New Guinea 
(Figure 1.5). The town is circled by pen-urban settlements where around 13,000 people 
live, many of them migrants from other parts of the country. The area around the town is 
secondary rainforest, in which most people live by subsistence agriculture in villages of 
11 
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100-700 people. Around Madang, the parasite prevalence for the population as a whole 
was reported as 25.7 % in the dry season and 33.4 % in the wet season. Among children 
5-9 years old this rises to 44% and 49 % respectively. Spleen rates (the enlargement of 
the spleen is a determinant of long term exposure to malaria) for the area around Madang 
town defined three different areas. In the town and surrounding areas spleen rates were 
less than 70% while in the foothills of the Adelbert ranges spleen rates were >75%. In 
other more low lying areas such as the Gogol river basin area an intermediate spleen rate 
was measured (Figure 1 .5)(Cattani et al. 1983). Measurement of the mosquito biting rates 
showed that the entomological inoculation rate varied from 68 to 526 infectious bites per 
year with villages in the high risk area receiving more bites than those in the lower 
epidemiological zones (range 353-526 vs. 68-150 infected bites per year)(Burkot et al. 
1988). Transmission is by members of the Anopheles punctulatus complex including An. 
koliensis, An. funestus and An. punctulatus. While villages varied in which species was 
most prevalent the vectoral capacity of the three species was similar for P. falciparum. 
There was also no difference in the prevalence of the species in the different 
epidemiological zones(Burkot et al. 1988). 
The parasite prevalences in humans and the sporozoite inoculation rates are similar to 
those seen in many African situations. However the situation in Papua New Guinea 
differs in other ways. Firstly there is a high prevalence of P. vivax in the population 
making up around 25% of infections(Cattani et al. 1986; Bruce et al. 2000; Bruce et al. 
2000; Bruce et al. 2000). A polymorphism in the only invasion receptor for this parasite 
12 





Figure 1 .5: Epidemiological zones around Madang town, PNG. Dark shading represents 
the low epidemiological zone (spleen rate <70 %) medium shading represents the 
intermediate zone (spleen rate 70-75 %) while the light area is the area of most intense 
malaria transmission (spleen rate >75 %). 
the Duffy blood group antigen has rendered much of the West African population 
refractory to P. vivax infection and therefore it has almost been eradicated in much of 
Africa(Miller et at. 1976). Secondly the mortality due to malaria is much lower in Papua 
New Guinea. A survey of 16,500 individuals in 75 villages measured the percentage of 
deaths due to malaria as 1.3 % for the population as a whole and 12.5 % for children aged 
from 1 to 4 years (there were no deaths from malaria among children < 1 year). Far from 
being a leading cause of death malaria rates only as the 6th most common cause of death 
among young children and 9th overall(Moir et al. 1989). A comparable study in The 
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Gambia showed that malaria was a cause of 4% of deaths in children < 1 year and 25% of 
deaths in children aged 1-4(Greenwood et al. 1987). They also report that the death rate 
due to malaria is 6.3 - 10.7 per 1000 per year in children aged 0-4. The comparable 
figures for Madang would be of the order of < 1 per 1000 per year(Moir et al. 1989). In 
Kenya Snow et al. report a death rate due to malaria of 1.1 per 1000 per year in children 
aged 1-4 years however they only look at hospital deaths and estimate that only a third of 
deaths occur in a hospital setting. Co-infection with P. vivax has been suggested to be 
responsible for the lower levels of severe malaria compared to Africa( Williams et al. 
1996). Some authors have suggested an immunological mechanism for this though 
clinical data where Plasmodium infections were used to control syphilis suggests that 
exposure to P. vivax does not alter susceptibility to P. falciparum infections(Maitland et 
al. 1997). Chioroquine use is high in this population with one survey showing that up to 
14% of children being chioroquine positive in urine tests(Moir et al. 1989). However as 
the in vivo drug resistance rate is 85% in the most recent surveys this may have little 
effect other than to increase the problem of drug resistance(al-Yaman et al. 1996) and G.J 
Casey unpublished. Finally the role of human polymorphisms could be very important. 
Coastal Papua New Guineans probably have the greatest range and highest proportion of 
red cell disorders in the world, which means that many of them may never be at risk from 
severe malaria in the first place (see section 1.3). 
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1.1.6 Severe disease in Papua New Guinea 
There is an extensive literature on severe malaria in Papua New Guinea. Allen et al. 
report cases of severe malaria at Madang general hospital over 3 wet seasons (October 
1993- February 1996). Out of 311 children with severe malaria there were 103 cases of 
severe anaemia (33%) and 75 cases of cerebral malaria (24%)(Allen et al. 1996). The 
small proportion of children with the classical syndromes of severe malaria compared to 
African situations is interesting(Marsh et al. 1995). Instead many children suffer from 
metabolic disturbances such as hyperlactaemia (28%), acidosis (19%) and hypoglycaemia 
(5%). As in Africa this study found that the median ages of cerebral malaria patients was 
older than that of severe anaemia cases (43 months vs. 30 months). Genton et al. present 
a study of 134 "comatose" Papua New Guinean children in a study also based in Madang. 
A closer analysis reveals that in this instance "comatose" actually means impaired 
consciousness and only 52 of the children in this study meet the criteria of cerebral 
malaria, these data were collected over 2 wet seasons (April 1991 to October 1993). 
Moreover the case fatality for cerebral malaria in Madang has been reported as 
8.0%(Allen et al. 1996) or 1 1.9%(Genton et al. 1997) which are much lower than in 
African settings where typical values are around 16-25%(Molyneux 1990; Marsh et al. 
1995). It is often commented anecdotally that some severe malaria is rarer around 
Madang than in African regions with comparable transmission(Muller et al. 2003). While 
this is supported by some data that suggests a lower overall mortality due to malaria(Moir 
et al. 1989), and low case fatality rates(Allen et al. 1996; Genton et al. 1997), the 
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proportion of hospital cases being due to severe malaria is the approximately the same in 
Madang as in Kilifi (cf.(Marsh et al. 1995; Allen et al. 1996)) and the proportion of 
deaths due to malaria among hospitalised children is the same in PNG as in various 
African situations (cf.(Greenwood et al. 1991; Allen et al. 1996). 
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1.2 Malaria - a neglected disease 
How then should we tackle malaria? Despite malaria being one of the major killers world 
wide, it has been described as a "neglected disease"(Marsh 1992). Traditionally malaria 
control measures have been based on eradication either of the mosquito vector by 
insecticide spraying, or on eradication of the parasite by mass treatment with anti-
malarials. For as long as eradication was the ultimate aim, the disease itself (as distinct 
from asymptomatic infection) was not considered so important. As these measured failed 
and emphasis has switched to control and prevention of mortality, an understanding of 
the pathogenesis of disease has become a more important priority. In an article from over 
a decade ago, Kevin Marsh identified the key question for the study of malaria as a 
disease as "what factors put some children at risk of developing severe malaria?"(Marsh 
1992). He gives a list of these factors and identifies them as areas for study by basic 
scientists and clinicians alike. Twelve years on perhaps it is interesting to review this list 
and see what progress has been made (Table 1.1): 
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Table 1.1 Factors which may play a role in determining the clinical outcome 
of malaria infection (after Marsh 1992) 
1. Environmental 
I. 	Vectors - multiple factors summating to give variations in number of 
sporozoites inoculated over time 
ii. 	Socio-econOmiC - e.g. availability of health care 
2. Host 
Acquired immunity 
Behavioural factors - usage of anti-malarials, farming practices 
V. 	Nutritional Status - iron, riboflavin, p-aminobenZOic acid, others? 
vi. 	Genetic factors 
Red cell polymorphisms 
Immune response genes 
Others such as T cell receptors, polymorphisms in the acute phase 





X. 	Drug resistance 
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Environmental factors, and behavioural and social factors are beyond the scope of this 
thesis. However we are concerned with both host and parasite biology. It is fair to say 
that despite the efforts of a small number of excellent researchers our knowledge of host 
immunity to malaria is inadequate. In the scramble to find a vaccine antigen that provides 
effective immunity little thought has been given to what kind of immunity that vaccine 
should be generating. An understanding of the T cell phenotypes involved in malaria 
pathogenesis and protection is only just emerging(Good et al. 1999; Plebanski et al. 
2000; Carvalho et al. 2002; Hisaeda et al. 2004). The potential importance of antibody 
responses was demonstrated initially by passive transfer of immune IgG into individuals 
suffering from clinical malaria, resulting in almost complete clearance of parasitaemia 
(though some residual parasites remained)(Cohen et al. 1961; Sabchareon et al. 1991). 
The targets of these protective antibodies are poorly understood, though subsequent 
studies have suggested roles for red cell surface antigens(Bull et al. 1998) and merozoite 
surface protein 1 (MSP-1)(Conway et al. 2000). One area of interest is that of dendritic 
cell biology, in which P. falciparum infected erythrocytes have been found to prevent 
dendritic cell maturation and turn off their antigen presentation functions through CD36 
binding by parasites(Urban et al. 1999; Urban et al. 2001). In addition to having 
implications for the outcome of disease, any vaccination strategy will have to overcome 
this defect in antigen presentation in the malaria exposed immune system, as it has been 
demonstrated that downregulated dendritic cells can prevent proper T cell activation in 
malaria infections(Ocana-Morgner et al. 2003). 
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Overall our understanding of the molecular basis of drug resistance, cytoadherence, and 
growth and invasion is probably more complete. The genes for chioroquine and 
sulphodoxine resistance have been mapped(Wellems et al. 1991; Wu et al. 1996; Fidock 
et al. 1997; Fidock et al. 2000). Invasion is a process that is increasingly well understood 
largely due to the availability of gene knockouts of parasite proteins thought to be 
involved(Waterkeyn et al. 1999). Nonetheless the relative importance of different 
pathways and disease severity is an unknown area. Likewise our understanding of 
parasite adhesion and disease severity has increased enormously over the last decade, 
with the identification of the var genes encoding a family of Plasmodiumfalciparum 
erythrocyte membrane protein 1(PfEMP1) proteins as the major determinants of 
adhesion(Baruch et al. 1995; Smith et al. 1995; Su et al. 1995). Likewise many of the 
host proteins this molecule binds to have been identified (discussed below). One thing 
that has become clear though, is that a simple model of cytoadhesion correlated to disease 
severity is insufficient(Rogerson et al. 1999). A picture is emerging (discussed below) of 
adhesion to different receptors being "good" or "bad" though which receptors may 
depend on the population and parasites in question. 
The study of host polymorphisms (such as in this study) has been ongoing; many of the 
important genes and their significance are discussed in the next section. One development 
is the development of genome-wide scans for susceptibility genes (see section 1.3.4), 
which may allow not only for the identification of novel malaria resistance genes, but 
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also to compare the basis of resistance and pathogenesis in different 
populations(Kwiatkowski 2000). 
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1.3 Malaria resistance genes 
Long before the first incursions of molecular biology into the study of malaria J. B. S. 
Haldane first suggested the idea of "malaria resistance genes"(Haldane 1949). He argued 
that the distribution of the red cell disorders of sickle cell anaemia and thalassaemia could 
be explained if these deleterious, yet common, disorders protected against malaria. For 
many years direct evidence for the protective effects of these disorders was not found as 
most of these polymorphisms have little or no effect on parasitaemias or prevalences; 
their effect is through protection against death. Thus it was only when researchers 
examined patients with severe malaria that they were able to definitively link red cell 
disorders with malaria(Hill et al. 1991). This makes malaria resistance genes more than 
merely a good example of the action of disease selection on the human genome; it means 
they could be used to pinpoint processes of severe disease and mechanisms to protect 
against them. 
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Association Region 	 Reference Gene Allelic Variant 
(Disorder) 
Red Cell Polymorphisms 
a-globin tf-thalassaemia Protection (SM) 
Papua New Guinea 	(Allen et al. 1997) 
(a-thalassaemia) Susceptibility (CIM) 
Vanuatu 	 (Williams et al. 1996) 
-globin -thalassaemia Protection (CIM) 
Liberia (Willcox et al. 1983) 
Haemoglobin S Protection(SM) West Africa 
(Hill et al. 1991) 
(Sickle cell anaemia) 
Haemoglobifl C Protection (CIM) West Africa 
(Modiano et al. 2001) 
Haemoglobin E Protection(SM) Thailand 
(Hutagalung et al. 1999) 
Glucose-6- Various - deficiency Protection (SM) 





Band 3 South east Asian Ovalocytosis Protection (CMt) 
Papua New Guinea (Genton at al. 1995; Allen et al. 1999) 
Glycophorin C Gerbich blood group (Exon3) Decreases invasion? 
Papua New Guinea (Mayer et al. 2002; Maier et al. 2003) 
CR1 Knops Types Decreased rosetting 
West Africa (Rowe et al. 1997) 
The Gambia (Zimmerman et al. 2003) 
Severe Malaria 
Clinical Malaria 





ICAM-1 	 ICAM-1 (Kilifi) 
CD36 	 Deficiency Allele 
Susceptibility (SM) 	Thailand 	 (NagayasU et al. 2001) 
Protection (SM)  
Susceptibility (CM) 	Kenya 	 (FernandeZ-ReYes 
et al. 1997) 
Protection 	 Gabon (Kun etal. 1999) 
Susceptibility (SM) 	Gambia 	 (Pain etal. 2001) 
Protection (SM) Kenya/Gambia 	(Aitman et al. 2000) 
Immunity Genes 
Protection (SM) West Africa (Hill et al. 1991) HLA-Bw53 Class I 
Class II DQB1 *0501 
Protection (Various) Gabon (May et al. 2001)  
DRB1*1302 Protection (CM) Gambia (Hill etal. 
1991) 
MBP Deficiency Allele Susceptibility (SM) 
Gabon (Luty et al. 1998) 
FCylla Arg/Argl 31 Protection (SM) 
Kenya (Shi et al. 2001) 
iNOS-2 -969 promoter Susceptibility (CM) 
Gambia (Burgner et al. 1998) 
NOS2-69546 Protection Gabon 
(Kun et al. 2001) 
Protection (SM) Gambia 
TNF-a -308 promoter Susceptibility (CM) 
Gambia (McGuire et al. 1994) 
Susceptibility (SM) Sri Lanka (Wattavidanage et al. 1999) 
-238 Susceptibility (SM) Gambia, Kenya 
(McGuire et al. 1999) 
Gambia (Hill 1996) 
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Sickle cell anaemia is the most well known example of malaria resistance gene. 
Homozygotes for the mutation suffer a severe anaemia and rarely live beyond the age of 
20 but it is selected for because heterozygotes have only a 1/10 risk of suffering from 
severe malaria compared to individuals with normal haemoglobin genes(Hill etal. 1991). 
This explains why the gene can be maintained at frequencies of 20% in some populations 
in West Africa despite its lethality in the homozygous state(Flint et al. 1998). However 
despite arising on at least 5 separate occasions in Africa, India and the Middle East it is 
absent from Papua New Guinea. Instead the relatively small population of Melanesians 
has perhaps the greatest diversity of other protective genes(Flint et al. 1986; Flint et al. 
1998). Papua New Guinea is an interesting place to study these genes because of the 
varied degrees of malaria transmission across the country. The involvement of a gene in 
malaria can be inferred from the relative frequencies of the genes in one area (say the 
holoendemic north coast) relative to those in another (for example the highlands)(Flint et 
al. 1986; Williams et al. 1996). Here I examine some of the most common malaria 
resistance genes in Papua New Guinea to give an idea of the genetic background on 
which malaria infections are occurring. 
1.3.1 The thalassaemias 
Thalassaemia is a worldwide disorder but one that reaches its highest frequencies of 
around Madang. Thalassaemia is caused by a defect in one of the alpha-globin or beta- 
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globin genes (leading to a- or 13-thalassaemia respectively), which results in an imbalance 
of the globin chains, defective haemoglobin production and therefore tends to result in 
some degree of anaemia. Around 150 polymorphisms can cause 13-thalassaemia, while 
around 50 have been found that cause a-thalassaemia(Flint et al. 1993; Flint et al. 1998). 
13-thalassaemia is the more severe as the gene is present in only a single copy. 
Polymorphisms can be extremely harmful as in °-thalassaemia where the gene is deleted 
altogether, or less harmful for example due to polymorphism that causes a defect in the 
level of beta-globin production (3-thalassaemia). At least one -tha1assaemia variant 
has been characterised in Papua New Guinea and pockets of high frequency 
identified(Hill et al. 1988) though in general this polymorphism is relatively rare in 
Papua New Guinea compared with some African situations(Willcox 1983; Wilicox et al. 
1983). 
a-thalassaemia on the other hand is extremely common, perhaps the commonest single 
gene disorder in the world(Flint et al. 1998). As there are two tandem functional copies 
of this gene on chromosome 16 (figure 1.6). Deletions of one gene (known as c-
thalassaemia) often have no pathology and even homozygotes for this mutation only 
suffer a mild anaemia as they still have 2 functional gene copies left. Deletions occur as a 
result of cross over events at meiosis between homologous regions in the region of the 
gene. There are two major types of deletion -a 37 and -a42, with the latter being most 
common in coastal Papua New Guineans, though the rarer of the two in other parts of the 
world(Flint et al. 1993). a°-thalassaemia where both copies of the gene are lost from a 
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single chromosome is more severe (and much rarer). Homozygotes live short lives, and 
even this is only possible because their ct-globin gene is substituted for by foetal 
haemoglobin. In Papua New Guinea the gene frequency of a-thalassaemia ranges from 0 
to 0.70 with a strong correlation existing between the frequency and malaria 
endemicity(Flint et al. 1986). Around Madang 95% of people carry at least one a-globin 
deletion and this has been found to protect against severe malaria in a case-control 
study(Allen et al. 1997). The mechanism of protection has remained a mystery. Parasite 
invasion is normal in thalassaemic cells(Luzzi et al. 1991), so some investigators have 
suggested that reduced endothelial cytoadherence(Udomsangpetch et al. 1993) or 
rosetting may be the mechanism(Carlson et al. 1994). Other investigators have suggested 
immunological mechanisms such as increased antibody binding(Luzzi et al. 1991) or an 
increased susceptibility to P. vivax in early life that accord subsequent protection against 
P. falciparum(Williams et al. 1996). This latter explanation does not however explain 
why there is a-thalassaemia in areas of Africa where there is no P. vivax due to fixation 
of the Duffy negative polymorphism which forms an absolute block to parasite 
invasion(Miller et al. 1976; Horuk et al. 1993). None of the explanations is wholly 
compelling, though an understanding of the mechanism of protection could tell us about 
the mechanism of severe disease. 
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Figure 1.6 
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Figure 1.6 The a-globin gene structure (after(Flint et al. 1998)). There are two copies of 
the cx-globin gene tandemly repeated (al and a2). In the gene are regions of homology 
labelled X, V and Z. Cross over events between these regions at meiosis lead to 
deletions such as the -a37 and -a42 , the regions deleted are shown by the lines below. 
1.3.2 Southeast Asian Ovalocytosis 
Southeast Asian ovalocytosis (SAO) is potentially the most informative polymorphism 
for gaining an insight into cerebral malaria. Two studies have shown that it has no effect 
on susceptibility to most syndromes of severe disease, with the exception of cerebral 
malaria from which it appears to confer absolute protection (Ge nton et al. 1995; Allen et 
al. 1999). In the two studies combined there were 105 cerebral malaria patients none of 
whom had SAO while the prevalence among 410 controls was 8.0%. Southeast Asian 
ovalocytosis is characterised by elliptocytic cells with very rigid membranes due to a 
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mutation in Band 3, which is a chloride channel and the most common protein on the 
erythrocyte surface(Solomon et al. 1983). The mechanism of inheritance was a mystery 
until the mutation was identified. Individuals with SAO were found to be heterozygous 
for a 27 bp deletion in the Band-3 gene(Jarolim et al. 1991). No homozygotes for the 
deletion have been found, though thousands of individuals have been screened(Genton et 
al. 1995) so it is assumed to be lethal in utero. 
Some work has suggested that the rigid ovalocytic membrane might be a barrier to 
invasion ((Kidson et al. 198 1)and Alfred Cortes, personal communication), however as 
individuals with ovalocytosis are just as susceptible to other severe malaria syndromes 
this may not be the mechanism. Moreover some work suggests that ovalocytic cells 
"decay" more rapidly on storage than normal erythrocytes(Dluzewski et al. 1992) and 
this may cause them to be refractory to invasion. The specific protection against cerebral 
malaria suggests a more specific mechanism. Recent work has shown that ovalocytic 
cells show normal adherence to endothelial receptors in static condition, but in flow 
conditions binding to CD36 is increased (Alfred Cortes, personal communication). CD36 
is rarely expressed in the brain(Turner et al. 1998), suggesting that this may be a benign, 
even protective form of cytoadhesion. 
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1.3.3 The Gerbich blood group type 
The Gerbich blood group type is caused by the deletion of exon 3 in the glycophorin C 
gene(Chang et al. 1991). Glycophorin molecules (such as Glycophorin A and B) are very 
abundant red blood cell surface proteins and have been implicated as receptors for 
invasion(Pasvol et al. 1983; Hadley et al. 1987; Orlandi et al. 1992; Dolan et al. 
1994; 
Maier et al. 2003). Their functions remain unknown though there involvement in a 
variety of disease process has shown them to be under strong selective pressure(Baum et 
al. 2003). The Glycophorin C molecule is attached to the cytoskeleton and so its various 
blood group polymorphisms are often associated with eliptocytosis(Telen et al. 1991). 
The blood group is probably only present at low frequencies in much of PNG but in one 
region of the Sepik river basin, the Wosera, it reaches a frequency of 0.47(Patel et al. 
2001). Strikingly the same population has an almost complete absence of Southeast Asian 
ovalocytosis. While no epidemiological studies have formally shown a protective effect 
of this polymorphism Glycophorin C has recently been identified as a receptor for the 
merozoite red blood cell adhesion molecule BAEBL, and is therefore important in the 
process of parasite invasion(Maier et al. 2003). However as there is great degeneracy in 
pathways of P. falciparum invasion it is unclear whether the loss of one pathway of 
invasion could exert the necessary selective pressure to account for the high frequencies 
of the Gerbich blood group seen. Interestingly the BAEBL gene also exhibits some 
functional polymorphism, with some BAEBL proteins binding receptors other that 
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Glycophorin C. Some authors have suggested that this is a result of selective pressure on 
the parasite by the presence of mutations in the Glycophorin C gene(Mayer et al. 2001). 
1.3.4 The future of association studies 
Whereas the basis for protection due to the thalassaemias, ovalocytosis and G6PD 
deficiency is incompletely known, some polymorphisms have been identified through 
more "rational" means(Kwiatkowski 2000). The search for genetic resistance factors is 
now pursued along two lines. Attempts have been made to trace genetic susceptibility to 
disease through segregation analysis on family studies. Studies in Cameroon and Burkina 
Faso have identified a locus involved in control of blood parasitaemia which contains a 
variety of genes for cytokines and other immune factors(Abel et al. 1992; Garcia et al. 
1998; Rihet et al. 1998) while another study in Papua New Guinea showed that antibody 
responses to segregated between family members(Stirnadel et al. 1999). In the study of 
severe malaria such family studies are impossible (as they would require information on 
both the parents and children's susceptibility to severe malaria) however genome-wide 
gene association studies for severe malaria are being attempted currently. Additionally a 
candidate gene approach has been taken where polymorphisms are searched for in 
proteins involved in the pathogenesis of severe disease. One classic example of this has 
been the identification of MHC class 1 allele HLA-Bw53 as protective in malaria, 
presumably because it is most effective at displaying epitopes derived from P. falciparum 
sporozoites that have invaded the liver(Hill et al. 1991). Common African 
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polymorphisms have been identified in the cytoadhesion ligands ICAM- 1 (Fernandez-
Reyes et al. 1997; Bellamy et al. 1998)and CD36(Aitman et al. 2000) which are 
discussed below. Surprisingly case-control studies have shown that often the "African" 
variants cause susceptibility rather than protection, perhaps because the parasite has 
already had a chance to evolve to the new genetic background. We may be looking at 
evolutionary fossils rather than currently protective genotypes. Nonetheless this is 
evidence for the involvement of cytoadhesion in the pathogenesis of severe malaria. 
32 
Chapter 1: Introduction 
1.4 Cytoadhesion: ligands and receptors 
1.4.1 Cytoadhesion and Antigenic Variation 
In the late nineteenth century Bignami and Bastianelli observed that mature trophozoite 
and schizont stages of P. falciparum are rarely found in the peripheral 
circulation(Bignami etal. 1889). The mature parasites have been found to sequester in 
the microvasculature of the brain and other tissues(MacPherson et al. 1985), perhaps to 
avoid the lethal immune activity of the spleen, which removes "aberrant" red blood cells 
including those significantly distorted by Plasmodium infection(Barnwell etal. 1983; 
Barnwell et al. 1983). An interest in cytoadherence stemmed from the role it was 
believed to play in the pathology of cerebral malaria - it was hypothesised early on that 
the binding of parasites to the endothelium of the brain would obstruct oxygen uptake, 
damage the blood brain barrier and lead to cerebral malaria(MacPherson et al. 1985). 
Finding the parasite antigens responsible for this process was and remains an important 
focus of research, as a vaccine against such a molecule could prevent malaria associated 
pathology if not infection. Early on, however, it was noted that cytoadherence phenotypes 
varied(Udeinya et al. 1983) with immune pressure and so adhesion became linked with 
the phenomenon of antigenic variation. Many parasites undergo antigenic variation(Borst 
et al. 1995) generally in order to evade the immune response. Most famously 
Trypanosomes which live freely in the serum cover their surfaces with one of about 1000 
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variant surface glycoprotein (VSG) genes. Thy can generate further diversity by splicing 
these to create further variation(Borst 1991). The parasite needs these genes to be able to 
evade the immune response in the serum. Antigenic variation was described as early as 
1965 in malaria parasites(Brown et al. 1965). The linking of cytoadhesion and escape 
from clearance by the spleen to antigenic variation also solved the theoretical problem of 
why the malaria parasite which was capable of surviving inside the red blood cell would 
express antigens on the erythrocyte surface. At the molecular level these paradoxes were 
resolved with the discovery of Plasmodiumfalciparum erythrocyte membrane protein 1 
(PfEMP1), the protein that mediates antigenic variation and all-known cytoadhesion 
phenotypes. 
1.4.2 The parasite ligand: PfEMP1 
PfEMP1 was originally discovered by Leech et al. who identified novel antigens on the 
infected red blood cell (iRBC) surface(Leech et al. 1984). They showed that the antigens 
were strain specific and bound to by strain specific serum. Moreover they showed that 
both the antigen and cytoadhesion disappeared upon treatment with trypsin and 
subsequently that the novel antigens were associated with "Knobs" on the infected 
erythrocyte surface which appeared to be associated with cytoadherence(Aley et al. 
1984). Evidence that these novel antigens were of parasite rather than host origin came 
from metabolic labelling experiments and the proteins were named PfEMP1(Howard et 
al. 1988). The same experiments also showed that Knobs were made up of other parasite 
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derived proteins under the host cell membrane. The derivation of a variety of different 
antigenic types from a single cloned parasite showed that each genetically distinct 
parasite probably carried a range of PfEMP1 molecules(Biggs et at. 1991). Roberts et al. 
then showed that antigenic switching in a cloned line could be correlated with switching 
in the adhesion phenotype(Roberts et al. 1992). The major breakthrough came in the 
cloning of the genes responsible for antigenic variation by a variety of groups in 1995. Su 
et al. discovered the gene family encoding PfEMP1 molecules fortuitously while 
sequencing a region of the genome to which chloroquine resistance had been mapped by 
classical techniques. They named the gene family var1 . Probes to var genes showed that 
there were from 50-150 different var genes present in the genomes of particular parasite 
isolates(Su et al. 1995). The work of collaborators showed that expression of different 
antigenic determinants was correlated with the expression of different members of the 
multigene family var(Smith et al. 1995). At the same time Baruch et al. identified the 
var 
genes by screening an expression library of the malaria parasite with serum raised against 
PfEMP1(Baruch et al. 1995). The proteins are formed from common domains and consist 
of a variety of "Duffy binding-like" (DBL) domains with cysteine rich interdomain 
regions (CIDRs) on the extracellular surface, as well as a small transmembrane region 
and intercellular domain called the acidic terminal sequence (ATS) (Su et al. 1995; Smith 
1  var was not the original name of these genes, due to the problems Su et al. 
had in 
sequencing them they were originally called gfli genes an abbreviation of gene from hell 
(K. Deitsch personal communication) 
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et at. 2000)(Figure 1.6). The genes are made up of two exons, one for the extracellular 
and one for the intracellular regions of the genes. var 
genes were found to be largely sub-
telomeric with some internal var genes too(Hernandez-RiVaS 
et at. 1997; Gardner et al. 
1998; Bowman et at. 1999). 
The malaria genome project enabled the sequencing of the 
entire range of var genes from a single parasite line (3137), 
which had 59 var 
genes(Gardner et al. 2002). The var genes had 16 different arrangements of their 
constituent domains though 38 of them were of a single type. All 
var genes except 1 
began with a DBL-a domain with certain preferred parings of domains existing. 
Nonetheless 3137 may have an unusual var 
gene repertoire as it can neither be selected 
for rosetting (J. A. Rowe, unpublished) or adhesion to ICAM-1 (Alistair Craig, personal 
communication), alternatively the repertoire of var genes may be normal and instead 
there may be a defect in the transport of proteins to the cell surface in this strain (C. 
Newbold, personal communication). Given that there is very little overlap between the 
var gene repertoires of different parasites there are a huge number of 
var genes in nature. 
Ward et al. sequenced a variety of DBL-1 sequencies from various isolates and showed 
that much of the diversity in this family was generated by recombination between 
conserved sequences(Ward et al. 1999). In addition to classical recombination this 
process may have been accelerated by ectopic recombinatiOn(Freita5Ju1j0 
et al. 2000): 
i.e. recombination between non-homologous chromosomes occurring at telomeric ends 
due to similarity between these sequences and the presence of elements that tether 
together telomeric ends(O'Donnell et at. 2002). 
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Though parasites have a large repertoire of var genes they only express one at a 
time(Chen et al. 1998; Scherf et al. 1998). They must also do this in a co-ordinated 
fashion to avoid expressing all epitopes at once and allowing the host to develop total 
protective immunity. Thus much work has gone into attempting to determine the 
elements controlling var gene expression. Voss et al. showed that different 5' flanking 
regions exist in upstream of var genes in subtelomeric and internal locations and that 
these are bound to by different transcription factors(Voss et al. 2000; Gardner et al. 2002; 
Voss et al. 2003). Most interestingly Deitsch et al. identified a role for the var gene 
intron in transcriptional silencing in cooperation with the promoter, which occurred in a 
cell cycle dependant manner(Deitsch et al. 2001). Some groups have suggested that many 
var gene transcripts are expressed but only one is translated(Chen et al. 1998), however 
closer analysis shows that only one var gene transcript is generally made to full 
length(Kyes et al. 2000). Nonetheless how the parasite expresses one var gene while 
repressing the remainder (especially given similarity between promoters) remains 
unclear. 
1.4.3 Receptors and disease severity 
P. falciparum binds to a range of host endothelial molecules. The current list is: 
Thrombospondin(Roberts et al. 1985), CD36(Oquendo et al. 1989), intercellular 
adhesion molecule-i (ICAM1)(Berendt et al. 1989), chondroitin sulphate A 
(CSA)(Rogerson et al. 1995), vascular cell adhesion molecule-1 (VCAM-i), E- 
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selectin(Ockenhouse et at. 1992; Treutiger et al. 1997), CD31(Treutiger et al. 1997) and 
heparan sulphate(Vogt et al. 2003). Of these the most important quantitatively (and well 
studied) are CD36 and ICAM1: All isolates from children bind to CD36 usually at high 
frequency(Newbold et at. 1997). Second in both prevalence and binding strength is 
binding to ICAM-1(Newbold et al. 1997; Rogerson et al. 1999). In addition to 
endothelial binding, P. falciparum infected red blood cells can bind to other red blood 
cells (rosettes) through CR1(Rowe et at. 1997), platelets through CD36(Pain et al. 2001) 
and to the syncytiotrophoblast cells of the placenta through CSA(Fried et at. 1996; Achur 
et al. 2000) to cause placental malaria (see section 1.4.4). 
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Figure 1.7 
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Figure 1.7 Adhesion receptors and PfEMP1 binding specificity. A theoretical PfEMP1 
structure is shown. The molecule is made up of discrete Duffy binding like (DBL) 
domains numbered according to their position on the molecule. Greek letters refer to the 
type of DBL domain according to the classification of Smith et al. In between DBL 
domains are cysteine-rich interdomain regions (CIDRs). At the end of the molecule is a 
transmembrane region followed by the acidic terminal sequence (ATS). The location of 
various receptor-binding sites has been determined which is shown, though it is unlikely 
that a single molecule would possess all these binding specificities. 
Which if any of these cytoadhesion process are involved in disease pathology? Rosetting 
is the only cytoadhesion phenotype to be consistently associated with disease severity 
(discussed below - section 1.5). Much interest recently has been focussed on the 
involvement of platelet adhesion in severe disease. Infected erythrocytes can bind to 
CD36 on platelets, which cause the parasitised cells to auto-agglutinate(Cooke et al. 
1995; Pain et al. 2001). This process has been associated with disease severity(Roberts et 
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al. 2000; Pain et al. 2001). Other work has shown that platelets adhere to the 
microvasculature in cerebral malaria(Wassmer et al. 2003). In mouse models inhibition 
of this process by knock-out of some of the main receptors for platelet adhesion (P-
selectin and ICAM- 1) has led to a decrease in the pathogenesis of murine cerebral 
malaria(Chang et al. 2003; Li et al. 2003; Sun et al. 2003) though this is not necessarily 
relevant to human malaria. Endothelial binding has been less consistently associated with 
disease severity. Though as sequestration is a universal feature of P. falciparum 
infections (present in asymptomatic, mild and severe infections) this is, perhaps not 
surprising. Endothelial cytoadherence has been hypothesised to cause severe disease by 
microvascular obstruction, restricting blood and oxygen flow. Association studies have 
shown that adhesion to the endothelium per-se is not associated with severe malaria 
under static (Newbold et al. 1997; Rogerson et al. 1999) or flow conditions(Cooke et al. 
1993; Cooke et al. 1995). Other studies have focussed on looking at adhesion to 
particular receptors(Newbold et al. 1997; Rogerson et al. 1999; Heddini et al. 2001). 
Rogerson et al. report no association between adhesion and disease severity, surprisingly 
severe disease was associated with reduced binding to CD36 and ICAM- 1. Anaemia in 
particular was associated with low levels of adhesion, with high haematocrit being 
associated with increased binding. Newbold et al. find no difference in adhesion 
prevalence to different receptors between cerebral malaria, severe anaemia, mild malaria 
and asymptomatic infections. They do however report that there is an increase in the 
strength of binding to ICAM- 1 in cerebral malaria patients. These ex-vivo studies are 
hampered by only looking at one side of the adhesion process. In severe disease there 
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may not be more parasites capable of binding to a given receptor, but that certain 
receptors are up-regulated in severe disease. Autopsy experiments have been use to 
demonstrate the role of adhesion in cerebral malaria(MacPherson et al. 1985) and 
particularly adhesion to ICAM-1(Turner et at. 1994). Heddini et at. argue that multiple 
adhesion phenotypes are associated with disease severity, however if rosetting and 
immunoglobulin binding (which correlates with rosetting) were removed from the 
analysis the results would not be significant. Human genetics gives little support for a 
role for adhesion in causing severe malaria either. A polymorphism in CD36 coding for a 
stop codon and thereby truncating the protein has been implicated as a risk factor in The 
Gambia and Kenya(Aitman et at. 2000) though in Kenya this is contradicted(Pain et at. 
2001). Similarly an ICAM-1 polymorphism associated with low binding is associated 
with malaria susceptibility(FernandeZ-ReYe5 et al. 1997) in one study, protection in 
another(Kun et at. 1999) has no effect in another(Bellamy et at. 1998). 
Perhaps it is time to reassess the paradigms of adhesion and disease severity. A simple 
equation of cytoadhesion=severe disease is clearly insufficient. Instead certain binding 
phenotypes are associated with severe disease. Binding to CD36 is probably a benign 
event, though it is probably quantitatively the most important receptor for adhesion, it is 
not expressed in the brain so is unlikely to be involved in cerebral malaria. Moreover if 
all CD36 binding parasites were lethal, then P. fatciparum would be far too virulent a 
parasite to be evolutionarily successful. Some evidence from Papua New Guinea supports 
this hypothesis. Around 10% of individuals in Papua New Guinea have ovalocytes in 
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their blood due to Southeast Asian ovalocytosis; these individuals are completely 
protected from cerebral malaria but not anaemia(Genton et al. 1995; Allen et al. 1999). 
Infected ovalocytes bind 2 times better to CD36 under flow conditions than normal 
infected erythrocytes (Alfred Cortes personal communication). "Bad" forms of adhesion 
may include rosetting, ICAM-1 binding(NeWbOld et al. 1997) and binding to CD36 on 
platelets. There is a large element of host involvement in this: the inflammatory response 
to disease can result in the upregulation of parasite receptors, for example TNF-ct can 
cause the upregulation of ICAM-1 in the brain(Turner et al. 1994). 
1.4.4 placental malaria 
Placental malaria represents a special case of Plasmodiumfalciparum adhesion. It is also 
some of the strongest evidence for the role of cytoadhesion in malaria pathogenesis. 
During pregnancy women are at risk of maternal malaria. Maternal malaria is a distinct 
clinical syndrome from childhood malaria and is associated with premature delivery, 
interuterine growth retardation and prenatal mortality in the child (especially in endemic 
areas), and anaemia and death in the mother (more common in non-immune 
women)(McGregOr 1987; Beeson et al. 2001). The risk is greatest in the first and second 
pregnancies, but less so in multigravid women(McGregor 1984). This suggests (i) that 
global immunosupPreSsiOn associated with pregnancy is not the mechanism and (ii) that 
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immunity is acquired with exposure to a distinct parasite type that causes placental 
malaria. 
In pregnant women with malaria, the placenta is often a site of heavy sequestration of 
parasites, though the periphery may be free even of young, ring-stage parasites( Walter et 
al. 1982; Brabin 1983). It was shown that parasites from the placenta bind preferentially 
to CSA rather than any other matrix proteins or endothelial receptors(Fried et al. 1996). 
The site of binding to CSA was found to be the syncitial trophoblasts(Achur et al. 2000). 
The ligand for CSA binding was subsequently found to be the duffy-y domain of 
PfEMP 1 (Buffet et al. 1999; Reeder et al. 1999) which was hard to reconcile with 
observations that sera from multigravid women in one region of the world were able to 
prevent binding to CSA of placental isolates from other parts of the world suggesting a 
high degree of conservation in the CSA ligand(Fried et al. 1998). Rowe et al. identified 
two conserved var genes that bound to CSA, at least one of which was found expressed 
in placental isolates(Rowe et al. 2002). They suggest that certain var genes may be 
conserved as a result of selection acting on a particular gene with an important function 
or that some var genes have a different orientation relative to the telomere and are 
therefore unlikely to undergo normal or ectopic recombination. 
Some observations are challenging the emerging orthodoxy on CSA binding and 
placental malaria(Beeson et al. 2002). One group has reported adhesion of ring stages to 
a limited range of endothelial cells(Pouvelle et al. 2000). This adhesion was only 
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observed in isolates that matured to express CSA binding var genes. It suggests a 
mechanism for the "cryptic" circulation of placental parasites which have distinct 
phenotypes from the parasites found in the periphery of women with maternal malaria. It 
is unclear what the ligands or receptors for this adhesion phenomenon are. Binding of 
immunoglobulins may also be important in placental malaria, IgG was found to be bound 
to many parasites from placental isolates which failed to bind CSA(Flick et al. 2001). 
This was not entirely matched by work with a laboratory strain, TM284S2 a rosetting 
parasite, which apparently also bound non-immune IgG. It is unclear though whether the 
IgG bound to the placental isolates was non-immune or parasite specific, moreover the 
work with TM284S2 has been impossible to reproduce(Creasey et al. 2003). Instead it 
appears that CSA binding parasites bind non-immune IgM(Creasey et al. 2003). An 
unresolved paradox is that 1gM binding is also important in rosette formation and yet 
placental malaria and rosetting are almost mutually exclusive phenomena(Rogerson et al. 
2000). It was the hope of many researchers that an understanding of the apparently 
simpler syndrome of maternal malaria (one ligand, one receptor) would represent "trial 
run" in trying to fight childhood malaria. That "simplicity" may turn out to be an illusion 
based on not enough data rather than any biological effect. 
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1.5 Rosetting 
1.5.1 Rosetting and the pathology of severe disease 
While disease associations between adhesion and syndromes of severe malaria have been 
inconsistent and suggest a more complex pattern of disease than originally hypothesised, 
one adhesion phenotype that has been consistently associated with severe disease is that 
of rosetting. Early studies in the Gambia(Carlson et al. 1990; Treutiger et al. 1992) and 
Kenya(Rowe et al. 1995) reporting this association have been confirmed in a various 
other African sites(Ringwald et al. 1993; Newbold et al. 1997; Kun et al. 1998; Heddini 
et al. 2001; Pain et al. 2001; Rowe et al. 2002). Out of the African studies only one study 
in Malawi has found no association between rosetting and disease severity(Rogerson et 
al. 1999). In Southeast Asia and Melanesia the picture appears to be different with two 
large (>100 isolates studied) showing no association between severe malaria(al-Yaman et 
al. 1995; Angkasekwinai et al. 1998) and a couple of smaller studies giving conflicting 
results(Ho et al. 1991; Udomsangpetch et al. 1996). In their discussion to the study in 
Malawi, Rogerson et al. suggest that the lack of correlation between rosetting and disease 
severity could be because of host factors, such as receptor polymorphisms, a hypothesis 
that we test here. Associations have been made with both cerebral malaria and severe 
anaemia which suggests at least two potential mechanisms by which malaria may cause 
severe disease, firstly rosettes may be implicated in microvascular obstruction, blocking 
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blood flow and oxygen to the brain(Kaul et al. 1991) or they may potentiate invasion and 
enhance parasite multiplication rates though in vitro experiments have found no evidence 
of this(Clough et al. 1998). However this work was carried out in the absence of immune 
pressure and so may not be a good model of rosetting in semi-immune children. 
Nonetheless it remains unclear if rosetting is a cause or merely a correlate of severe 
disease. Some work argues that rosetting could perhaps be a marker for some other 
adhesion process(Fernandez et al. 1998), while other work hypothesises that rosetting 
isolates could enhance TNF-a release from macrophages(O'Dea et al. 2003). 
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Table 1.3: Rosetting and severe malaria worldwide 
Reference Site Mean* or mediant P n 
rosetting value (severe) 
Severe Mild 
African studies: 
Carison et al. 1990 The Gambia 
35%* 17% <0.001 81(24) 
Treutiger et al. 1992 The Gambia 28 . 3%* 8.5% <0.001 130 (24) 
Ringwald et al. 1993 Madagascar 30.5%t 5% <0.002 21(12) 
Rowe etal. 1995 Kenya 7%t 1% <0.003 154 (36) 
Newbold etal. 1997 Kenya 
95%* 5.4% <0.05 185 (144) 
Kun etal. 1998 Gabon 16%* 8% <0.05 137 (74) 
Rogerson etal. 1999 Malawi 15%* 14.6% NS 126 (64) 
Pain etal. 2001 Kenya 6.5%t 4.1% =0.02 121 (57) 
Heddini etal. 2001 Kenya 21 .4%* 12.9% =0.01 111 (55) 
Rowe etal. 2002 Kenya 14%t 3.5% <0.001 74(25) 
Rowe etal. (unpublished) Mali 12%t 1% <0.01 
Southeast Asian and Melanesian studiest 
Ho etal. 1991 Thailand 18.3%t (9%) 10.7% NS 35(25) 
al-Yaman etal. 1995 PNG 
9%* 8.6% NS 232 (81) 
UdonmsangpetCh et al. Thailand 20%t (8%) 5% =0.02 60 (32) 
1996 
Angkasekwinai etal. 1998 Thailand 11 . 1%* 4.1% NS 263 (100) 
(5.1%) 
For studies in Southeast Asia values for severe malaria studies are given mean or 
median for cerebral malaria with the mean or median for other severe malaria in 
brackets. 
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1.5.2 Physiology of rosettes 
By standard methods rosettes are counted in the laboratory as the proportion of mature 
stage infected red blood cells binding to two or more other red blood cells. When 
parasites are cultivated from infected individuals it is necessary to grow the parasites to 
maturity as the vast majority of parasites in the peripheral circulation will be immature, 
ring-stage trophozoites, the later forms having sequestered in deep microvascular beds 
(see section 1.4). One important question this raises is whether the rosettes observed in 
static culture are physiologically significant and capable of obstructing blood flow in the 
microvasculature. Kaul et al.(Kaul et al. 1991) tested this hypothesis directly using an 
ex-
vivo preparation of rat mesocecum vasculature through which they perfused rosetting and 
non-rosetting Malayan Camp parasites. Perfusion through tissues did not lead to the 
disruption of rosettes. They were also able to show rosette formation in the venular 
circulation but not on the arterial side, moreover there was higher peripheral resistance 
(ie. a slowing of blood flow) when tissues were perfused with the rosetting rather than the 
non-rosetting line. Other experiments have looked measured the forces required to 
directly detach red cells from rosettes. The direct detachment forces required to pull 
rosettes are apart are around 4.4x10 1°  N - around 5 times the force required to detach 
IRBC from the surface of endothelium(NaSh et al. 1992). The types of forces generated in 
the circulation tend to be of high sheer caused by friction between the blood vessel walls 
and the blood flow. Therefore a variety of experiments have been performed which show 
that not only can rosettes withstand high sheer stresses associated with the arterial 
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circulation (around 1.4 to 1.6 Pa)(Nash et al. 1992; Chotivanich et al. 2000), but also that 
they can form in the conditions found in the circulation(Chu et al. 1997; Chotivanich et 
al. 2000). 
1.5.3 Ugands and receptors for rosetting 
Rosetting like other parasite adhesion phenotypes is mediated by PfEMP1(Rowe et al. 
1997; Chen et al. 1998), and a variety of uninfected RBC surface receptors including 
complement receptor 1(Rowe et al. 1997), CD36(Handunnetti et al. 1992), ABO blood 
group sugars(Carlson et al. 1992; Barragan et al. 2000), heparan sulphate-like 
molecules (B arragan et al. 2000) and serum factors(Scholander et al. 1996; Somner et al. 
2000). 
Early on it was identified that rosettes were sensitive to disruption by heparin, along with 
many other cell-cell interactions(CarlsOn et al. 1990). Subsequent work showed that a 
family of suiphated glycoconjugate molecules shared this ability(Rowe et al. 1994). 
However there remains little evidence that these glycoconjugates are present on the red 
cell surface, Immunofluorescence assays (IFAs) and western blots of the red blood cell 
surface have failed to reveal these molecules (J. A. Rowe unpublished). The only direct 
evidence we have for the involvement of GAGs in rosetting is that enzyme digestion of 
red cells with heparinases reduces their ability to rosette(Barragan et al. 2000), though we 
cannot rule out the possibility that heparinase is cross reacting on other molecules with 
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similar sugar units which are the true receptor. It has also been shown that PfEMP 
involved in rosetting is bound to by GAGs explaining the basis of their ability to disrupt 
rosettes(Chen et al. 1998). Strain specific preferences among rosetting isolates for 
particular blood group types was also noted early on with A and B blood group 
erythrocytes forming larger rosettes than 0 erythrocytes(Carlson et al. 1992). The role of 
blood group A was confirmed by the demonstration that A sugars bind to infected red 
blood cells and can disrupt rosettes albeit at high concentrations(Barragan et al. 2000). A 
number of field studies have shown that the A blood group may be a risk factor for severe 
disease which could be explained by this effect on rosetting(Hill et al. 1991; Fischer et al. 
1998; Lell et al. 1999). 
CD36 was also suggested early on as a as a rosetting receptor after it had been identified 
as an endothelial receptor(Oquendo et al. 1989). Adherent lines of PfEMP1 were found 
to rosette in a manner that could be reversed with anti-CD36 antibodies(Handunnetti et 
al. 1992). However CD36 is only present in low amounts on the surface of red blood 
cells(van Schravendijk et al. 1992) while anti CD36 antibodies do not reverse rosetting in 
field isolates(Rowe et al. 2000). 
Electron micrographs from autopsy samples from cerebral malaria patients showed 
rosettes held together by dense fibrillar strands(Scholander et al. 1996). A similar 
observation had been seen in binding to endothelial cells previously(MacPherson et al. 
1985). Two rosetting laboratory strains TM284+ and PAR+ were subsequently shown to 
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also have these fibrils. On TM284+ these were associated with knobs while on PAR+, 
which is a knobless parasite the fibrils are less dense. Antibodies to human 
immunoglobulins were found by immunogold transmission electron microscopy to bind 
to these strands. The involvement of immunoglobulin M (1gM) was confirmed by some 
painstaking work in which whole serum fractionated by a variety of means and the 
fractions capable of supporting rosetting were identified. In addition to 1gM at least two 
other, unidentified, components were found to be involved in rosette formation(Somner 
et al. 2000). 1gM binding has since been shown to be involved in rosetting in field 
isolates and associated with disease severity(Rowe et at. 2002). 1gM binding has been 
associated with the DBL2I3(Flick et al. 2001) and CIDR1a(Chen et al. 2000) domains of 
PfEMP 1, however this domain specificity has been impossible to reproduce in our 
laboratory. However 1gM does bind to PfEMP1 on western blots of native proteins (J.A. 
Rowe and J-P Semblat unpublished data) supporting the notion that this too is a PfEMP1 
mediated adhesion phenotype. 
CR1 may be the most important rosetting receptor. The DBL domains of PfEMP1 from a 
strongly rosetting line: R29+ were cloned and expressed in COS cells. The DBL-1 
domain was found to bind red cells. A subsequent screen of red cell types showed that 
red cells deficient in CR1 showed reduced rosetting(Rowe et al. 1997). Subsequent work 
mapped the PfEMP-1 binding site to C3b and C4b binding domains on CR! (see section 
1.6.2) and showed that specific antibodies could reverse rosetting in laboratory strains 
and most field isolates(Rowe et al. 2000). Moreover the existence of polymorphisms in 
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the CR1 gene that are prevalent in African (Rowe et al. 1997; Zimmerman et al. 2003) 
and Papua New Guinean populations (this study) suggests that while rosetting may be a 
degenerate process, prevention of CR1-mediated rosetting may protect against severe 
disease. 
Is PfEMP1 the only rosetting ligand? PfEMP1 is highly trypsin sensitive yet a subset of 
rosettes show a degree of resistance to disruption at high tryp sin concentrations(Kyes et 
al. 1999). Early on a screen of antibodies to then-known parasite membrane associated 
proteins showed that monoclonal antibody (mAb) specific for histidine rich protein 
(PfHRP) disrupted rosettes(Carlson et al. 1990). However these experiments were 
pefformed in PAR+ parasites, a strain that does not express PfHRP (which means that it 
is Knob-), instead the mAb appeared to be cross-reacting with a 28kDa parasite derived 
protein. This protein in turn was found to be related to a 22kDa protein which could also 
apparently mediate rosetting as antibodies raised against this protein could disrupt 
rosttes(Helmby et al. 1993). Members of this family of small proteins were named 
"rosettins" though little subsequent work was done on this until Kyes et al. described the 
rifin family of clonally variant parasite antigens which match "rosettins" in their trypsin 
resistance, approximate size and correlation with "trypsin resistant" rosetting(Kyes et al. 
1999). 
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1.6 Complement receptor 1 
Complement receptor 1 (CR1, also known as CD35) has been implicated as receptor for 
rosetting. Nonetheless, as stated above it remains unclear if rosetting is a cause or 
correlate of parasite virulence. The presence of a variety of polymorphisms in this gene 
(described below) suggests that it has been subject to selective pressure. We hypothesise 
that some of these polymorphisms may have been caused by immune selection as a result 
of a malaria. If this were true it would be strong evidence that rosetting is a parasite 
virulence factor and therefore a target for anti-disease intervention. Here I describe the 
normal and malaria related functions of CR1 and the polymorphisms present in the gene. 
1.6.1 Functions of CR1 
CR1 is an immune regulatory protein expressed on the surface of erythrocytes, 
leukocytes, macrophages, glomerular podocytes and follicular dendritic cells(Ahearn et 
al. 1989). Complement is an effector system of the humoral immune response (reviewed 
in(Janeway et at. 1999)); CR1 can bind to certain complement components and modify 
their activation or be involved in their uptake by phagocytic cells. The classical 
complement pathway and the role of CR1 are outlined in figure 1.8. Complement 
components exist in inert forms in the bloodstream until they are altered by proteolytic 
cleavage by various proteases that are stimulated by the binding of antibody to antigen 
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and its subsequent conformational change (Figure 1.8 a). The end products of the 
complement pathway may act in a variety of ways. Firstly a foreign cell surface may 
become opsonised or coated in C3b fragments, it may then be taken up by complement 
receptors that can bind C3b such as CR1 (Figure 1.8 b). Secondly small fragments (C3a, 
C4a) formed as products of the cleavage of major early complement components (C3 and 
C4) may stimulate inflammation (Figure 1.8 a and b). Thirdly a membrane attack 
complex (MAC) consisting of the terminal complement components (C5b, C6, C7, C8 
and C9) may be precipitated lysing the cell it forms on (Figure 1.8 c). An alternative 
pathway of complement exists in which the same cascade is initiated by spontaneous C3b 
binding to pathogen surfaces. The C3b can then bind a protein B (analogous to C2) which 
is cleaved by a protease D to form Bb. C3b-Bb complexes are active C3 convertases. 
This C3 convertase acts in same way as the C4b-C2b-C3b complex and from then the 
same downstream events as in the classical pathway can proceed (as in figure 18 b,c and 
e). CR1 is involved in this process in a variety of ways. As the complement system can 
potentially damage host cells as well as those of non-self components, it is important that 
host cells are protected from damage. An important role of CR1 is to control the 
activation of complement. CR1 can bind to C4b and displace C2b from the C3 convertase 
(decay accelerating activity, DAA). Once bound to C4b CR! can act as a cofactor for 
factor I - a protease that breaks down some of the enzymes of complement activation - 
and enhance the breakdown of C4b (CA- cofactor activity) blocking the complement 
pathway (Figure 1.8 d)(Iida et al. 1981). In an analogous process CR! may displace C3b 
from the C5 convertase and act as a cofactor for it's decay by factor I (Figure 1.8 e). On 
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red blood cells this complement control activity may not be the principal function of CR1 
as decay accelerating factor (DAF) is present in much larger numbers and can perform a 
similar role (Figure 1.8 d). Instead the main role of CR1 on erythrocyte may be the 
clearance of immune complexes. Immune complexes are formed when antibody bound to 
antigen is directly opsonised by C3b fragments(Schifferli et al. 1989). In this case the 
complexes may bind to CR1 on the surface of RBC and be carried in the circulation to 
the liver where the immune complex will be cleared from the blood stream(Cornacoff et 
al. 1983; Ng et al. 1988; Schifferli et al. 1988). CR1 on B cells has also been implicated 
in giving a downregulatory signal to these cells(Jozsi et al. 2002). CR1 may be involved 
in malaria pathogenesis through a mechanism other than by acting as a receptor for 
rosetting. Erythrocyte CR1 levels are reduced in severe malarial anaemia along with 
other complement control proteins such as decacy accelerating factor (DAF; CD55). The 
authors suggests that this could lead to red cell lysis by complement as part of the 
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Figure 1.8: The classical complement pathway and its control by CR1: a the classical 
pathway is initiated when antigen is bound to by anbody which fixes the large molecule 
Cl. Cl has a protease domain Cl s, which cleaves inert C4 and C2 to 4b and C2b 
respectively. The other products of cleavage are C2a and C4a, which are soluble 
inflammatory mediators. b C4b-C2b has C3 convertase activity - it can convert inert C3 
to C3b which is either remains bound to the C3 convertase or is deposited on the cell's 
surface (opsonisation). C3b on the cell surface may be bound to by complement 
receptor 1 and lead to the uptake of the opsonised cell. c Alternatively the C3b-C4b-C2b 
complex formed may act as a C5 convertase changing inert soluble C5 to C5b which 
can fix the terminal components of complement (C5-C9) to form a membrane attack 
complex which forms pores in the surface of the cell. d CR1 is involved in this process in 
a number of ways, either it can displace C2b from the C3 convertase and act as a 
cofactor for factor I which may breakdown C4b (the role of CR1 -factor I may also be 
performed by decay accelerating factor (OAF) or e CR1 with factor I may displace C4b 
and C2b from the C5 convertase and act with the protease I to breakdown C3b. 
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1.6.2 Structure of CR1 
The predominant form of CR! (figure 1.9), CR1*1  is a 190kDa protein consisting of 30 
complement control protein (CCP) repeats, arranged into four blocks of seven CCPs, 
called long homologous repeats (LHRs) designated A to D and each homologous to each 
other(Klickstein et al. 1987) (Figure 1.9). There are three C4b binding sites in the first 
three CCPs of each LHR(Krych-Goldberg et al. 2001). The site on LHR-A is also the 
location of the decay accelerating activity of CR1. The C4b binding sites on LHRs B and 
C show >90% homology to each other and also bind to C3b(Vik et al. 1993) and have the 
cofactor activity for factor I. Recently Smith et al. determined the solution structure of 
CCPs 15-17 (residues 901-1095) which corresponds to the C3b/C4b binding domain. 
They showed that the repeats were in an extended head to tail arrangement with 
flexibility at the module 16-17 junction. They also showed a positively charged region on 
CCP 15 which is critical for C4b binding(Smith et al. 2002). The CR1 gene is linked to a 
variety of proteins such as decay accelerating factor (DAF; C1355), complement receptor 
2(CR2; C21) membrane cofactor protein (MCP; CD46) and C4b binding protein (C4BP) 
at a locus called the regulators of complement activation locus (RCA) at chromosome 1 
band q32. 
Western blot analyses revealed over time that there were 4 size variants of the CR1 gene. 
Subsequently it was determined that the structural polymorphisms (which varied in 
30kDa size increments) had additions or deletions of LHR units (Table 1 .4)(Dykman et 
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al. 1983; Dykman et al. 1984; Dykman et at. 1985). The size polymorphisms appear to 
have arisen as a result of unequal crossing over events between homologous regions of 
the gene at meiosis(Wong et al. 1989; Wong et al. 1991). 
Table 1.4: Size variants of the CR1 molecule (after(Krych-GOldberg et al. 
2001)) 
Variant CR1 size CR1 size No. of LHRs Frequency 
(kDa)* (kDa)t (Caucasians) 
CR1 *1 190 220 4 0.83 
CR1*2 220 250 5 0.15 
CR1 *3 160 190 3 0.01 
CR1 *4 250 280 6 <0.01 
* Under non-reducing conditions 
f Under reducing conditions 
The frequency of different size allotypes varies between population. Of interest is the 
fractionally increased frequency of the CR1*3 allele in some African populations (Table 
1.5) which lack a C3b and PfEMP1 binding site. 
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Table 1.5 Global distribution of CR1 size polymorphisms (from(Cohen et al. 
1999)) 
Ethnic Group 	n CR1*1 (190) CR1*2 (220) CR1*3 (160) CR1*4 (250) 
Black - USA 715 0.83 0.13 0.03 0.003 
Black - Mali 87 0.79 0.14 0.05 0.02 
Caucasian - USA 426 0.86 0.11 0.01 
0.002 
Chinese / Taiwanese 112 0.95 0.04 0.01 
0 
Choctaw Indian 220 0.97 0.01 0.01 0.005 
French 106 0.87 0.13 0.01 0 
Italian 71 0.84 0.15 0 0.01 
Mexican 203 0.88 0.1 0.01 0.005 
Peruvian 169 0.94 0.05 0.01 0.003 
Spaniard 22 0.8 0.18 0.02 0 
391 
Figure 1.9 
LHR-A 	 LHR-B 	 LHR-C 	LHR-D 
Alternative deletions for CR1*3  allele 
t t t 
Single nucleotide polymorphisms 
	
Ex22 	lnt27 	SlaIKn Ex33  
Location of epitopes 
J3B11 	recognised by 
I antibodies used for 
Eli 	
I flow cytometry and 
Western blotting and 
J rosette disruption J3D3  
CCP involved in binding of C4b and decay 
accelerating activity 
CCP involved in C3b binding and with cofactor activity 
S for protease 
61 
Chapter 1: Introduction 
1.6.3 Expression level polymorphisms 
The level of CR1 on erythrocytes is determined by a number of genetic and 
environmental factors( Wilson et al. 1982; Ross et al. 1985; Wilson et al. 1986). In 
Caucasians CR! expression level varies between 100 and 1000 per RBC. Expression on 
RBC (but not the other cells expressing CR1) is controlled by two alleles associated with 
high (H) and low (L) expression of CR1, which are co-dominant and linked to a Hindill 
RFLP in intron 27 of the CR1 gene(Wilson et al. 1982; Wilson et al. 1986). Subsequent 
research has shown that the Hindlil RFLP is linked to around nine other polymorphisms 
which form two distinct haplotypes again associated with high and low levels of CR1 in 
Caucasians(Herrera et al. 1998; Xiang et al. 1999). In the L haplotype two of the 
polymorphisms replace other amino acids with arginine which may make the protein 
more susceptible to proteolytic cleavage and explain why this haplotype is associated 
with low copy number of CR1(Herrera et al. 1998; Xiang et al. 1999), accordingly we 
studied these polymorphisms as well. The particular polymorphisms under investigation 
in this study are described in table 1.6. The same work also showed that these haplotypes 
exist in African Americans too, however in African Americans CR1 copy number is not 
related to these haplotypes. This is important as it has been reported in the literature that 
the L allele is not protective against severe malaria based on samples from a case-control 
study in the Gambia(Bellamy et al. 1998) which were typed for this polymorphism. 
However the lack of an association between CR1 expression and H and L haplotypes in 
African populations suggests that this study has no functional significance(Herrera et al. 
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1998; Rowe et al. 2002).Conversely a study on Thai adults showed that in this population 
the L allele is present at a prevalence of 0.52 and is associated with CR1 
expression(Nagayasu et al. 2001). They report in a case-control study that the LL 
genotype is a risk factor for severe malaria. They do not report, though, that their data 
also shows that the heterozygous state is associated with protection from severe disease. 
Two caveats of this study are its sample size (55 severe cases) and the fact that rosetting 
is not associated with disease severity in this population suggesting different mechanisms 
for disease severity in this population, consistent with the different pattern of disease in 
Southeast Asia compared to Africa. 
Table 1.6 SNPs in the CR1 gene linked to red cell CR1 expression level 
exon 22 intron 27 exon 33 
Red cell Size of genomic 
nucleotide 	amino acid nucleotide 	amino acid 
phenotype* DNA RFLP 
High (H) CR1 
A3650 	Hisi 208 7.4 kb C5507 	Pro1827 
expression 
Low (L) CR1 
G3650 	Arg1208 6.9kb G5507 	Arg1827 
expression 
* Typical in all populations studied to date except those of African origin (Herrera et al. 
1998; Rowe et al. 2002) 
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1.6.4 Knops blood groups types 
The Knops blood group types were mapped to CR1 in 1991(Moulds et al. 1991). The 
Knops blood group antigens are not important for transfusion medicine and were not 
formerly associated with any disease. However they have been a focus of interest since it 
was discovered that certain Knops phenotypes were associated with reduced rosetting in 
vitro(Rowe et al. 1997). There are at least 3 allelic pairs in the blood group system Si 1 
and Si 2, McC" and McCb,  and Kn' and Kn' corresponding to the blood types SI: 1 and 
S1:2, McC(a+) and McC(b+) and Kn(a+) and Kn(b+). The situation is further complicated 
by another phenotype caused by low expression of CR1 such that none of the antigens 
can be detected by serotyping techniques; this is known as "Helgeson" phenotype. 
Rowe et al. initially identified CR1 as a potential rosetting receptor because Helgeson 
cells were found to show reduced rosetting with the R29+ parasite clone. Even before it 
was discovered that there was a link between Knops types and rosetting existed it had 
already been suggested that these blood group types might have a link to malaria 
pathogenesis on account of their difference in prevalence between Caucasian and African 
populations (Table 1.7)(Miller 1994). Two of the antigens S1:2 and McC(b+) are 
common only in African populations and at least one of these S1:2 has been shown to 
have reduced ability to bind to COS cells expressing the DBL- 1 domain that mediates 
rosetting in R29+ parasites(Rowe et al. 1997). These two important polymorphic sites 
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have recently been attributed to non-synonymous mutations in the region coding for the 
in the LHR-D region (Table 1 .8)(Moulds et al. 2001). 
Table 1.7 Allele frequencies of Knops group types in Malians and West 
Africans (Moulds et al. 2000; Zimmerman et al. 2003) 
Study Group n 
Allele 
S12 	MCCb 
Mali 99 0.75 0.30 
West Af rica* 182 0.79 0.31 
The Gambia 853 0.80 0.39 
Caucasian American 100 0.005 0 
Asian American 99 0.03 0.02 
Hispanic American 100 0.03 0.03 
*West Africa includes Senegal, Guinea, Sierra Leone, Ivory Coast and Ghana 
Genotyping typing of samples from a case-control study in the Gambia showed no 
association between the frequency of the different Knops group alleles and severe 
malaria(Zimmermafl et al. 2003) however a separate study in Mali has found a significant 
genotype-phenotype mismatch which makes these results difficult to interpret (J.A. 
Rowe, personal communication). A prospective case-control study is ongoing to examine 
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rosetting and disease associations with Knops phenotypes in Mali (J.A. Rowe and J.M. 
Mould unpublished). There is very little data on the Knops blood group antigens in Papua 
New Guinea though an early report in the literature stated that though Helgeson 
phenotype was rare among Caucasians and Africans 28 out of 67 Melanesians were 
nulls(Molthan 1983). It was this suggestion that lead us to examine CR1 polymorphisms 
in Papua New Guinea more closely. 
Table 1.8 The molecular basis of the of the knops blood group 
antigens(Moulds et al. 2001) 
Blood Group Antigen Allele 	- Amino Acid Nucleotide 
McC(a+) McCa McCa K1590 A4795 
McC(b+) McCb McCb El 590 G4795 
Sl:l Sli Sli R1601 A4828 
SI:2 S12 SI 2 G1601 G4828 
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1.7 Aims of this thesis 
It is unclear whether rosetting is a correlate or cause of parasite virulence. As rosetting is 
mediated by CR1, we would expect malaria to select beneficial forms of this gene but 
only if rosetting is a direct cause of severe disease. We are interested in particular in 
Papua New Guinea as this is a malaria endemic area where an early report suggested that 
CR1 deficiency might be common as many individuals were of the Helgeson (CR1 
deficient) phenotype(Molthan 1983). Preliminary studies showed that 8/15 samples from 
neighbouring Vanuatu were also CR1 deficient. Otherwise little is known about CR! 
polymorphisms in Melanesia. The aims of this study are therefore to: 
To optimise an assay for CR1 expression that can be used in the field, or on cells 
collected in the field and analysed later 
To determine the prevalence of CR1 polymorphisms and CR1 deficiency in Papua 
New Guinea 
To determine the genetic basis of CRl deficiency in Papua New Guinea 
To determine whether common CR1 polymorphisms protect against severe malaria in 
Papua New Guinea 
To investigate the effect that CR! polymorphisms have on rosetting in Papua New 
Guinea. 
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Materials and Methods 
Here are described the laboratory techniques used in this study. Details of designs for 
epidemiological studies are given in the appropriate results chapter. Methods are ordered 
approximately according to their appearance in the subsequent text. All reagents were 
from Sigma, Poole, U.K unless otherwise stated. 
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2.1 Determination of CR1 expression by flow cytometry(Cohen 
et al. 1987; Cockburn et al. 2002) 
The mean erythrocyte CR1 expression level on freshly drawn blood samples was 
determined using a modification of a previously published method(Cohen et al. 1987). 
50 p1 of whole blood was washed three times in phosphate buffered saline (PBS - 0.01M 
phosphate buffer, 2.7 mM potassium chloride and 0.137M sodium chloride, PH7.4), 
supplemented with 4 % RPMI 1640 (Invitrogen, Paisley, UK) and 1 % non-immune AB 
serum (ABS) (Scottish Blood Transfusion Service, Edinburgh, UK) (PBS-RPMI-ABS). 
The cells were resuspended in 1 ml of PBS-RPMI-ABS and 100 p.1 of this suspension 
(i.e. approximately 2.5 p.1 of cells) was placed in a 96 well plate, spun at 1000 g for 
minute and the supernatant removed. The cells were then incubated at 4 °C with 40 p.1 of 
0.5 p.g/ml of the CR! monoclonal antibody (mAb) J3133 (Immunotech, Marseille, 
France) in PBS-RPMI-ABS for one hour with occasional agitation. The cells were 
washed three times in PBS-RPMI-ABS and resuspended in 10 p.g/m! of Alexa FluorTM 
488-conjugated goat anti-mouse IgG (Molecular Probes, Leiden, the Netherlands) 
followed by incubation at 4 °C for one hour with occasional agitation. Alexa Fl uorTM 
488 is equivalent to fluorescein isothiocyanate (FITC) but is more stable and sensitive 
and less prone to photo-bleaching. Negative control samples were treated as above but 
without the primary antibody. After the secondary incubation, cells were washed 3 times 
in PBS-RPMI-ABS and resuspended in PBS-RPMI-ABS supplemented with 0.37 % 
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formaldehyde (BDH, Poole, UK), and analysed on a FacSCAN flow cytometer (Becton 
Dickinson, San Jose, CA). The mean fluorescence intensity of each sample, minus the 
mean fluorescence intensity of the negative control was determined. A standard curve 
was obtained by plotting the fluorescence intensities of blood samples from donors of 
previously determined CR! number (initially determined by Scatchard analysis using 125! 
labelled mAb,(Cohen et al. 1987)), ranging from 200 to 1000 molecules per cell (Figure 
2.1). The standard curve was used to read off the CR1 expression level of unknown 
samples as shown in Figure 2.1. Typically each sample would have its CR1 expression 
tested in triplicate, with new standard curves generated for each determination. 
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Figure 2.1: A standard curve used to determine the mean erythrocyte CR1 expression 
level of unknown samples. The standard curve was plotted with data from five 
standards of previously determined CR1 expression levels (0), with the point at the 
origin representing the negative control sample with no primary antibody. The mean 
fluorescence intensity of six unknown samples is read off the standard curve to 
determine the number of CR1 molecules per cell (dotted lines). The mean CR1 
expression levels of the six unknown samples were therefore determined as 448, 727, 
796, 814, 894 and 967 molecules per cell. 
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2.2 Preservation of erythrocyteS for flow cytometry and 
parasite culture 
2.2.1 Preservation of erythrocytes or Plasmodium falciparum cultures by 
freezing in glycerol 
To prepare uninfected erythrocytes or erythrocytes infected with early ring-stage 
trophozoites the following protocol was used. 5 volumes of glycerolyte (42.25 % w/v 
glycerol, 0.1 M sodium lactate, 4 mM potassium chloride, 0.1 M sodium dihydrogen 
phosphate adjusted to pH 6.8) were added drop-wise to 3 volumes of erythrocytes. After 
the first volume had been added the cells were allowed to osmotically equilibrate for 5 
minutes before the remainder of the solution was added. The samples were frozen 
overnight at —70 °C before cryopreservatiofl in liquid nitrogen. To use the cells for 
subsequent experiments or parasite culture cryopreserved cells were thawed at 37 °C and 
200 p1 of 12 % NaCl solution was added slowly and drop-wise to each sample. The cells 
were allowed to osmotically equilibrate for 5 minutes before a further drop-wise addition 
of 10 ml of 1.8 % NaCl followed by lOmi of 0.9 % NaCl, 0.2% glucose solution. The 
cells were washed in twice incomplete RPMI1640 (iRPMI; RPMI 1640 medium with 
sodium bicarbonate (Invitrogen, Paisley, UK), supplemented with 2 mM L-glutamine, 25 
mM HEPES, 20 mM D-glucose and 25 pg/m1 gentamicin). 
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2.2.2 Preservation in 5 % formaldehyde(Bianco et al. 1986) 
Erythrocytes were first washed three times in iRPMI. 50 p1 of whole blood was 
resuspended at 4 % haematocrit in complete RPMI-ABS (as incomplete RPM! but with 
the addition of 10 % ABS) and an equal volume of fixative solution (10 % w/v 
formaldehyde, 4 % w/v glucose in Tris-saline (10 mM Tris, 150 mM NaCl, 10 mM 
sodium azide adjusted to pH 7.3)) was added. Cells could then be left at 4 °C until 
needed. In order to be used for flow cytometry the cells were spun down and washed 
three times in incomplete RPMI prior to the primary antibody incubation. 
2.2.3 Preservation in 0.25 % glutaraldehyde 
Erythrocytes washed thrice in iRPMI were resuspended in 0.025 % (vlv) glutaraldehyde 
in PBS at 2 % haematocrit for 20 minutes before being washed in PBS and resuspended 
at 50 % haematocrit in PBS supplemented with 1% BSA. In order to be used for flow 
cytometry the cells were spun down and washed three times in incomplete RPM! prior to 
the primary antibody incubation. 
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2.3 Polymerase chain reaction (PCR) and restriction fragment 
length polymorphism (RFLP) genotyping of samples 
2.3.1 Basic polymerase chain reaction (PCR) proceedure 
Polymorphic sites in the CR1 gene were detected by amplifying the surrounding region 
by polymerase chain reactions (PCR) of genomic DNA and cleaving the product with a 
restriction enzyme, which is specific for a site altered by the polymorphism. ct -
thalassaemia, Southeast Asian ovalocytosis and Gerbich blood grouping which are 
caused by deletions in the a-globin, band -3 and glycophorin C genes respectively were 
detected by PCR alone, with primers amplifying in or around the area of the deletion. All 
PCRs were performed using genomic DNA extracted from whole blood or white cells on 
the day of receipt (usually 1 day after drawing) using the BACC-2 nucleon test kit 
according to the manufacturers instructions (Amersham Pharmacia, Uppsala, Sweden). 
PCR reactions were performed on 100 ng to lj.ig DNA in lx PCR buffer (10 mlvi Tris-
HC1, 50 mM KC1 and 0.1 % Triton X-100), 1.5 - 2.5 mlvi MgC12 (depending on reaction - 
see relevant section), 0.2 mM of each dNTP (Roche, Lewes, UK), 0.5 pmollpi of each 
primer and either 0.1 U/jil Taq polymerase (Promega, Southampton, UK) for the Intron 
27 PCR reaction or 0.04 U/x1 Taq polymerase for the other PCR reactions. Total reaction 
volumes were 50 tl or 20 jil. 
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Table 2.1: PCR primers and conditions used; restriction endonucleases 






Allele Fragment Sizes 
Exon22 F: 5-TrCACATTGGATAGCCCAGAGC-3 63 Rsal H 520,162 
R: 5-CCAGAGGUAATCTCCCTGGA-3' L 458,162,62 
Intron27 F: 5'-CAGCAGGAGGCCCAACTTCTGACCC-3' 54 HindlIl H 1600,84 
R: 5-CCCTTGTAAGGCAAGTCTGG-3 L 1150,465,84 
Exon33 F: 5-AAGCGCACAGTCACAGGTCAC-3' 59 Mnhl H 11180,37,33,33,11 
R: 5-GAACAGAAAGTTCACAGCGAGG-3' L 111,80,70,33,11 
Knops blood F: 5-TGAGCCACCTCCAACCATAT-3 55 Mfel SI 1 386 
groups R: 5-TGGAGCCGTGTGGCAGCTTG-3 S12 239,147 
Bsm 1 McCa 386 
McC° 210,170 
a-thalassemia a2/3.7F: 5-CCCCTCGCCAAGTCCACCC-3 60 N/A normal 1800 
3.7/20.5R: 5-AAAGCACTCTAGGGTCCAGCG-3 -a 	mutation 1628 
a2-R: 5'-AGACCAGGAAGGGCCGGTG-3 mutation 2022/2029 
4.2F:5'-GGTTTACCCATGTGGTGCCTC-3 
4.2-R:5-CCCGTTGGATCTTCTCATTTCCC-3 
ovalocytosis F: 5-GGGCCCAGATGACCCTCTGC-3 70 N/A normal 175 
R: 5'-GCCGAAGGGGTGATGGCGGGTG-3' ovalocytosis 148 
Gerbich blood GPCup 5-CAGATTCTTGTCCTCTGTTCACAG-3 60 N/A normal 240,264 
group GPCdn 5-TCAAAACCACCTTCGAGGGAGAG3' GPCex3 264 
Cycling conditions were 2 minutes at 95 °C for the hot start at which point the 
polymerase would be added having been left out of the original reaction mixture, 
followed by 35 cycles of 15 seconds at 95 °C (melting phase), 15 sec at the annealing 
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temperature(see table 2.1) and an extension phase of 72 °C for 1 minute per kb of 
expected product. Details of specific primers, cycling conditions and subsequent 
restriction digests are given above (Table 2.1) and in the relevant section. 
2.3.2 CR1 expression associated polymorphisms 
Exon 22, intron 27 and exon 33 polymorphisms (see section 1.6 for an explanation of 
polymorphisms in the CR1 gene) were determined by PCR followed by restriction digest 
according to the method of Xiang et al.(Xiang et al. 1999). For the population survey 
(Chapter 4) PCR was carried out using the basic PCR reaction outlined in section 2.3.1. 
in a volume of 50 tl. Primers and cycling conditions are outlined in Table 2.1. For 
samples from the case-control study (Chapter 5) a modification of this procedure was 
used. The template used was a primer extension preamplification (PEP) PCR product. 
The PEP procedure is a "whole genome" PCR reaction that allows large amount of PCR 
template to be produced from small amounts of genomic DNA(Zhang et al. 1992). The 
reactions were performed in 20 p1 volumes on 96 well PCR plates. A thermostable Taq 
polymerase was used (Platinum Taq, Invitrogen, Paisley, UK) with its associated buffer. 
An initial incubation at 95 °C for 2 minutes was added at the beginning of the usual 
cycling to activate the polymerase. 
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Restriction digests were performed to determine the genotype of the samples at three 
linked polymorphisms in the CR1 molecule. For exon 22 RsaI (Promega Southampton, 
UK), was used, for intron 27 HindIll (Promega, Southampton, UK) was used and for 
exon 33 MnlI (New England Biolabs, Beverly, MA). In each case 5 U of enzyme was 
added to 1 tl of lOx the appropriate restriction enzyme buffer (as supplied by the 
manufacturer with the enzyme) and 0.1 il bovine serum albumin (BSA), total reaction 
volume was made up to 10 R1 with the PCR product (typically 10-100 ng) and deionised 
water. Samples were incubated at 37 °C for 5 hours before the reactions were stopped by 
cooling to 4 °C. Products were run on 2% agarose gel to determine fragment sizes, the 
expected fragment sizes for each polymorphism are given in table 2.1. 
2.3.3 Knops blood group genotyping 
The genotypes that determine the Knops blood groups in CR! were determined by PCR 
of a region of SCR24 and SCR25 (both in one exon) that contains both the 
polymorphisms associated with both the Sl 2 and M cCb mutations. Primers for the 
reaction are given in table 2.1. The basic reaction given in 2.3.1 was used with an MgC1 2 
concentration of 1.5 mM. To distinguish the Si 2 genotype from Si 1 digestion with MfeI 
(New England Biolabs, Beverly, MA) was performed as follows 5 U of enzyme were 
added to 10 p1 PCR product, 2 p1 lOx buffer, made up to 20 p.1 with dH 20, and incubated 
as in section 2.3.2. To distinguish the McC" and McCb alleles 5 U of BsmI (New England 
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Biolabs, Beverly, MA) was used instead of MfeI. Expected fragment sizes for both 
typings are given in table 2.1. 
2.3.4 Ovalocytosis genotyping 
Genotyping for the deletion in the band-3 gene associated with Southeast Asian 
ovalocytosis was carried out according to the method of Jarolim et al.(Jarolim et al. 
1991). This PCR amplifies a region of genomic DNA around the 27bp deletion that 
causes the ovalocytosis phenotype therefore heterozygotes for this gene will have an 
additional small 148 bp fragment in addition to the normal 175 bp fragment. The 
homozygous state for this condition has never been observed and is presumably lethal in-
utero. The basic PCR reaction was used (Section 2.3.1) with 2.5 mM MgC12 ; primers and 
conditions are given in table 2.1. 
2.3.5 a-thalassaemia genotyping 
cC-thalassaemia genotyping was carried out according to the method of Chong et 
al.(Chong et al. 2000). Only the -a 37 and -0 42  deletions were typed as these are the most 
common in coastal Papua New Guinea(Flint et al. 1998). This uses a multiplex PCR to 
amplify different PCR products depending on the chromosomal structure around the a-
globin locus. A different reaction mixture was used from the basic mixture given in 
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section 2.3.1. The MgC12 concentration was 1.5mM, in addition dimethyl suiphoxide 
(DMSO) was added to the reaction mixture at a final concentration of 5% while betaine 
was added to a final concentration of 1M. DMSO prevents non specific amplification in 
multiplex PCR reactions, while betaine stabilises primer annealing for GC rich 
sequences(Chakrabarti et al. 2002). Each of the primers was used at a final concentration 
of 0.4 pmoLlpi; primer sequences and cycling conditions are given in table 2.1. 
2.3.6 Gerbich blood group genotyping 
The Gerbich blood group phenotype is caused by the deletion of exon 3 from the 
glycophorin C gene. To determine if an individual is homozygous for this deletion we 
used a PCR strategy using genomic DNA as described by Patel et al(Patel et al. 2001). 
They use a primer pair that recognises sequences in both exon 2 and exon 3 amplifying 
different sized products from each (264 bp and 240 bp respectively) absence of an exon 3 
(240bp) product signifies homozygosity for the exon 3 deletion and Gerbich phenotype. 
This protocol gives no way of distinguishing glycophorin C A exon 3 heterozygotes from 
normal individuals. 
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2.4 Determination of CR1 allotypes 
2.4.1 Preparation of solubilized red blood cell membranes 
Red blood cell membranes were prepared by adding imi of hypotonic lysis solution (5 
mM Na2HPO4 with the following protease inhibitors: 0.348 mg/ml 
phenylmethanesulfonyl fluoride (PMSF), 1.16 pg/ml ethylene diaminetetracetic acid 
(EDTA), 0.686 tg/ml pepstatin A and 3.7 tg/m1 iodoacetamide) to 0.4 ml RBC. This 
was centrifuged at 13000 g for 10 minutes at 4 °C and the supernatant removed. The 
process was repeated approximately 4 times until all of the red colour due to 
haemoglobin had been removed. 
2.4.2 SDS-PAGE; Western Blotting 
2 pJ of ghosts per sample were taken and added to 4x loading buffer (4.36 M Glycerol, 
564 mM Tris base, 424 mM Tris HC1, 292 mM lithium dodecyl sulfate (LDS), 2.04 mM 
EDTA, 0.88 mM Serva Blue, 0.7 mM Phenol Red), adjusted to lx with distilled water 
and heated to 70 °C for 10 mins before being loaded onto a prepoured 3-8 % NuPAGE 
tris acetate gel (Invitrogen, Paisley, UK) and run at 150 V in running buffer (0.05 M 
Tricine, 0.05 M Tris Base, 3.5 mM sodium dodecyl sulfate (SDS)). The gel was then 
blotted onto a nitrocellulose membrane according to the manufacturers instructions 
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(Invitrogen, Paisley, UK). Briefly the gel and membrane were sandwiched between 
blotting paper and sponge pads held in a blotting module consisting of cathode and anode 
plates and saturated with transfer buffer (10 % methanol, 25 mTvI Bicine, 25 mM Bis-
Tris, 1 mM EDTA), the blot was maintained at 30V for an hour whereupon the blot was 
retained for probing and the gel discarded. Blots were blocked with 5 % powdered milk 
solution in PBS-Tween (0.1 % Tween20 diluted in PBS) for an hour, they were then 
totally immersed in a petri dish with 0.5 j..tg/ml Eli anti-CR 1 mAb in PBS Tween for an 
hour. The blot was then washed for 15 minutes in PBS-Tween, 5 further minutes in fresh 
PBS-Tween, 5 minutes in 5 % blocking solution prepared as above, and 5 more minutes 
in PBS-Tween. The blot was then immersed in 5 pg/ml horseradish peroxidase (HRP)-
conjugated Goat anti Mouse Ig antibody (Dako, Kidlington, UK) in PBS-Tween, for 1 
hour and then washed as above before being exposed using an enhanced 
chemiluminescence system (Amersham Pharmacia, Uppsala, Sweden) according to the 
manufacturers instructions. Both short and long exposures were developed. 
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Figure 2.2 







Figure 2.2: CR1 allotype determination. Western blot erythrocyte ghosts from New 
Ireland probed with the El 1 antibody to identify CR1 allotypes. All samples are 
homozygous for the CR1 *1  allotype (190 kDa) except for samples 17 and 20 which are 
heterozygotes for the CR1 *1  and CR1 *3  allotype (160 kDa). Numbers on the left are the 
sizes of protein markers (in kDa). 
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2.5 Glucose-6-phosphate dehydrogenase activity assay 
To assay for glucose-6-phsophate dehydrogenase (G6PD) activity we used a commercial 
test (Sigma procedure no. 400, Sigma Diagnostics, Poole, UK). The natural enzyme 
activity of G6PD catalyses the conversion of glucose-6-phosphate to 6-phosphogluconate 
with the reduction of nicotinamide adenine phosphate (NADP) to NADPH. NADPH can 
reduce a blue dye (dichlorophenol indophenol) in the presence of phenazine 
methosuiphate (PMS), to form NADP and a colourless dye complex. 
To prepare a red cell haemolysate 50 p1 of blood is added to water. The amount of water 
depends on the haemoglobin (Hb) concentration of the sample. For PNG samples from 
healthy individuals we assumed an Hb concentration of 12 g/dl so blood was lysed in 2 
ml of distilled water, whereas for Europeans we assumed an Hb concentration of 15 g/dl 
and blood was lysed in 2.5 ml distilled water. The mixture was allowed to stand for 
minutes at room temperature. The substrate solution in a "single determination vial" was 
reconstituted with 1 ml of Trizma buffer solution andi ml of lysate was then added to the 
vial and 2m1 of Mineral Oil layered over the top of the reaction mixture. The vial was 
then placed in a 37 °C water bath and observed at 10 minute intervals to determine the 
reaction endpoint (the colour should have changed to reddish brown). If the reaction time 
was greater than 60 minutes the sample was considered G6PD deficient. Control samples 
from Caucasians were used as positive controls (with normal G6PD activity) while a 
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commercial standard deficient preparation was used as a negative control, this was 
treated in the same way as a normal blood sample. 
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2.6 Direct anti-globulin test for ABO typing 
ABO typing was performed by the method of slide agglutination. Briefly two drops of 
blood of —20 pJ each were dropped on either end of a normal microscope slide. To one 
drop was added a drop of anti-A serotyping reagent (Diagnostics Scotland, Edinburgh, 
UK) and to the other a drop of anti-B serotyping reagent (Diagnostics Scotland, 
Edinburgh, UK). Agglutination of the blood was detected by eye and could be seen as 
clumping of the red cells. If the blood was agglutinated by the anti-A reagent alone the 
sample was A, likewise if the blood was agglutinated with the anti-B reagent. If both 
reagents gave positive tests the sample was AB, and if neither agglutinated the samples 
the sample was 0. 
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2.7 Parasite culture methods 
2.7.1 Medium and Red cells 
Parasites were growth in complete RPMI (cRPMI), while incomplete RPMI (iRPMI - see 
section 2.2.1) was used for washing parasites. To make cRPMI 10% normal pooled 
human serum, (all ABO types permissible - Scottish Blood Transfusion Service, 
Edinburgh, UK) was added to iRPMI. 
Parasites were cultivated in 0 blood group red blood cells, which were either provided by 
the local blood transfusion service (Scottish Blood Transfusion Service, Edinburgh, UK) 
or from local donors. In either case the blood was treated the same. 10 ml of blood was 
layered over lymphocyte separation medium (Bio-Whittaker, Walkersville, MD) and 
spun at 1800 g on a bench top centrifuge. Lymphocyte separation medium separates the 
red blood cells, which spin to the bottom of the tube from the peripheral blood 
mononuclear cells (PBMC5), which are suspended in the layer of lymphocyte separation 
medium and the plasma, which forms the top of the supernatant. The blood was then 
washed twice in iRPMI (by resuspending in iRPMI and spinning down for 5 mins at 1800 
g). Before being resuspended at 50 % haematocrit and stored at 4 °C until use. 
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2.7.2 Parasites 
Parasites in this study are of three varieties: i. "strains" or "lines" are named and defined 
parasite cultures maintained in vitro, ii. "clones" are populations derived from a single 
cell and iii. "isolates" are samples taken from patients infected with P. falciparum. 
Parasite cultures used in this work are: 
R29 a rosetting clone derived from the ITOR strain (originally from 
Brazil)(Roberts et al. 1992) 
TM284 a rosetting line derived from a Thai patient with severe malaria.(Carlson 
etal. 1992) 
Palo Alto R+ (PAR+) is a rosetting clone isolated from a Ugandan strain: Palo 
Alto(Helmby et al. 1993). PAR+ is also known as FCR3S in some 
publications(Chen et al. 1998). 
It should be noted that despite these presumed different origins of these parasites 
extensive RFLP analysis of these strains especially around the chioroquine resistance 
locus has shown that both PAR+ and R29+ are descended from the FCR3 line originally 
isolated by Trager in 1976(Trager et al. 1976). The misattribution of these lines is 
probably a result of laboratory contamination (D. Wallilcer, personal communication). 
TM284+ is however genetically distinct. 
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2.7.3 Culture procedures 
Parasites were grown under low oxygen tension using modifications of the method of 
Trager and Jensen(Trager et al. 1976). All procedures were carried out in laminar flow 
hood using aseptic techniques and the plastics used in the handling of parasites or human 
blood products were decontaminated by rinsing in 1% virkon (Alpha Labs, Eastleigh, 
UK). 
Cultures were maintained at 2-5% parasitaemia in human group 0 erythrocytes in 
cRPMI. Flasks were incubated at 37 °C under an atmosphere of 96 % nitrogen, 3 % 
carbon dioxide and 1 % oxygen. Fresh red cells were added approximately every 48 
hours, depending on parasitaemia. The packed cell volume of red cells was 
approximately 2 % haematocrit; i.e. 200 p.1 of red cells would be maintained in 10 ml of 
media. Typically laboratory parasite lines such as those used in this study would give 5-
fold reinvasion in a 48 cycle, thus cultures would typically have to be diluted 1 in 5 with 
fresh blood every 2 days to maintain constant parasitaemia. 
Maturity of cultures was assessed using Giemsa stained thin films. A small aliquot 
(typically 200 p.1) of culture would be and spun down by brief spinning in a microfuge. 
The supernatant would be removed, leaving enough media to resuspend the cells at 40% 
haematocrit. 5-10 p.1 would be used to make the smear and the slide would be dried with 
a hair dryer. The smear would be fixed by brief emersion in methanol and then stained 
ray. 
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with freshly prepared Giemsa. Giemsa is prepared with 10% Giemsa staining solution 
(BDH, Poole, UK) in Giemsa buffer (BDH, Poole, UK) 
2.7.4 Freezing and thawing parasites 
To allow for the long term storage and transport of parasites, parasites are stored frozen 
in liquid nitrogen. The same techniques are used as for the storage of red blood cell 
samples (see Section 2.2.1). 
2.7.5 Synchronising parasites(LambrOs et al. 1979) 
Synchronous cultures of parasites are required for experimental work. Only parasites 
older than 20 hours post-invasion are permeable to sorbitol. They can therefore be lysed 
(by osmotic lysis), leaving younger ring forms and uninfected erythrocytes. 
Parasite cultures are spun down (2 mins 1000 g) and the medium (supernatant) removed. 
The culture is then incubated in 5 % D-sorbitol (made up in distilled water and 
autoclaved) and incubated at 37 °C for 15 mins, before being washed twice in 10 ml 
iRPMI. Once the cells are washed the culture may be resuspended in cRPMI and gassed 
and incubated as usual. 
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2.8 Rosetting protocols 
2.8.1 Measuring the rosetting frequency 
An aliquot of parasite culture adjusted to 2 % haematocrit was stained by adding 
ethidium bromide to a final concentration of 20 tg/ml (1 t1 of a 1 mg/mi solution in 50 
tl of culture suspension). 10 t1 of this suspension was placed on clean glass slide and 
covered with a 22 mm x 22 mm coverslip that had previously had the edges sealed with 
Vaseline. Slides were blinded before counting in experiments where several slides were 
analysed, and then viewed on an epifluorescence microscope using a combination of 
fluorescence and bright field. The illumination was adjusted so that ethidium bromide 
stained infected erythrocytes and unstained uninfected erythrocytes could be viewed 
simultaneously. At least 200 infected cells were counted and assessed for rosetting, with 
the binding of two or more uninfected erythrocytes constituting a rosette. The rosetting 
frequency is the percentage of mature (pigmented trophozoite) infected erythrocytes 
forming rosettes. 
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2.8.2 Enrichment of cultures for rosetting parasites 
Enrichment for rosetting was performed by two methods, one for knob+ parasites such as 
TM284+ and R29+ and the other for knob- parasites such as PAR+. 
For knob+ parasite the parasitçs in culture medium were spun down and the supernatant 
removed, the parasites were then resuspended in 1 volume of iRPMI and then mixed with 
2 volumes of gelofusine (Milipledge, Clarborough, UK). The tube would be incubated for 
15 minutes at 37 °C in which time the contents would separate into two layers. The top 
layer contained non-rosetting knob+ parasites, while the bottom layer would contain 
rosetting trophozoites, ring stage parasites, and uninfected erythrocytes. To enrich for 
rosetting parasites the bottom layer would be retained and washed twice in iRPMI before 
being returned to culture in cRPMI. 
For PAR+, which is knob-, a different technique was used. Parasite cultures would be 
spun down and resuspended in 5m1 of fresh cRPMI. This parasite suspension would be 
layered over a layer of 60 % percoll. Percoll solutions of a given concentration would be 
made by diluting 90 % percoll stock (90 ml percoll, 10 ml lOx RPMI made up from 
powdered RPMI with L-Glutamine according to the manufacturers instructions 
(Invitrogen, Paisley, UK)) with the appropriate amount of iRPMI. Having layered the 
parasites over the percoll the tube would be spun at 1800 g in a bench-top centrifuge for 
01 
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10 minutes. Rosetting trophozoites, and uninfected erythrocytes would be spun down to a 
pellet at the bottom of the tube while a non-rosetting trophozoite layer would be 
suspended above this. To select for rosetting parasites the pellet would be retained 
washed in iRPMI and returned to culture in cRPMI. 
2.8.3 Labelling erythrocytes with 5-carboxyfluorescein diacetate (c-FDA) 
To label 10 tl of packed erythrocytes with c-FDA, a stock solution of 15 mg/mi c-FDA 
in PBS should be diluted 50x in cRPMI-ABS to make the labelling solution (300 
pg/ml). 1 ml c-FDA labelling solution was incubated with 10 tl of packed cells for 30-45 
minutes at 37 °C. The cells were then washed four times in iRPMI and resuspended in 
200 p.1 cRPMI-ABS. 
2.8.4 Assessment of rosette formation and competition with c-FDA-
labelled RBC(Carlson et al. 1992) 
To assess the capacity of red cells from a given donor to form rosettes we used a 
competition assay in which "test" cells labelled with c-FDA competed to form rosettes 
against control cells in which the culture was grown. For our experiments the control 
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cells were 0+ erythrocytes from a single donor with a CR1 expression of 996 molecules 
per cell. 
Cultures of rosetting parasites grown in control cell by normal means would be spun 
down and resuspended at 5 % haematocrit in cRPMI-ABS. Existing rosettes were 
disrupted by addition of heparin. The amount of heparin depended upon the strain used 
from 100 ig/m1 for PAR+ and R29 to 1mg/mi for TM284+ as the sensitivity of rosettes 
to heparin varies(Rowe et al. 1994). The cultures were checked as above (Section 2.8.1) 
that the disruption was complete. 10 tl of packed cells were added to 10 p1 of test cells 
labelled as in section 2.8.2. The mixture was washed three times to remove heparin and 
resuspended in binding medium with 10 % AB serum. Binding medium is similar to 
iRPMI but made with powdered RPMI (Invitrogen, Paisley, UK) without the addition of 
sodium bicarbonate, it is less sensitive changes in the oxygen tension than normal iRPMI 
so can be used for short periods where the cultures are not gassed. The mixture of test 
cells is left under agitation for 1 hour to allow rosettes to reform. The samples then had 
ethidium bromide added and slides were prepared as above. The slides were viewed 
under UV light with a green filter. 100 cells in rosettes were counted and scored as green 
or unstained. This proportion was divided by the ratio of stained to unstained cells in the 
mixture as a whole (from at least 200 counted cells) to give a "rosetting quotient". 
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2.8.5 Rosette reversal by mAbs and polyclonal Abs in laboratory strains 
and field isolates(Rowe et al. 2000) 
To try an qualitatively dissect the contributions of different rosetting receptors in a robust 
assay that could be used in a field setting we used a panel of antibodies that interact with 
different previously identified rosetting receptors to disrupt rosettes. 
20 jfl aliquots of parasite culture were spun down and resuspended in binding medium 
with AB serum and reagents were added to the correct final concentration. J3B 11 (a gift 
of J. Cohen (University of Reims, Reims, France) was added to a final concentration of 1 
tg/m1. J3B 11 an antibody specific for the C3b binding sites in CR1 has been previously 
shown to disrupt rosettes in lab strains and field isolates(Rowe et al. 2000). Disruption 
was compared to results with an IgGi isotype control at the same final concentration 
(Serotec, Oxford, UK). A rabbit polyclonal to human immunoglobulins A, G and M 
(Dako, Kidlington, UK) has been shown to disrupt rosettes in strains such as 
PAR+(Rowe et al. 2000) in which immunoglobulins play a large role in rosetting 
adhesion interactions(Somner et al. 2000). This antibody was used diluted 1/50 in 
binding medium, rabbit serum at the same final immunoglobulin concentration (1/100 
dilution) was used as a negative control. Heparin has also been shown to disrupt 
rosettes(Rowe et al. 1994), though it is unclear whether it is a rosetting receptor(Barragan 
et al. 2000). This was added to a final concentration of 100 tg/m1. The samples were 
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incubated in the reagents for 1 hour at 37 °C before the rosetting frequency was counted 
by the usual means (section 2.8.1). 
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2.9 ImmunofluoreSCenCe assay (IFA) for the detection of 
human Igs on erythrocytes(ROWe et al. 2002) 
The immunofluorescence assay (IFA) to detect human immunoglobulin on the surface of 
iRBCs was carried out with unfixed parasite cultures at the mature pigmented trophozoite 
stage. Only monoclonal antibodies and immunoglobulin free BSA were used to prevent 
cross reactivity of reagents. Aliquots of culture suspension at 2 % haematocrit were 
washed once in 750 p1 cold PBS then in 750 p1 of cold PBS-i % Immunoglobulin free-
BSA (PBS-i% BSA). Mouse mAbs to human 1gM (Serotec, Oxford, UK) and an isotype 
control (Mouse IgGi (Serotec, Oxford, UK) were then incubated at a final concentration 
of 1 pg/m1 in 50ml of PBS-BSA for 1 hour on ice with regular agitation. An anti CR1 
mAb (7G8 (a gift from R. Taylor, University of Virginia School of Medicine, 
Charlottesville, VA) at the same concentration was used as a positive control for the 
detection of molecule associated with the red cell surface. 
Following the incubation in primary antibody the cells were washed twice in 750 ml cold 
PBS and incubated for 45 minutes on ice in 50 ml of PBS-i% BSA with the highly cross 
absorbed Alexa Flour 488-conjugated goat anti-mouse IgG (Molecular Probes, Leiden, 
The Netherlands) at a 1:200 dilution and 1 pg/m1 4',6'-diamidino-2-phenylindOle (DAPI). 
After washing firstly in 750 ml cold PBS and then in 750 ml PBS-1% BSA the cells were 
resuspended at 30 % haematocrit in PBS-i% BSA and then used to make a smear on a 
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clean microscope slide. After air drying the smear was fixed briefly with methanol and 
then dried. The smear was then overlaid with 15 ml of vectashield mountant( Vector 
Laboratories, Peterborough, UK) and a coverslip (22 mm x 22 mm). The edges of the 
coverslip were sealed with nail varnish. Slides were viewed with an Olympus BX-50 
microscope and images recorded with a digital camera and OpenLab software. The 
percentage of iRBCs binding 1gM was determined by counting at least 200 infected cells. 
Figure 2.3 
Figure 2.3 IgM binding of rosetting parasites: the figure shows three multinucelate 
parasites (schizonts) detected with DAPI staining, the top parasite is binding 1gM as 
detected by mouse mAb to 1gM and Alexa Fluor 488TM  conjugated goat anti mouse lgG. 
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2.10 Statistical analysis 
Details of statistical procedures are given in each results chapter. Unless otherwise stated 
statistics were calculated using StatView (SAS Institute, Cary, NC). 
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Chapter 3: 
A simple method for accurate quantification of 
complement receptor 1 on erythrocytes preserved by 
fixing or freezing 2 
3.1 Introduction 
Before we can study erythrocyte complement receptor 1 (CR1) in populations in Papua 
New Guinea we need a suitable assay for determining the mean CR1 expression per cell. 
2  These results are published as Cockburn et al. 2002 (see Appendix) 
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When drawing blood from children only small blood volumes are available, on which a 
variety of assays must be performed. Additionally the loss of CR1 on storage of 
blood(Pascual et al. 1993) means that the assay must either be performed immediately or 
the cells must be preserved such that the assay can be performed later. Several methods 
currently exist to quantify the mean number of CR1 molecules per erythrocyte including 
an ELISA method and a flow cytometry method(Cohen et al. 1999). Both methods give 
equivalent results however we prefer to use the flow cytometry technique as only small 
quantities of blood are required. Nonetheless the technique has previously only been 
validated for fresh blood samples(Cohen et al. 1987). Erythrocyte CR1 loss during 
sample storage, though, would be a problem when working in field areas for malaria 
where facilities for flow cytometry are rarely available. We therefore tested a variety of 
methods for erythrocyte preservation in order to accurately determine the CR1 expression 
level on erythrocytes after storage. 
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3.2 Results 
3.2.1 Erythrocytes from healthy donors fixed in 5% formaldehyde and 
frozen in glycerol can be used for CR1 determinations. 
To determine if we could quantify CR1 expression using healthy preserved erythrocytes 
we perfomed the following experiment. We drew blood into Vacutainers containing 
0.12ml of 15% EDTA (BD Vacutainer systems, Plymouth, UK) from five individuals 
with known CR! expression. These individuals are used as standards in our laboratory 
and have had their CR1 levels determined by flow cytometry compared to a standard 
curve based on individuals who have had their CR! expression level determined by 
Scatchard analysis using 1251  labelled mAb(Cohen et al. 1987). We also drew blood from 
six healthy individuals of unknown CR1 expression and determined their CR1 expression 
by flow cytometry when fresh (see section 2.1). Aliquots of all 11 samples (standards and 
test samples) were preserved in four different ways (described in 2.2). The first was 
simply left in the EDTA vacutainer (EDTA), the second was fixed in 0.25% 
glutaraldehye(Pattanapanyasat et al. 1993), the third was fixed in 5% formaldehyde as 
outlined by Bianco et al.(Bianco et al. 1986) and the final aliquot was frozen in 
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Figure 3.1: CR1 expression levels determined after preservation of healthy erythrocytes 
compared to CR1 levels determined on fresh erythrocytes. a erythrocytes stored in 5% 
formaldehyde at 4°C for 8 weeks. b erythrocytes stored in EDTA at 4°C for 6 weeks. c 
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erythrocytes cryopreserved in liquid nitrogen for 8 weeks. The CR1 expression levels of 
the six test samples determined by comparison to freshly drawn (absolute) standards 
are shown as black squares (•), whereas the CR1 expression levels of the six test 
samples determined by comparison to preserved (relative) standards are shown as 
white squares (0). The relationship between the CR1 levels measured on preserved 
cells compared to fresh cells was analysed by linear regression. The regression line for 
relative standards is given and a dashed line while a solid line is the regression line for 
the data derived with absolute standards. Equations are given at the top of each graph. 
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frozen samples underwent flow cytometry to assess erythrocyte CR1 expression. To 
determine the optimum method of measuring CR1 levels on stored cells we assessed 
them in two ways. Firstly we compared them to a standard curve derived from freshly 
drawn standards at each time point (absolute standards) and secondly, we compared them 
to a standard curve derived from the standards at each time point that had been drawn and 
preserved in an identical way to the test samples at the start of the experiment (relative 
standards). 
For each of the six healthy test samples, the CR1 level measured on the preserved cells 
using both absolute and relative standards was compared to the CR1 level of the samples 
when freshly drawn, and the data were analysed by linear regression. The best results 
were obtained with the samples fixed in 5% formaldehyde. Comparison to relative 
standards gave accurate results throughout the 8 weeks of the experiment (Table 3.1 and 
Figure 3.1a white squares), whereas comparison to absolute standards was accurate up to 
4 weeks after the blood was drawn, but thereafter gave an underestimate of true CR1 
numbers (Table 3.1 and Figure 3.1a, black squares). Preservation in EDTA also gave 
good results providing the test samples were compared to relative standards (Figure 3.1 b, 
white squares). This was true up to 6 weeks from the date of drawing (Figure 3.1b), after 
which time, the extent of haemolysis of the samples became too great for further use. 
When absolute standards were used to assess the CR1 level of EDTA-preserved cells, this 
was accurate up to two weeks after the blood was drawn, and thereafter resulted in an 
underestimation of the number of CR1 molecules per cell (Figure 3.1b, black squares). 
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Fixation of erythrocytes in 0.25% glutaraldehyde resulted in high background 
fluorescence of all samples and made the forming of a standard curve impossible (data 
not shown), therefore this method was not suitable for CR1 quantification. Preservation 
of erythrocytes by freezing in glycerol gave accurate results when relative standards were 
used (Figure 3. ic, white squares), and this was true throughout the course of the 
experiment. The use of absolute standards gave good results at some time points (eg 
week 8, Figure 3.1c, black squares), however, at earlier time points the use of absolute 
standards gave widely varying estimates of CR1 numbers, therefore we would not 
recommend the use of absolute standards with frozen cells. 
Table 3.1 Assessment of CR1 expression level over the course of 8 weeks 
on erythrocytes fixed with 5% formaldehyde 
- 
448 
No. of CR1 molecules 
727 	796 	814 
per cell when fresh 
894 	967 
CR1 measured using absolute standards 
Week 1 425 719 816 826 929 1072 
Week 2 421 860 886 1064 1308 1173 
Week 4 436 740 804 833 889 1014 
Week 6 294 529 585 606 632 746 
Week 8 350 575 645 690 760 788 
CR1 measured using relative standards 
Week 1 427 757 865 877 993 1152 
Week 2 355 732 754 907 1117 1001 
Week 4 442 760 826 856 915 1045 
Week 6 408 753 835 866 904 1071 
Week 8 406 682 769 824 909 944 
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3.2.2 Erythrocytes from systemic lupus erythematosus (SLE) patients 
can also be preserved for flow cytometry 
Having determined the efficacy of freezing and fixing in 5% formaldehyde for preserving 
healthy erythrocytes we set out to verify these techniques with erythrocytes from patients 
with a disease known to affect CR1 level on erythrocytes such as systemic lupus 
erythematosus (SLE)(Ross et al. 1985; Jouvin et al. 1986; Wilson et al. 1987). 
Accordingly we repeated the experiment using the same CR1 standard donors and 
unknown test samples from 7 French SLE outpatients. On this occasion we preserved the 
cells only by fixing in 5% formaldehyde and freezing and assessed the CR1 expression 
with relative and absolute standards at 4 and 8 weeks only. 
The repeated experiment using samples from donors with a disease in which CR1 levels 
are affected (SLE) confirmed that fixing in 5% formaldehyde and freezing give good 
results with relative standards are used (Figure 3.2 a and b, white squares). Systematic 
underestimation of CR1 expression is observed when fixed samples are used with 
absolute standards (Figure 3.2a, black squares). However fair determinations of CR1 
expression are also possible using absolute standards and frozen cells (Figure 3.2b, black 
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possible. Crucially both techniques worked well with samples showing low (<100 
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Figure 3.2: CR1 expression levels determined after preservation of erythrocytes from 
SLE outpatients compared to CR1 levels determined on fresh SLE erythrocytes. a 
erythrocytes stored in 5% formaldehyde at 4°C for 8 weeks. b Erythrocytes 
cryopreserved in liquid nitrogen for 8 weeks. Legend and analysis as in Figure. 3.1. 
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3.3 Discussion 
We have therefore shown that accurate CR1 quantification may be performed after 
preservation of either diseased or healthy erythrocytes using either a freezing technique 
or fixation in 5% formaldehyde, providing that the CR! expression level standards are 
collected and fixed in an identical fashion. Cryopreservation of erythrocytes in glycerol 
is reliable and allows for potentially long-term storage of samples, but does require liquid 
nitrogen for freezing and transportation of cells, which may not always be available 
during field studies. Fixation of erythrocytes in 5% formaldehyde is quick and 
economical and gives an accurate determination of CR1 level for at least 2 months after 
sample collection. A summary of the advantages of each method is given in Table 3.2. 
These methods will facilitate further studies of CR1 expression level and disease 
susceptibility in areas lacking facilities for flow cytometry. 
MIN.  
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Table 3.2 Comparison of methods for the preservation of samples for CR1 
level determination 
Preservation 	Maximum time of storage for accurate CR1 
Method* 	 determination 
Using absolute standards 
EDTA 
	
Up to 2 weeks after blood drawn 
5% formaldehyde 
	Up to 4 weeks after blood drawn 
Freezing in glycerol 
	
Inconsistent results - not recommended 
Using relative standards 
EDTA 
	
Up to 6 weeks after blood drawn 
5% formaldehyde 
	Up to 8 weeks after blood drawnt 
Freezing in glycerol 
	
Up to 8 weeks after blood drawnt 
* Fixation in 0.25% glutaraldehyde was also tested but was not acceptable at any 
timepoint due to high background fluorescence 
t Longer periods of storage may be acceptable but this would require validation. 
Samples were tested only up to 8 weeks in these experiements. 
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Chapter 4: 
High frequency of erythrocyte complement receptor 1 
(CR1) deficiency in Papua New Guinea due to 
independent effects of CR1 mutations and a-
thalassaem ia3 
4.1 	Introduction 
In 1949 J B S Haldane proposed that the distribution and prevalence of a variety of red 
blood cell disorders could be explained if they were to provide protection against 
These results are previously published as Cockburn et al. 2004 
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malaria(Haldane 1949). In coastal regions of PNG there is a high prevalence of at 
thalassemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency and ovalocytosis, all 
of which have previously been associated with malarial protection(Yenchitsomanus et al. 
1986; Genton et al. 1995; Allen et al. 1997; Allen et al. 1999). Recently a variety of new 
potential disease associations with blood group types have been reported. Many 
individuals in the Wosera region in North West Papua New Guinea are Gerbich negative. 
Erythrocytes of this type lack glycophorin C - an abundant red cell protein of unknown 
function. Gene disruption studies have shown that glycophorin C is the receptor for the 
invasion ligand erythrocyte-binding antigen 140 (EBA-140 also known as 
BAEBL)(Maier et al. 2003). Other studies have identified an emerging Duffy negative 
polymorphism that makes erythrocytes refractory to invasion by P. vivax(Zimmerman et 
al. 1999). 
Red cell polymorphisms are not merely biological curiosities. They can be used to 
determine important disease processes. While we have extensive evidence that rosetting 
is associated with severe disease ((Carlson et al. 1990; Rowe et al. 1995)and see 
introduction) we do not know if it is an a priori cause of severe malaria, or merely a 
marker for some other underlying disease process. Given that CR1 is an important 
rosetting receptor(Rowe et al. 1997; Rowe et al. 2000), we reasoned that if rosetting is 
directly involved in malaria pathology then CR! polymorphisms should protect against 
severe disease by reduced rosette-mediated microvascular obstruction. The Knops blood 
group antigens S12 and McCb are common in West Africa but rare in Caucasians, a 
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distribution that suggests malarial selection, however direct evidence for a protective 
effect is lacking(Zimmerman et al. 2003). CR1 deficiency is thought to be rare in most 
populations, however, a review article(Molthan 1983) stated that 28/67 Melanesians had 
CR! deficient red cells (Helegeson phenotype). No experimental details were given, and 
no further information was published to validate this claim. A pilot study in our 
laboratory found that 9/15 samples from Vanuatu were also Helgeson phenotype (J.A. 
Rowe and J.M. Moulds unpublished data). In Caucasians red blood cell CR! expression 
varies between 50 and 1200 molecules per cell(Moldenhauer et al. 1987; Cohen et al. 
1989)], with levels of less than around 200 molecules per cell being associated with 
Helgeson phenotype(Moulds et al. 1991). CR1 expression is genetically determined and 
is associated with at least three linked single nucleotide polymorphisms (SNPs) in the 
CR! gene (in exon 22, intron 27 and exon33 - see section 1.6)(Wilson et al. 1986). These 
SNPs comprise high (H) and low (L) CR1 expression haplotypes associated with CR1 
level on erythrocytes alone but not other cell types such as B cells and 
macrophages( Wilson et al. 1986; Xiang et al. 1999). Given the prevalence of individuals 
with Helgeson blood and the burden of malaria in Melanesia we wanted to examine the 
erythrocyte CR1 expression level of individuals from Papua New Guinea and determine 
if this was under the same genetic control as in Caucasians. We also wanted to examine 
the prevalence of Knops group types and size polymorphisms. 
112 
Chapter 4: CR1 polymorphisms in Papua New Guinea 
4.2 Study sites and sample collection 
We obtained blood samples from three sites within PNG and also from a control sample 
in Edinburgh. In all cases informed verbal consent was given by all donors following an 
explanation of the aims of the project. The PNG Medical Research Advisory Committee 
approved all protocols. Blood samples came from New Ireland and Madang, both of 
which have holoendemic malaria with a spleen enlargement rate >70%(Cattani et al. 
1986; Flint et al. 1986). Buffy coats from blood samples collected in East Highlands 
Province in 1985 were kindly made available to us by the PNG Institute of Medical 
Research. These samples enabled us to genotype a highlands population to compare with 
the coastal and island ones. The highlands samples came from Andakombi, a village 
2000m above sea level, where transmission is rare as the parasite cannot complete its 
lifecycle at the lower temperatures within the lifespan of the mosquito vector. Malaria is, 
at worst, epidemic in this population Samples from each study site were collected and 
processed in slightly different ways. In Edinburgh blood was drawn from healthy 
volunteers and processed fresh. In New Ireland 5m1 of blood was drawn from 49 adult 
volunteers into EDTA and shipped to the UK, which took 2 weeks, the blood was then 
processed as fresh. In Madang blood was collected, the buffy coat was used for DNA 
extraction and the red cells from each samples were both frozen in glycerolyte and 
transported to Edinburgh by dry shipper, or fixed in 5% formaldehyde according to the 
method of Bianco et al.(Bianco et al. 1986) and kept at 4°C until used for flow cytometric 
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analysis. The Buffy coats from East Highlands Province had been stored at -60 °C since 
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Figure 4.1: Map of Papua NewGuinea (excluding Bougainville Island) showing locations 
of study sites for this study ( u) and principal towns ( 0). 
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4.3 Results 
4.3.1 CR1 expression in Papua New Guinea 
We measured the RBC CR1 levels of healthy adult volunteers from two highly malarious 
regions of PNG (Madang and New Ireland) and from a control Caucasian population 
from Edinburgh (UK). CR1 levels in Edinburgh varied between individuals in the range 
253-1181 molecules per cell, with a mean of 786 (Figure 4.2). These results are similar 
to CR1 levels described in other Caucasian populations (Table 4.1), showing that our 
assay for CR1(Cockburn et al. 2002) is comparable to those used previously. In PNG, 
CR1 levels were significantly lower than in Edinburgh (Figure 4.2, P <0.001), with 79% 
of individuals in Madang and 55% of individuals in New Ireland having fewer than 200 
CR1 molecules per cell, this is the approximate maximum expression level of Helgeson 
phenotype erythrocytes associated with reduced rosetting(Moulds et al. 1992; Rowe et al. 
1997). The mean RBC CR1 levels in Madang and New Ireland are the lowest in the 
world (Table 4.1). These results indicate that in malarious regions of PNG, CR1 
deficiency is extremely common and could therefore play a major role in influencing 
susceptibility to severe malaria. 
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Figure 4.2: Low CR1 expression is common in Papua New Guinea. Graph shows CR1 
expression of individuals from two Papua New Guinea populations and a control sample 
from Edinburgh. CR1 expression is in molecules per cell; each data point represents a 
single individual. To the right are shown the means and standard deviations for each 
population. 
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Table 4.1: Red cell CR1 levels and frequency of the CR1 low expression 
allele in different populations 
Population 
Mean red cell CR1 Gene frequency 
(range) 	(L allele) 
Reference 
France 613 (161-712) 0.21 (Cohen etal. 1989) 
UK 624(119-1220) 0.27 (Moldenhauer etal. 1987) 
USA (Blacks) 635 (158-1023) 0.25 (Herrera et al. 1998) 
USA (Whites) 547 (89-1166) 0.25 (Herrera et al. 1998) 
India 648 (140-1 294) 0.23 (Kumar etal. 1995) 
Mali 415 (58-1 032) 0.14 (Rowe etal. 2002) 
China 446 (27-1 039) 0.28 (Moulds etal. 1998) 
Edinburgh (UK) 786 (253-1181) 0.23 This Study 
New Ireland (PNG) 253 (40-839) 0.73 This Study 
Madang (PNG) 124 (0-439) 0.60 This Study 
Eastern Highlands 0.41 
ND This Study 
(PNG) 
ND, not determined 
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4.3.2 CR1 expression in Papua New Guinea is associated with 
polymorphisms in the CR1 gene 
We wanted to see if CR! deficiency in Papua New Guinea was due to the L allele that 
causes low CR1 in Caucasians and all populations studied to date outside 
Africa(Moldenhauer et al. 1987; Kumar et al. 1995; Herrera et al. 1998; Nagayasu et al. 
2001; Rowe et al. 2002). We genotyped 25 samples from Edinburgh, 45 samples from 
New Ireland and 36 samples from Madang at the three CR1 SNPs in exon 22, intron 27 
and exon 33. In 3 samples from New Ireland and 11 from Madang there was discordance 
between at least one of the SNPs and the expected haplotypes. In all populations there 
was a significant association between CR1 expression and all three SNPs (P < 0.05). In 
Madang where there was a higher degree of discordance the P values for association by 
one way ANOVA were P < 0.00 1 for exon 22, P = 0.020 for intron 27 and P = 0.040 for 
exon 33. As the strongest association with CR! expression was shown by the exon 22 
allele we typed the remaining samples for this polymorphism alone. At all three study 
sites the exon 22 genotype was associated with a highly significant effect on RBC CR1 
level, with carriers of the G3650 low (L) expression allele having significantly lower 
CR! levels than HH individuals (Figure 4.3, F2 ,96=50, P < 0.001). The frequency of the 
CR1 L allele in the malarious regions of PNG is the highest described in the world to date 
(Table 4.1), and significantly different to Edinburgh, (X 2 >6, P<0.01). DNA samples 
were also studied from the non-malarious Eastern Highlands Province of PNG, and the 
frequency of the L allele was found to be significantly lower than in the malarious 
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regions (Table 4.1, x2=8.1'  P < 0.01). This may indicate selection for the L allele in 
areas with high malaria mortality, although other explanations cannot be excluded such 
as founder effects and inbreeding (which are likely to occur in isolated populations such 
as those found in PNG(Flint et al. 1993; Flint et al. 1998)) or some other, as yet 
unknown, disease association. Another test was made to determine whether the HL 
heterozygotes had a CR! expression level that was different to the weighted mean of the 
two homozygotes (using the CONTRAST option in SAS): no significant difference was 
found confirming that the alleles were acting in a co-dominant fashion (P>0.05, F196 = 
0.2). The above data indicate that RBC CR1 levels in Melanesians are associated with 
polymorphisms in the CR! gene. However, even when matched for exon 22 genotype, 
CR1 expression levels in Edinburgh, Madang and New Ireland remained significantly 
different from each other (F 296 = 66.0, P < 0.001). For example, the CR1 levels of HH 
individuals from PNG are lower than those of HH individuals from Edinburgh (Figure 
4.3), suggesting that additional factors influence CR1 levels in Melanesians. 
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LL 	HL 	HH 
n 	 1 	 12 	18 
mean (Sd) 	235(na) 639(159) 915(136) 
Figure 4.3: CR1 expression is associated with SNPs in the CR1 gene. Each point 
represent the CR1 expression of a single individual in molecules per cell. Results are 
displayed by population of origin and CR1 genotype. CR1 genotype is based on typing 
at the n3650 polymorphism in exon 22. 
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4.3.3 a-thaIassaemia is associated with low CR1 expression 
We investigated whether other RBC polymorphisms that occur commonly in PNG such 
as ovalocytosis(Allen et al. 1999), glucose-6-phosphate dehydrogenase (G6PD) 
deficiency(YenchitSOmaflus etal. 1986) and alphathalassaemia(YeflchitsOma11uS etal. 
1986) could affect RBC CR1 levels. Ovalocytosis is known to reduce the expression of 
many RBC surface antigens(Booth etal. 1977), therefore it seemed a likely candidate for 
an additional modifying influence on CR1 levels. Ovalocytosis and G6PD deficiency 
were both relatively uncommon, occurring in up to 15% of individuals, and were not 
associated with RBC CR1 level (ovalocytosis, F1,115 = 0.2, P> 0.10 and G6PD 
deficiency, F 1,115 =  1.8, P> 0.10). Alpha-thalassaemia occurred in 89% of individuals in 
Madang, and 23% of individuals in New Ireland. In both populations only -a 42 mutations 
were observed except for one individual in the New Ireland population who was 
homozygous for the -a 37  mutation, this individual was subsequently excluded from the 
analyses. At both sites, individuals with one or more alpha-thalassaemia mutations had 
RBC CR1 levels significantly lower than those of non-thalassaemic individuals (Figure 
4.4 a, F1,111 = 12.4, P < 0.001). The effect of alpha-thalassaemia genotype on RBC CR1 
level was independent of the CR1 exon 22 polymorphism, as both genotypes were 
statistically significant when simultaneously included in the analysis (F2,110 = 10, P < 
0.001 for alpha-thalassaemia genotype; F 2 , 110 44, P < 0.001 for exon 22 genotype). 
Thus, an individual's REC CR1 level is dependent upon both their CR1 exon 22 
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Figure 4.4: CR1 expression is related to f-thalassaemia as well as SNPs in the CR1 
gene a. CR1 deficiency in Papua New Guinea is associated with cC-thalassaemia. CR1 
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expression in New Ireland and Madang is shown in molecules per cell. Data is 
subdivided by population and a-thalassaemia genotype. b The effects of cC-
thalassaemia and CR1 polymorphisms are independent of each other. Mean CR1 
expression for the Madang population subdivided by CR1 genotype (n3650 
polymorphism) and cC-thalassaemia (-a42 deletion) is given, error bars are standard 
errors. Thalassaemia genotypes are -alaa - heterozygotes for the -a42 deletion, -a/-a 
homozygotes for the same deletion and acdaa normal a-globin gene structure. Dark 
bars represent the HH genotype, grey bars the HL genotype and white bars the LL 
genotype. * = no representative of this genotype. 
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4.3.4 Individuals with low CR1 expression are more susceptible to 
asymptomatic infection 
Even after accounting for differences in the frequency of the CR1 L allele and a-
thalassemia mutations, there were still significant differences between the populations in 
red cell CR1 expression level (see Figure 4.4 b). Waitumbi et al. have shown that 
Kenyan children with malaria have reduced CR! expression that is restored upon 
recovery of the patient(Waitumbi et al. 2000). We therefore considered whether malaria 
infection could be influencing the level of red cell CR1 in Melanesians by assessing the 
blood samples collected in Madang for the presence of malaria parasites. All samples 
came from healthy adult donors: therefore clinical malaria was not seen, though low level 
asymptomatic parasitaemia was common, with 31/96 individuals having detectable 
parasites (14 P. falciparum infections, parasitaemia range 2.60 - 4.07 log(parasites4tl); 17 
P. vivax infections, parasitaemia range 2.90 - 4.62 log(parasites/.tI), 3 P. malariae 
infections, parasitaemia range 3.08 - 3.20 log(parasites/jil), and zero P. ovale infections). 
The CR1 levels of individuals infected with P. malariae or P. vivax were not significantly 
different to individuals not infected with these species (P>0.05). However, the mean red 
cell CR1 expression level of P. falciparum-infected individuals was 70 molecules per cell 
compared to 133 in individuals not infected with P. falciparum which was statistically 
different P < 0.01, F 173=8.0). When the exon 22 CR1 genotype was included in the 
statistical model, the difference in CR! expression level between P. falciparum-infected 
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and uninfected individuals was no longer significant (Table 4.2; P> 0.05, F 171 =1.3). This 
could be explained if the lower level of CR! expression observed in infected individuals 
is due to preferential infection of individuals with low CR1 expression rather parasite 
infection causing low CR1 levels. 
Table 4.2: The relationship between CR1 expression, CR1 genotypes and 
asymptomatic malaria infection in adults 
Infection 
All genotypes 
Mean CR1 expression (n) 
LL 	HL HH 
P. falciparum + 70* (14) 61(12) 105 (1) 143 (1) 
P. falciparum - 133 *(82) 67 (26) 155 (38) 180 (18) 
P. vivax + 125 (17) 75(8) 78(4) 93(5) 
P. vivax - 123 (79) 63 (30) 90 (35) 89 (14) 
P. malariae + 49 (3) 21(2) 105 (1) N/A (0) 
P. malariae - 126 (93) 68 (36) 155 (38) 178 (19) 
*s ign ificant difference (P < 0.01 by one-way ANOVA) 
We therefore examined the disthbution of P. falciparum-infected and uninfected 
individuals across the exon 22 CR1 genotypes (Table 4.3). We found that 12 out of the 14 
(86%) of the infected individuals were homozygous for the L allele compared with 26 out 
of 82 (32%) of non-P. falciparum infected individuals: this was a significant departure 
from expected values (P < 0.001 by X2  test). These results suggest that P. falciparum may 
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preferentially infect people with low CR1 expression or low CR! individuals being less 
effective at clearing parasites, rather than the presence of the parasite being the cause of 
reduced CR1 levels. No association was found between ct-thalassemia genotype and P. 
falciparum infection (P>0. 10 by x2  test). 






rate (%) 1/19 (5) 1/39 (3) 12/38 (32) 
0.0007* 
median densityt 3.32 2.94 3.11 0.99* 
(range) (-) (-) (2.60-4.08) 
P. vivax 
rate(%) 5/19 (26) 4/39 (10) 8/38 (21) 
0.21* 
median density 2.90 3.08 3.20 0.15* 
(range) (2.90-3.08) (3.08-4.62) (2.90-3.55) 
* x2  test 
tparasite density given in log (parasites4tl) 
Kruskal Wallis test 
126 
Chapter 4: CR1 polymorphisms in Papua New Guinea 
4.3.5 CR1 size variant frequencies in Papua New Guinea 
Samples from New Ireland and Madang were typed for the CR1 size variants. There were 
7 CR13 chromosomes out of 192 in Madang (gene frequency = 0.04) with the remainder 
being CR! *1.  In New Ireland, 4 out of 94 genes were CR1 * 3 (gene frequency = 0.04), 
1/94 was CR1*2 (gene frequency = 0.01) and the remainder were CR1*! (gene frequency 
= 0.95). These frequencies were not significantly different by Fisher's exact test (P> 
0.10). After grouping all individuals with the CR1*3 genotype across both populations 
this polymorphism had no significant effect on CR1 expression level (P > 0.10, 17 1115 = 
0.3) 
4.3.6 Knops Blood Group antigens in Papua New Guinea 4 
The 47 samples from New Ireland were typed by direct agglutination assays with anti-
sera to Sl:1, McC(a+), McC(b+) and Kn(a+). 30/47 (64%) were of the Helgeson 
phenotype (i.e. negative for all antigens, usually due to low expression with less than 
100-200 molecules CR1 per cell(Moulds et al. 1992)). Of the Helgeson phenotype 
individuals, 10 had fewer than 100 CR1 molecules per cell, 13 had 100-200 CR1 
"These serotyping assays were carried out by Dr Joann Moulds (Drexel University 
College of Medicine, Philadelphia, PA) 
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molecules per cell, and 7 had more than 200 CR1 molecules per cell. Of the samples that 
were positive for at least one Knops antigen, there were no examples of the McC(b) 
phenotype, suggesting that this antigen may not occur in Melanesian populations. In 
addition, ten samples from each of the three PNG sample sites were typed by PCR for the 
Knops allelic pairs, SI 1 and Si 2, and McCa and Mcd'. Consistent with the typing data, 
all samples were homozygous for Si 1 and McCa, and the Si 2 and Mcd' alleles that have 
been reported at high frequencies in malarious regions of Africa were not detected. 
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4.4 Discussion 
Here we show that erythrocyte CR1 deficiency is extremely common in Papua New 
Guinea. Individuals from lowland and island populations have the lowest recorded levels 
of CR1 in the world. The low level of CR1 expression is associated with an extremely 
high frequency of the L allele of CR1 in this population and, surprisingly, with alpha-
thalassaemia which is likewise extremely common in the northern coastal regions of 
Papua New Guinea with 89% of individuals in Madang having at least one alpha-
thalassaemia mutation. Moreover we show that there is a relatively high frequency of the 
small CR1*3  size allele (0.04 overall) which is rare in non-malarious populations(Cohen 
et al. 1999). 
Given the involvement of CR1 in P. falciparum rosetting we hypothesise that CR1 
deficiency has been selected for by malaria. We have tested this hypothesis directly by 
analysing samples from a severe malaria case control study (see chapter 5). Some 
circumstantial evidence in this study for the involvement of CR1 in protection from 
malaria comes from the genotyping of some blood samples from the PNG highlands, an 
area that has at worst, epidemic malaria. Here the gene frequency of the L allele is 0.41, 
significantly lower than in Madang (0.61) or New Ireland (0.73) (P < 0.001 for both 
populations, x2  test). Though we cannot be sure that in the highlands this allele is linked 
to CR! expression it seems probable given the common ancestry of these 
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populations(Kirk 1992; Redd et al. 1999). Despite a possible malaria based hypothesis to 
explain the low levels of CR1 in PNG populations, the only study so far done(Nagayasu 
et al. 2001) suggests that low CR1 levels are actually a risk factor for malaria in 
Thailand. Nagayasu et al. found firstly that the intron 27 RFLP in CR1 is linked to 
expression level in this population with the low expression allele having a frequency of 
0.52. The high frequency of the L allele suggests malarial selection, however a small 
study of severe and mild malaria patients compared to healthy individuals found that 
homozygotes carrying the low expression allele are more susceptible to severe disease, a 
fact they suggest may be attributed to a failure to control complement induced damage 
and the deposition of immune complexes(Adam et al. 1981; Gupta et al. 1988). This kind 
of pathology is typical of South East Asian patterns of disease characterised by multi-
organ failure including renal failure(White 1998). The data they present shows some 
evidence that heterozygotes are protected from severe disease a fact concordant with the 
gene frequency of the low expression allele seen in this study. In addition to the previous 
study in Thailand, our own data shows that low levels of CR! predispose to the presence 
of infection, especially with Plasmodiumfalciparum. Most protective polymorphisms 
result in lower or unaltered parasite prevalence (ovalocytosis(Cattani et al. 1987; Allen 
et al. 1999), 13-thalassemia(Willcox et al. 1983)sickle cell anaemia(Ntoumi et al. 1997), 
and G6PD(Ruwende etal. 1995)), so this would suggest that the G3650 allele is a risk 
factor for malaria in PNG. One study has however shown increased parasite prevalence 
among ct-thalassemic heterozygotes in Vanuatu(Williams et al. 1996). The observation 
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that individuals with low CR1 are more prone to infection could in part explain this 
observation. 
Case control studies on the ICAMVIth mutation, another polymorphism believed to 
affect adhesion characteristics of malaria parasites, have shown that a given 
polymorphism can be protective in some populations but a susceptibility factor in 
others(Craig et al. 2001). ICAM1kifi  is associated with susceptibility to cerebral malaria 
in Kenya(Fernandez-Reyes et al. 1997), has no effect in The Gambia(Bellamy et al. 
1998) and is protective in Gabon(Kun et al. 1999). The reasons for these differences are 
unknown but probably lie in the patterns of disease and population genetic factors. In 
PNG the pattern of disease is different from Southeast Asia and the host genetics are 
different, notably the much higher prevalence of ct-thalassemia mutations in this 
population which also affects CR! expression(Flint et al. 1993; Flint et al. 1998). 
The reduction CR1 expression among a1 -thalassemic individuals, is one of the most 
striking results from this study. cC-thalassemia has previously been shown to confer 
protection from severe disease in the Madang region with heterozygotes having a relative 
risk of 0.6 while homozygotes have a relative risk of 0.4(Allen et al. 1997). But while the 
protective effect of this disorder is well known, the mechanism is debated. Parasite 
growth is unimpaired in thalassaemic cells (Luzzi et al. 1991) so investigators have 
sought explanations based on reduced cytoadherence or immune 
recognition(Udomsangpetch etal. 1993). Carlson etal. (Carison et al. 1994)showed a 
131 
Chapter 4: CR1 polymorphisms in Papua New Guinea 
large reduction in rosetting with thalassaemic RBC. They argued that this could be a 
result of microcytosis - thalassaemic cells have around 15% less surface area than normal 
cells(Luzzi et al. 1991). However the thalassaemic cells still rosetted less well than 
microcytic controls with normal haemoglobin. Microcytosis is also insufficient to explain 
CR1 reduction, which is around 50% in thalassaemic individuals (Figure 4.4). As CR1 is 
preferentially lost in vesicles from the cell surface as RBC age or become ATP-
depleted(Pascual et al. 1993) it is possible that biochemical abnormalities in thalassaemic 
RBC promote a similar process that would reduce their CR1 expression. We might 
speculate that low CR1 levels on thalassemic red cells could enhance immune recognition 
of parasite antigens as it could theoretically increase the deposition of complement 
components like C3b on infected red cells and hence facilitate phagocytosis of infected 
cells. Another notable result from the both Madang and New Ireland group is a gene 
frequency of 0.04 for the small CR1*3 size allele. This is higher than in other populations 
studied other than populations in Mali and Black Americans(Cohen et al. 1999). The 
CR1 * 3 allele could confer protection as these alleles lack one of the potential binding 
sites for PfEMP1 and may allow only weak rosetting(Rowe et al. 2000). This hypothesis, 
though, has yet to be tested, even in in-vitro experiments. 
I have argued that low CR1 has been selected for as it reduces parasite rosetting and 
therefore severe disease. However a previous study showed no correlation between 
rosetting and severe disease in PNG(al-Yaman et al. 1995), how can these observations 
be reconciled? This study was based at the town hospital in Madang and the patients and 
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controls came from region from which encompasses the village from which our Madang 
samples came. The study showed rosettes forming in every isolate studied at rates higher 
than those seen in African studies where many isolates do not rosette at all(Rowe et al. 
1995). These otherwise anomalous results could be explained if the rosettes observed 
were formed in the effective absence of CR1 and were therefore not physiologically 
significant. If the rosettes were bound only by weak interactions they may not have been 
sustainable in the conditions of shear stress that would be encountered in the capillary 
systems of the human body and could not contribute to severe disease pathology. In the 
remaining chapters I have tried to resolve these paradoxes and questions. Firstly by 
testing the hypothesis that CR1 deficiency is a result of malarial selection and secondly 
by studying rosetting in this population, the extent to which it occurs, its disease 
associations and the receptors involved. 
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Chapter 5: 
The CR1 L allele protects individuals against severe 
malaria5 
5.1 Introduction 
We have demonstrated the high frequency of CR1 polymorphisms in Papua New 
Guineans that are rare in other populations. High frequencies of an otherwise rare allele 
results are published as Cockbum et al. 2004 (see Appendix) 
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may be the result either of chance - acting through the processes of genetic drift and 
founder effects, or they may occur as a result of natural selection in a particular 
environment(Flint et al. 1998). Given the high level of malaria transmission in coastal 
populations of PNG(Flint et al. 1986; Burkot et al. 1988) and the involvement of CR1 
binding in Plasmodiumfalciparum pathology(Rowe et al. 1997) we decided to test the 
hypothesis that the high frequency of CR1 deficiency in this population was due to 
protection it provides from severe malaria. If CR1 deficiency did protect against severe 
malaria it would also provide strong indirect evidence that rosetting is a cause and not a 
correlate of disease severity. In order to do this we were fortunate to have access to DNA 
samples from a large case-control study carried out previously at the Madang general 
hospital(Allen et al. 1997; Allen et al. 1999). These samples had been previously typed 
for cC-thalassaemia and ovalocytosis, and full clinical information was available for each 
patient6. We were able to type these samples at the exon 22 polymorphism to determine if 
the CR! L allele does indeed protect against severe malaria. 
6  The painstaking work of carrying out a case-control study over a period two years was 
done by Steve Allen and Angela O'Donnell. The genotyping of samples and statistical 
analysis is my work. 
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5.2 Study design 
5.2.1 Case-control study 
The case-control study design has been described extensively previously(Allen et al. 
1997; Allen et al. 1999) and only an outline is given here. Samples were collected from 
children admitted to the paediatric ward of the Madang general hospital between October 
1993 and February 1996. The hospital is the main referral hospital for the province 
including the village of Udisis from which our community blood samples described in 
Chapter 4 came. Only individuals who had lived in Madang province for more than a 
year were included in the study. In this case-control study individual severe malaria cases 
were paired with a community control matched for age, sex, ethnicity and residence. 
Severe malaria was defined according to World Health Organisation criteria(Warrell et 
al. 1990). Coma was defined as a Blantyre coma score of :5 2 with asexual stages of P. 
falciparum in the peripheral blood and no alternative diagnosis. The Blantyre coma score 
is a modification of the more commonly used Glasgow coma score adapted for use with 
pre-verbal children(Molyneux 1990). Severe anaemia was defined as a haemoglobin <5 
g/dl and a parasitaemia> 10 000 parasites /l though lower parasite densities were 
admissible if the child had taken anti-malarial drugs prior to admission. Acidosis was 
defined as plasma bicarbonate < 15 mmol/1, hypoglycaemia as plasma glucose <2.2 
mmol/l and hyperlactaemia as ~! 5 mmoIIl. Clinical features of the cohort of severe 
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malaria patients in this study have also been described extensively previously(Allen et al. 
1996). 
One matched community control child was recruited for each index case. A child was 
found from a family neighbouring the house of the index case. The child had to be of the 
same age (±1 year), the same ethnicity (defined according to the languages spoken by the 
parents) and the same sex as the index child. Controls were collected within one month of 
admission of the index case. 
5.2.2 Laboratory analysis 
Blood was drawn into EDTA tubes for white cell counts and into heparin and fluoride 
oxalate for biochemical analysis. White and red cell counts were done on a coulter 
counter (Coulter Electronics, Luton, UK) Biochemical analyses on samples were carried 
out by dry slide chemistry (Kodak-Ektachem, Rochester, NY). Samples had been 
previously typed for ovalocytosis according to the method of Jarolim et al.(Jarolim et al. 
1991), for cC-thalassaemia by southern blotting and haemoglobin electrophoresis(Old et 
al. 1983), and for glucose-6-phosphate dehydrogenase deficiency using Sigma procedure 
no. 400 (Sigma, Poole, UK) as described in Section 2.5. The samples were typed for the 
exon 22 polymorphism in the CR1 gene as described in section 2.3. Exon 22 PCRs were 
performed on DNA samples that had previously been amplified by primer extension 
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preamplificaction (PEP or whole genome) PCR as the remaining genomic DNA from the 
case-control study was small. This technique amplifies genomic DNA non-specifically to 
increase the amount of template available(Zhang et al. 1992). 
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5.3 Results 
5.3.1 The CR1 HH genotype is a risk factor for severe malaria 
Out of 311 case-control study pairs we were able to genotype 186 index cases and 186 
controls for the CR! polymorphism. The other samples could not be genotyped either 
due to the unavailability of DNA samples or PCR insensitivity. We had complete 
genotypic information (ovalocytosis, cC-thalassaemia and CR1 exon 22) for 180 cases 
and 178 controls. We performed logistic regression using case or control status as the 
outcome variable and incorporating thalassaemia and ovalocytosis genotypes into the 
model. This form of regression analysis takes no account of the pairing samples and 
simply compares the two groups as whole. We found that CR1 HL heterozygotes were 
strongly protected against severe malaria relative to the HH genotype (OR [95% 
confidence interval]: 0.33 [0. 14-0.78], P = 0.01; Table 5.1) while LL homozygotes had 
reduced odds ratios but this was not statistically significant (OR [95% confidence 
interval: 0.55 [0.24-1.28], P = 0.16; Table 5.1). HH individuals were found to have a 
odds ratio of severe malaria of 2.26(95% confidence interval: 1.00-5.12; P = 0.05) 
compared to the other two genotypes combined. The LL genotype is apparently less 
protective than the heterozygous state (though this difference in itself is not statistically 
significant (Table 5.1)), which implies that there may be a malaria-associated cost to 
having a level of CR! expression that is extremely low. We also carried out conditional 
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logistic regression analysis. While this is a more sensitive statistical test as it compares 
matched pairs directly, many case-control pairs without complete data for both 
individuals had to be removed from the analysis. The results from this analysis were not 
materially different from those with ordinary logistic regression analysis. 
5.3.2 Difterent disease types 
Some malaria-associated polymorphisms protect against one severe syndrome but not 
another, for example ovalocytosis has been shown in two studies to be protective against 
cerebral malaria but not any other complication of severe disease(Genton et al. 1995; 
Allen et al. 1999), while a-tha1assaemia protects against severe malarial anaemia, 
acidosis and hyperlactaemia(Allefl et al. 1997). We therefore subdivided the cases and 
controls into overlapping groups of the following syndromes (defined as in section 5.2.1): 
severe anaemia, cerebral malaria, acidosis, hyperlactaemia and hypoglycaemia. Due to 
the relatively small numbers in the last three groups we also pooled these samples as 
"metabolic complications". 
The HL genotype confers significant protection against severe anaemia (Table 5.1), while 
the LL genotype has a trend towards protection. The HL and LL genotypes also have low 
odds ratios relative to the HH genotype for susceptibility to cerebral malaria, however the 
P values for this are large reflecting the small sample size. Conversely there is a trend 
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towards the LL genotype being a risk factor for the three metabolic determinants of 
disease severity both when they are pooled or treated separately but this does not reach 
statistical significance. 
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Table 5.1: Case-control study: summary of results 
Genotype Cases (%) Controls (%) Adjusted odds ratio 
(95% Cl) 
P value 
All severe cases 
n=180 n=178 
HH 21(12%) 9(5%) 
HL 57 (37%) 81(46%) 0.33 (0.14-0.77) 0.01 
LL 102(56%) 88(49%) 0.55 (0.24-1.28) 0.16 
Severe anaemia 
n=113 n=109 
HH 15 (13%) 5(5%) 
HL 34 (30%) 45 (41%) 0.30 (0.10-0.93) 0.017 
LL 64(57%) 59(54%) 0.46 (0.15-1.40) 0.15 
Cerebral malaria 
n=45 n =47 
HH 4 (9%) 2 (4%) 
HL 15 (33%) 21(46%) 0.40 (0.06-2.50) 0.33 
LL 26(58%) 23 (50%) 0.60 (0.10-3.69) 0.55 
Hyperlactaemia 
n=44 n=42 
HH 4(9%) 4(10%) 
HL 14(32%) 18(43%) 1.07 (0.20-5.54) 0.93 
LL 26 (59%) 20 (47%) 1.99 (0.38-10.37) 0.41 
Acidosis 
n=29 n=32 
HH 2 (7%) 2 (6%) 
HL 12(41%) 15(47%) 1.41 (0.13-14.93) 0.78 
LL 15(52%) 15(47%) 1.80 (0.17-1 8.84) 0.62 
Hypoglycaemia 
n=13 n=12 
HH 1 (8%) 0 (0%) 
HL 6 (46%) 4 (32%) oo (0-oo) NA 
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HH 	5(9%) 	 6(10%) 
HL 18(31%) 27(44%) 	1.10 (0.27-4.47) 	0.89 
LL 	35 (60%) 	 28 (46%) 2.13 (0.54-8.49) 0.28 
Odds ratios for the HL and LL genotypes are calculated in relation to the HH genotype 
after adjusting for the potential confounding factors ovalocytosis and alpha-
thalassaemia. 
t Hypoglycaemia, acidosis and hyperlactaemia. 
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5.3.3 Interaction between a-thaIassaemia and CR1 genotype 
Since both f-thalassaemia and the CR! L allele are associated with both low CR1 and 
protection against severe malaria one hypothesis is that the protection these mutations 
afford is through their effect on CR! expression. A second hypothesis is that o-
thalassaemia has an effect on severe malaria which is independent of CR1 expression - 
this might be the only protective effect of thalassaemia or could act side by side with 
effects on CR! expression. It is also possible that CR1 genotypes are protective through 
an effect independently of CR1 expression, i.e. if the two alleles were functionally 
distinct for which there may be some evidence. These models are summarised in Figure 
5.1. 
As no information exists for the actual erythrocyte CR1 expression of samples in this 
study, to try and differentiate between these models we determined the odds ratio of 
developing severe malaria for each combination of CR! and thalassaemia genotype. If 
both genotypes were acting through CR1 expression we would expect the odds ratios to 
correlate with expected CR1 expression for that genotype. Nonetheless this may be 
confounded by the relatively small sample size, and the possibility that the LL genotype 
carries a malaria-associated cost, probably independent of its effect on rosetting. 
Cpa+--tthal l  
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Figure 5.1 
Figure 5.1 Models of the protective effects of cC-thalassaemia and CR1 polymorphisms 
against malaria. Either they act together through CR1 expression (light arrows) or 
a+thalassaemia and CR1 may have effects on severe malaria independently of CR1 
expression (dark arrows). 
We calculated odds ratios by logistic regression compared to the remainder of the 
population, which had a case to control ratio of 1:1 (182 cases, 179 controls). Only two 
genotype odds ratios differ significantly from 1 (Table 5.2). The HL (CR1 genotype); a-
Ia- (thalassaemia genotype) combination combines the most beneficial alleles of both 
genotypes and provides the strongest protection relative to all other alleles (OR = 0.39; P 
= 0.0009), however is not associated with the lowest CR1 expression. This may be 
expected as very low CR1 expression could be a risk factor for malaria (section 5.3.1). 
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Conversely HH; cLa/cLcL individuals are most at risk of severe malaria (P = 0.015) as none 
of these 7 individuals were in the control category. This tentatively suggests that the two 
effects are acting through CR1 expression as this genotype is associated with the highest 
CR1 expression. 
Table 5.2: Combined thalassaemia and CR1 genotypes 


















































* Odds ratios for each two-locus genotype are expressed relative to the remainder of the 
population, which had a case to control ratio of 0.50 (182 cases, 179 controls). They 
were calculated using logistic regression fitting two-locus genotype as a 2-level fixed 
effect factor (i.e. of or not of that genotype). 
t 
Not estimable because all people in this class had severe malaria. 
1:Tested for deviation in frequency from the remainder of the population using Fisher's 
exact test. 
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Another way of attempting to distinguish between the two models would be look for 
evidence of linkage disequilibrium between thalassaemia and CR1 genotypes. If there is 
linkage disequilibrium and particular combinations of genotypes are favoured that may 
be evidence for both genotypes acting through a common mechanism, perhaps CR1 
expression. The control samples alone (which should represent an unbiased population 
sample with respect to individuals genotypes) were analysed for linkage disequilibrium 
using the a number of permutations method in the program Genetix (Universite de 
Montpellier, Montpellier, France). This method gives the probablility of linkage 
disequilibrium for two loci where there is information on the genotype at two loci but 
does not require family information. Also being a permutations (exact) test it makes no 
assumptions about the distribution of the genotypes - in other words it can be used with 
alleles not in Hardy-Weinberg equilibrium. Nonetheless there is no statistically 
significant evidence for linkage disequilibrium between these two loci (P = 0.08). 
However an examination of the distribution of genotype combinations (Table 5.3) shows 
that there is significant departure from the expected values if the genotypes were in 
Hardy-Weinberg equilibirum, giving further evidence for strong selection on these two 
loci (x2 = 18.485; df= 4; P <0.001). 
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Table 5.3: Distribution of CR1 and thalassamia genotypes among control 
indviduals 
Thalassaemia genotype 
aa/aa a-/aa a-/a- Total 
CR1 genotype 	 HH 	 0(1*) 7 (6) 3 (7) 10(14) 
HL 	 9 (6) 25 (29) 47 (38) 81(73) 
LL 	 13 (7) 24 (37) 51(47) 88 (91) 
Total 	22 (14) 56 (72) 101 (93) 179 
* expected value given in brackets 
5.3.4 Clinical Parameters 
No significant difference was observed among any of the clinical parameters measured 
between the different CR1 genotypes in the group of severe disease patients (Table 5.3). 
The median value for haemoglobin is slightly lower in the HH genotype reflecting the 
susceptibility to anaemia, while the lactate level in individuals with the LL genotype is 
higher which accords with the result that the LL genotype may predispose to 
hyperlactaemia. Finally there is a trend towards lower mortality in the LL group. 
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Table 5.3: Indices of severity of malaria and mortality subdivided by 
genotype for the CR1 exon 22 polymorphism 
HH 	 HL 	 LL 	P value 
Haemoglobin (g/dl) 
median (range) 4.45 (2.4 - 10) 4.85 (2.3 - 16.6) 4.70 (1.4 - 13.3) 0.66 
n 22 60 	 104 
Lactate (mmolIl) 
median (range) 2.8 (1.7 - 8.0) 2.85 (1.2 - 15.4) 3.40 (1.2 - 15.6) 0.55 
n 20 58 	 103 
Bicarbonate (mmol/l) 
median (range) 13.9 (8.8 - 32.5) 14.9 (8.4 - 48.3) 	14 (4.4 - 40.7) 0.36 
n 18 47 	 89 
Pma (log parastesljtl) 
median (range) 3.91 (1 .60-5.41) 4.09 (1 .60-5.60) 4.24 (1.60-5.63) 0.65 
n 22 55 	 92 
Coma 
n/total for genotyp (%) 4/21 (19) 15/59 (25) 	28/103 (27) 0.74 
Death 
n/total for genotype (%) 1/22 (4.5) 5/60 (8.3) 	3/104 (2.8) 0.29 
Analyses for haemoglobin, lactate, bicarbonate and parasitaemia are by Kruskal-WaIlis 
test. For coma and death analysis is by x2  test. 
5.3.5 Infection in control individuals 
In section 4.3.4 we found that in a population survey of healthy adults infection with 
slide-detectable P. falciparum was significantly associated with the LL genotype. The 
control sample from the case-control study gave us an opportunity to determine if this 
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observation was also true in children. However we found that for both P. falciparum and 
P. vivax there was no association between genotype and infection prevalence (Table 5.4). 









median densityt (range) 
P. vivax 
rate (%) 










32/87 (37) 	0 .50* 
3.11 (1.60-5.09) 0.33t 
16/87 (18) 	0.17* 
1.99 (1.60-3.47) 0.091 
* 2 test 
tparasite density given in log (parasites/tl) 
Krucksal Wallis test 
The reasons for the difference between these two samples are unclear. It may be that the 
small sample size of the survey in chapter 4 gave an artefactual result. However this 
survey is not directly comparable to the population survey described in chapter 4. In this 
case the samples were from children who would have yet to develop functional immunity 
to malaria, whereas the individuals in the other survey were adults. As these individuals 
were controls they would have been collected largely in the wet season, whereas the 
samples from the adults were collected in June: the dry season. A difference in infection 
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rate or clearance of parasites among CR! genotypes depending on season and age could 
be interesting, though to confirm that this difference was real a variety of cross sectional 
studies in different seasons would have to be analysed. 
5.3.6 Gene frequencies of the L allele vary significantly between 
populations 
As the children in this study came from a variety of genetic backgrounds we could also 
use the control sample to study the gene frequency of the L allele in population from 
different parts of Papua New Guinea with different malaria endemicities (Table 5.5). The 
186 controls were grouped according to their parents' language into groups of Madang, 
Sepik, Highlands, Other Coastal and Mixed. The Sepik has some of the most intense 
malarial transmission in the country(Genton et al. 1995; Genton et al. 1995). While the 
other coastal regions include the southern coastal areas that have less intense transmission 
than the north coast(Brown 1995). 
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Madang 	Sepik 	Highlands 	Other 	Mixed 
Coastal 
6 2 1 5 0 
61 3 1 15 3 
60 14 0 15 0 
127 19 2 35 3 
0.71 0.82 0.25 0.64 0.5 
- 0.027 0.015 0.14 0.21 
*p=difference between population from the Madang population (x2  test) 
The data show that there are significant differences in the gene frequency of the L allele 
between different populations in Papua New Guinea. The Sepik individuals have the 
highest L allele frequency in the world, which is significantly higher than in Madang. The 
Highlanders have a much lower gene frequency though as the sample number is very 
small we should not infer anything from this data. Better evidence for low frequencies of 
the L allele in this population comes from data presented in 4.3.2. Individuals from the 
southern coastal regions had a lower overall frequency of the L allele but this did not 
reach statistical significance. These data support the notion of a geographical distribution 
of the L allele that correlates with the transmission intensity of malaria and therefore a 
role for CR1 in malaria pathogenesis. 
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5.4 Discussion 
This study shows that alleles associated with CR! deficiency, found commonly in Papua 
New Guinea, protects against severe malaria. Genotypes associated with low CR1 in both 
the a-globin gene(Allen et al. 1997) and the CR1 gene itself have now been associated 
with protection against severe malaria. There is also evidence for variation in the 
prevalence of the L allele depending on malaria endemicity. As parasites invade and 
grow normally in both CR1 deficient(Soubes et al. 1999) and thalassaemic red blood 
cells(Luzzi et al. 1991) the simplest interpretation is that these polymorphisms are 
protecting against severe disease through their known effects on rosetting(Carlson et al. 
1994; Rowe et al. 1997). Positive selection of rosette-reducing polymorphisms is strong 
evidence that CR1-mediated rosetting plays a causal role in the pathogenesis of severe 
malaria. 
CR1 deficiency appears to be rare in African populations studied to date(Herrera et al. 
1998; Rowe et al. 2002) despite its protective effect in Melanesians. The H and L 
haplotypes do exist in Africa but are not associated with CR! expression(Herrera et al. 
1998; Rowe et al. 2002). This suggests (though other explanations are plausible) that the 
SNPs themselves are non-functional and that the lesion causing CR1 deficiency arose on 
an L chromosome only after humans left Africa. We would have a better understanding 
of these issues if the functional basis of CR1 deficiency is definitively identified. Instead 
African populations possess other CR! polymorphisms - particular Knops blood group 
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antigens (Si 2 and MCCb)  localised to the CR! protein reach high frequencies in West 
Africa. 51 2 has been associated with low rosetting(Rowe et al. 1997) but not through 
CR1 deficiency(Moulds et al. 1991). We might also speculate that 
in order for CR1 expression to be sufficiently low to prevent rosette formation both CR1 
and a-thalassaemia mutations have to be present in a population i.e. there must be 
linkage disequilibrium between the genes. While there is no direct evidence for that 
presented here, we cannot rule it out as our sample size is small. This might account for 
the exceptional frequency of both alleles in coastal Papua New Guineans, but their lower 
prevalence elsewhere. Clearly the selective pressure of malaria has acted in different 
ways on the CR! gene in diverse populations. 
The rarity of CR1 deficiency in much of the rest of the world suggests that without 
malaria the L allele carries a cost. The high prevalence among our healthy adult donors 
demonstrates that it is clearly not responsible for a severe syndrome like sickle cell 
anaemia. One study has linked the L allele to systemic lupus erythematosus (SLE) in 
which immune complexes accumulate( Wilson et al. 1987), but most find no 
association(Moldenhauer et al. 1987; Cohen et al. 1989; Yen et al. 1989; Satoh et al. 
1991; Kumar et al. 1995; Kiss etal. 1996). In this study we find that HL individuals are 
more protected than LL individuals, raising the possibility that very low CR1 expression 
prevents proper parasite clearance or contributes to pathology. In the previous chapter we 
referred to the a small study of CR1 polymorphisms in Thailand , this also showed a high 
frequency of the L allele (f = 0.52) showing that it had undergone selection, though they 
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report that LL homozygotes are at risk of severe malaria(Nagayasu et al. 2001). Our 
analysis of their data indicates that HL heterozygotes in Thailand, as in PNG, may be 
protected from severe disease. However, perhaps due to the small number of cases, this 
effect was not statistically significant (severe malaria cases versus healthy controls, HL 
versus HH, OR 0.395, 95% Cl 0.126-1.23, P=0.11). Our findings and those of Nagayasu 
et al. support some older work that argued that impaired handling of immune complexes 
contributes to some severe malaria syndromes such as renal failure and pulmonary 
oedema, which are common in South East Asia(Adam et al. 1981; White 1987). 
The case-fatality rates for severe malaria are high, even in areas with intensive care 
facilities, so there is an urgent need for new approaches to treatment(Warrell 1999). Our 
results suggest that therapies aimed at inhibiting CR1-mediated rosetting(Rowe et al. 
1997), such as soluble recombinant CR1(Weisman et al. 1990), could be of benefit in 
severe malaria. Alternatively, development of a vaccine against the parasite rosette-
mediating ligand PfEMP1 may prevent some cases of severe disease. The selective 
pressure of malaria on a major rosetting receptor indicated by our results strongly 
supports a direct role for CR1-mediated rosetting in the pathogenesis of severe disease, 
and emphasises that further research to develop rosette-inhibiting interventions should be 
a high priority. 
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Chapter 6: 
Rosetting is infrequent in Papua New Guinea, not 
associated with disease severity and rarely mediated by 
CR1 
6.1 Introduction 
Our previous work has shown that CR1 deficiency is extremely common in Papua New 
Guinea and that genotypes associated with low CR1 on erythrocytes are protective 
against severe malaria. We have hypothesised that the mechanism of protection is 
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through reduced rosetting. Here I set out to test that hypothesis firstly by testing the 
ability of a range of CR1 deficient erythrocytes to adhere to rosetting laboratory isolates, 
and secondly by studying rosetting in isolates from severe and uncomplicated malaria 
patients from Papua New Guinea. A previous study found that rosetting in Papua New 
Guinea was not associated with disease severity(al-Yaman et al. 1995) in contrast to most 
studies in Africa(Carlson et al. 1990; Ringwald et al. 1993; Rowe et al. 1995). This 
challenged the idea of rosetting as a cause of severe disease. However the data presented 
in the previous chapter suggests an alternative idea: that due to polymorphisms in one of 
the main receptors for rosetting in Papua New Guinea the nature and disease associations 
of rosetting may be significantly altered. The aim of this study is to understand the 
epidemiological difference between African and Papua New Guinean rosetting studies in 
molecular terms and so gain a better understanding of the molecular basis of severe 
disease. 
Combining two pieces of information - the importance of CR1 for rosetting in Africa and 
the low level of CR1 on the red blood cells of most Melanesians, we set out to test the 
hypothesis that the rosetting previously observed in malaria patients in PNG is mediated 
through receptors other than CR1. We hypothesise that the rosettes seen in CR1 deficient 
Melanesians are not as strong as those mediated via CR1 and may be unable to withstand 
physiological shear forces, therefore such rosettes are not implicated in the pathogenesis 
of severe disease. Furthermore, a minority of Melanesian individuals have sufficient 
CR! expression for this to be used by the parasite for rosetting, and we predict that in 
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these patients, stronger rosettes could be formed that may be associated with severe 
disease. We decided to test this hypothesis by comparing the host receptors for rosetting 
and CR1 expression in severe and uncomplicated malaria cases. The study also gave us 
an opportunity to observe ex-vivo if rosette formation was impaired as a result of any of 
the common red cell polymorphisms that exist in Papua New Guinea. In addition to c( -
thalassaemia we also typed samples for the deletion of exon 3 in glycophorin C 
responsible for the Gerbich blood group type and for Southeast Asian ovalocytosis. 
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6.2 Methods and Study Design 
6.2.1 In-vitro studies with laboratory rosetting clones 
We first of all set out to determine the ability of uninfected erythrocytes from a variety of 
donors from Papua New Guinea to form rosettes with three laboratory isolates: Palo Alto 
R+, TM284+ and R29+. These isolates vary in their use of different host receptors, R29+ 
forms rosettes through CR!, while PAR+ and TM284+ are known to bind 
immunoglobulins(Scholander et al. 1996; Somner et al. 2000). PAR+ seems to bind the 
A blood group antigen while TM284+ may preferentially bind the B blood group 
antigen(Carlson et al. 1992). The erythrocytes used for these experiments were frozen red 
blood cells from the Madang donor group described in section 4.2. To measure the 
rosetting ability of an erythrocyte sample we performed a competition assay in which 
fluorescently labelled "test" erythrocytes competed with control erythrocytes (in which 
the parasites were grown) to form rosettes. The relative proportion of cells in rosettes that 
were labelled gave a relative rosetting score for that isolate. The full method is described 
in section 2.8.4. 
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6.2.2 Field study design 
We wished to compare rosetting frequency and receptor usage between parasite isolates 
from severe and uncomplicated malaria patients. We also compared CR1 expression, 
CR1 genotypes and thalassaemia between severe and uncomplicated malaria patients, and 
asymptomatic controls. However as the number of severe cases collected was small we 
collected asymptomatic controls matched to uncomplicated malaria patients as well as to 
severe malaria patients. Severe malaria was defined according to World Health 
Organisation criteria described in(Warrell et al. 1990), in section 5.2.1. The various 
criteria are summarised in table 6.1. Uncomplicated malaria was defined as an acute 
febrile illness (axillary temperature ~! 37 °C) with detectable parasitaemia and no 
manifestation of severe malaria. As rosetting may be affected by drug 
treatment(Udomsangpetch et al. 1996; Chotivanich et al. 1998) we excluded patients who 
had take anti-malarials in the previous 2 weeks. All protocols were approved by the 
Papua New Guinea Medical Research Advisory Committee (Study Number 03.05). 
160 
Chapter 6: Rosethng in Papua New Guinea 
Table 6.1: Severe malaria criteria(Warrell etal. 1990) 
Syndrome 	 Criteria 













Blantyre coma score < 2 
Haemoglobin <5g/dI 
diagnosed by X ray 
plasma bicarbonate < 15 mmol/L 
> 5 mmol/L blood lactate 
glucose <2.2 mmol/L or 40 mg/dI 
creatinine > 265 imol/L (3mg/dI) 
>1 /24 hours 
Chest indrawing, grunting, flaring nostrils, irregular breathing 
systolic blood pressure < 60 
Other manifestations of severe malaria 
Hyperparasitaemia 	~! 20% 
Prostration 	 Inability to sit without support, or for infants inability to 
breastfeed 
Impaired 	 Blantyre coma score 3 - 4 
consciousness 
Jaundice 	 detected clinically or defined by serum bilirubin > 50 pmoI/L 
* Indicates criteria that we were unable to test for 
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6.2.3 Collection of patient samples 
Samples were collected at the paediatric outpatients department of Madang general 
hospital, which is the main referral centre for the region. This hospital was also the base 
for the case-control study described in chapter 5. Children were assessed by nursing staff 
and either treated as outpatients or admitted to the paediatric ward. No intensive care 
facilities exist, so treatment consists of oral/intramuscular drug treatment with quinine 
and artemether, and palliative care. Individuals were enrolled in the study that had a 
provisional diagnosis of malaria. A local nurse employed by the project took up to 2m1 of 
blood into EDTA tubes from each patient having obtained consent from the parents 
following an explanation of the aims of the project. The parents of the child would be 
asked questions about the patient history and a clinical assessment would be made to 
assess fever, coma score(Molyneux 1990), respiratory status and extent of prostration (if 
any). Diagnostic tests would be made on the spot for hypoglycaemia using Glucotrend 
test strips (Roche, Lewes, UK), hyperlactaemia using the Accutrend, Lactate system 
(Roche, Rotkrenz, Switzerland) and haemoglobin using the Hemocue B-Hemoglobin 
system (Hemocue, Lake Forest, CA) according to the manufacturer's instructions. Thick 
and thin smears for slide diagnosis of malaria were prepared. If the patient showed sign 
of impaired consciousness the nursing staff would take a CSF sample by lumber puncture 
and the hospital laboratories would check for meningococcal bacteria. As sample 
collection was slow and many patients had only been referred after receiving drugs at 
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local clinics, we also collected samples from the town clinic in Madang using identical 
protocols. 
6.2.4 Laboratory analysis of patient samples in Madang 
Samples were taken to the Papua New Guinea Institute of Medical Research campus at 
Yagaum about 10 miles south of Madang town. Here thick and thin smears were stained 
with giemsa and the parasitaemia counted to confirm or discount the provisional 
diagnosis of malaria. Slide positive samples with no alternative diagnosis were 
considered malaria cases and then used for experiments in Madang and prepared for 
analysis in the UK. Direct antiglobulin testing was used to determine the ABO blood 
group type of the patent (Section 2.6). Blood samples were spun through lymphocyte 
separation medium (Bio-Whittaker, Walkersville, MD), the white blood cells were then 
removed and used for DNA extraction using the Nucleon BACC2 DNA extraction kit 
according to the manufacturers instructions (Amersham, Little Chalfont, UK). The 
remaining red cells were washed twice in 10 ml iRPMI and up to 200 jfl of packed cells 
were put into culture according to standard methods (Section 2.7.3). 50 pA of blood was 
fixed for subsequent flow cytometry (Section 2.2.2) any remaining blood cells were 
frozen in glycerolyte (Section 2.2.1). The cultures were checked for growth 
approximately every 12 hours by giemsa staining (Section 2.7.3). Once most parasites 
reached the late trophozoite/early schizont stage the rosetting frequency was measured as 
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in Section 2.8.1. If the rosetting frequency was found to be >10 % then antibody 
disruption assays were performed with a panel of antibodies and reagents specific for 
various rosetting receptors to try and determine which of these may be used in rosetting 
in these isolates (Section 2.8.5). 
6.2.5 Laboratory analysis of patient samples in Edinburgh 
CR1 expression level was determined by now cytometry on the fixed red blood cells 
compared to fixed standards as described (Section 2.1)(Cockburn et al. 2002). Genotypes 
for the n3650 polymorphism in CR!, -a 37 and -a42  thalassaemia, South-East Asian 
ovalocytosis and AExon3 in Glycophorin C were carried out as described (Section 2.3 
and references therein). 
6.2.6 Collection of control samples 
Asymptomatic control samples were collected for 36/43 clinical malaria samples. 
Controls were matched by age (patient age T 20 %), ethnicity (determined by parents 
home province), location, and were collected in the same season as the clinical malaria 
samples. Location matching of samples was as follows: patients were considered to come 
from one of four areas, Madang town and periurban settlements; the North Coast, a 
narrow strip of plantations, villages and small offshore islands at sea level; the foothills 
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of the Adelbert ranges, and the south coast and trans-Gogol, the large basin and flood 
plain of the Gogol river which empties into the Pacific Ocean about 20 miles south of 
Madang (Figure 6.1). To collect samples we would inform the village leaders the day 
before of our intention to come and find children for the study. Once an appropriate child 
was found and informed consent obtained from the parents, 2ml of blood would be 
drawn, a slide prepared for parasite counts and the child's haemoglobin would be 
measured. In the lab the blood would be processed as for clinical samples but without 
parasite culture. 
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Figure 6.1: Madang town and the surrounding area showing the regions from which 
samples were collected and the villages in which controls were collected. 
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6.3 Results 1: Rosetting in Papua New Guinea 
6.3.1 Erythrocytes from Papua New Guineans rosette poorly with 
laboratory strains 
We tested a total of 46 different erythrocyte samples from the Madang population 
described in section 4.2 for their rosetting ability. Thirty samples were tested with R29+, 
10 with TM284 and 10 with PAR+ (4 samples were tested with more than two isolates). 
The control individual for these experiment was a Caucasian 0+ donor with a CR1 
expression determined as 996 per erythrocyte, the individual was HH for their CR! 
genotype. In addition to the Papua New Guinean samples we also tested 2 other 
Caucasian control samples with R29+ to ensure that our control donor did not have 
unusually highly rosetting red blood cells (Figure 6.1 a). One of the other Caucasians 
was 0+, their CR1 expression = 491 per erythrocyte and their CR1 genotype was HL, 
while the other Caucasian was 0-, their CR1 expression = 928 per erythrocyte and their 
CR! genotype was HH. Neither individual showed significantly different rosetting from 
the control donor. This result is supported by previous studies which have shown very 
little variation in the rosetting of red blood cells from Caucasians once blood group is 
accounted for(Carlson et al. 1992; Carison et al. 1994). 
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Figure 6.2: Rosetting of RBC from donors from PNG with rosetting laboratory clones. 
Clones are R29+ (a), PAR+ (b) and TM284+ (c). Bars are the relative rosetting abilities 
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of individual donor ABC each tested at least in duplicate. Error bars are standard errors. 
White bars represent 0 samples. In a dark bars represent A and AB samples and pale 
bars represent B blood group samples. In b and c A and B blood groups are represented 
collectively by dark bars. Numbers on the X axis represent the erythrocyte CR1 
expression level of the blood cells. 
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Rosetting was almost abolished in 13 0 RBC from 13 donors from Papua New Guinea 
tested with R29+ (Figure 6.2 a) with their mean (sd) relative rosetting ability being 0.154 
(0.121). Some rosetting was seen with A and B erythrocytes from Papua New Guinea 
though 10 out of 17 samples still showed significantly reduced rosetting relative to the 
control. R29+ is known to bind to CR1 but does not appear to bind to other rosette 
mediators such as IgM(Rowe et al. 2002). We therefore decided to look at some samples 
with two other strains: PAR+ and TM284+ which probably require 1gM for optimal 
rosette formation(Scholander et al. 1996; Somner et al. 2000). Rosette formation was 
also severely impaired with Papua New Guinea erythrocytes in these isolates (Figure 6.2 
b+c), particularly TM284, suggesting that CR1 is involved in the rosetting of these 
parasites in addition to other binding interactions. We compared the ability of these 
parasites to bind 0 erythrocytes from Papua New Guinea (to avoid the compounding 
factors of A and B blood groups for which parasites vary their affinity) and found 
significant differences between the ability of all the laboratory clones to form rosettes 
with melanesian erythrocytes (P < 0.01 all pairwise differences, one-way ANOVA). 
probably reflecting the fact that TM284+ and PAR+ use 1gM in addition CR1 as a 
rosetting receptor (Figure 6.3). 
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Figure 6.3: Laboratory strains vary in their ability to rosette with CR1 deficient cells. Y 
axis is the mean of the relative rosetting of 0 blood group samples tested with the 
respective strains. 
6.3.2 Rosetting is dependent upon blood group and thalassaemia in vitro 
We used the large number of samples we had tested with strain R29+ to try and 
determine the main factors affecting the ability of a given sample to rosette. We therefore 
analysed the data by ANOVA initially incorporating blood group, thalassaemia, and CR1 
expression into the statistical model. In this analysis the relative contributions of these 
variables to the final rosetting ability can be analysed. Unsurprisingly blood group was 
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the major determinant of the final rosetting ability (P = 0.0032; Figure 6.4 a). Strikingly 
there was a significant difference in rosetting between cells from non-thalassaemic 
individuals and homozygous thalassaemic individuals (P = 0.05) (Figure 6.4 b) with 
heterozygotes being similar to normal individuals. This was true when CR1 expression 
was included in the model. Thus it appears that the mechanism by which thalassaemic 
cells show reduced rosetting is both through reduced CR1 expression and a second effect 
- probably microcytosis(Carlson et al. 1994), but potentially altered binding of 
inimunoglobulins(Luzzi et al. 1991). Within the PNG sample increased CR1 expression 
did not significantly increase rosetting whether or not blood group was included in the 
model (P> 0.2). However all samples tested had low CR! expression and the range 
tested was small (minimum CR! expression = 0, maximum =258) so perhaps this not 
surprising (Figure 6.4 c). 
172 
















1 	3 	13 









n 8 	6 	14 











0LI 	On 	DO 	0 
0 50 100 150 200 250 300 
CR1 expression 
Figure 6.4: Factors potentially affecting R29+ rosetting in vitro a. blood group, b. 
thalassaemia and c CR1 epxression. Thalassaemia genotypes are aa/cxa: normal a-
globin gene structure, -alaa, f-thalassaemia trait and -cd-a for cC-thalassaemia. In a 
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and b the y axis is the mean of the relative rosetting abilities of samples with the given 
trait. In c individual observations are ploted against CR1 expression. 0 erythrocytes are 
denoted by squares (trendline is dotted) while other blood groups are denoted by circels 
with a solid trendline. Neither trendline denotes a significant relationship between Cr1 
expression and relative rosetting of the cells tested (P>0.6). 
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6.3.3 Rosetting is not associated with severe malaria in Papua New 
Guinea 
Having demonstrated that red cells from Papua New Guinea do not support rosetting well 
with laboratory strains we wanted to see if rosetting occurred naturally in Papua New 
Guinea. Accordingly we carried out a study in Madang to measure rosetting and to try to 
determine the receptors used for rosetting. It was possible to assess the rosetting 
frequency in 13 severe malaria cases and 25 cases of symptomatic non-severe malaria. 
The median rosetting frequencies were 2% and 3.5% respectively (Figure 6.5). Therefore 
rosetting was not associated with disease severity in PNG (P=0.74, Mann Whitney U 
test). In non-severe malaria cases the median rosetting frequency is comparable to figures 
from the rest of the world (Table 1.3 and references therein). The median frequency of 
rosetting for severe malaria cases is lower than any other severe malaria cohort in the 
world (Table 1.3). This data confirms the previous result in PNG that rosetting is not 
associated with severe disease in this population(al-Yaman et al. 1995). There are 
however a number of differences between the studies. The previous study is much larger 
and uses age-matched controls, it also only includes cerebral malaria cases. In our study 
there were only a few examples of each disease type so the results were not separated, 
hoWever taken together it appears that rosetting is not a major determinant of disease 
severity in PNG. Our median frequencies for rosetting were much lower than the other 
study in PNG suggesting a systematic difference in counting rosettes or preparing 
parasites. 
175 










median 	3.25 	 2 
IQR 	0 - 15 0.25 - 4.5 
n 25 	 13 
Disease Type 
Figure 6.5: Rosetting is not associated with severe disease in Papua New Guinea. Each 
point represents mean rosetting frequency of a single isolate. Rosetting frequency is the 
percentage of mature stage parasites forming rosettes, disease severity is according to 
WHO criteria(Warrell et al. 1990). 
Having confirmed the previous result that rosetting is not associated with severe disease 
in Papua New Guinea we wished to try and determine what is "different" about rosetting 
in Papua New Guinea compared to African situations. We hypothesised that rosettes in 
Africa and perhaps Papua New Guineans with severe disease might be stronger and held 
together by qualitatively and quantitively different interaction than rosetting in PNG 
patients with uncomplicated malaria. 
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6.3.4 CR1 is rarely a receptor for rosetting in Papua New Guinea 
To try and develop a qualitative picture of the receptors used for rosetting in Papua New 
Guinea we used the rosettes disruption assays described in Section 2.8.5. We used the 
antibody J3B1 ito disrupt rosettes which are formed via CR1. J3B1 1 is an anti-CR! 
monoclonal that binds to the region of CR1 which PfEMP1 uses as a receptor and is 
capable of disrupting rosettes as well as preventing de-novo rosette formation(Rowe et al. 
2000). As positive control we tested the ability of this antibody to disrupt rosettes from an 
R29+ culture (Figure 6.6 a), it was able to reduce rosetting to = 50% of the original 
culture and an isotype control. A similar result was also found for PAR+ though not for 
TM284+ (Figure 6.6 a). We were concerned that the presence of other receptors (such as 
the A blood group antigen) would prevent the J3B 11 from disrupting rosettes so we 
tested its ability to disrupt R29+ rosettes formed in A blood. A lower but still significant 
reduction was observed in this experiment (Figure 6.6 a). To test for the involvement of 
immunoglobulins in rosette formation we attempted to disrupt rosettes with a rabbit 
polyclonal serum raised against human immunoglobulins as described previously(Rowe 
et al. 2000). However this was not possible even with strains such as PAR+ and TM284+ 
which are known to bind immunolgobulins by other means(Somner et al. 2000) (Figure 
6.6b). 
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Figure 6.6: Rosetting through CR1 is rare and may be associated with higher CR1 
expression. a. Disruption of laboratory strains with the J3131 1 mAb (dark bars) compared 
to isotype control (light bars), results are expressed as % of the rosetting frequency of 
the parent culture, results are the mean and standard error of at least three experiments. 
All experiments performed in 0 blood except R29+(A) in which experiments were 
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performed with R29+ parasites in A blood b. A rabbit anti-immunoglobulins serum does 
not disrupt rosettes (dark bars) compared to a rabbit serum immunoglobuins control 
(light bars). c. Rosette disruption in field isolates from Papua New Guinea following 
treatment with a variety of reagents relative to control treatments is shown. Light shading 
is 25-50% disruption, medium shading is 51 -75% disruption and dark shading is 76-
100% disruption. CR1 copy number is in mean molecules per cell, rosetting frequency 
(ii) is expressed as percentage of late stage parasites. 
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For analysis of receptor use in PNG we used field isolates that rosetted at a frequency of 
> 10 % were included in the experiments. Out of 8 isolates tested only 3 showed rosette 
disruption with an anti-CR! antibody, J31311 (Figure 6.6 c) compared to 14/15 Kenyan 
isolates and 5/10 Malawian isolates(Rowe et al. 2000). Interestingly CR1 was a receptor 
for rosetting in the two isolates with the highest rosetting frequency and in two isolates 
that had amongst the highest CR1 expression. The anti-immunoglobulins polyclonal 
serum, which is recorded as disrupting rosettes in many African, isolates(Rowe et al. 
2000) only disrupted one isolate weakly. The failure of the positive control means that we 
should reject this data (Figure 6.6.b). An alternative way of assessing immunoglobulin 
binding in these isolates would be to analyse them by indirect fluorescence assay(Rowe 
et al. 2002). To test the efficacy of this technique we prepared anti-human 1gM IFAs on 
sample of the laboratory strains. The 1gM binding ability of TM284+ and PAR+ was 
clearly illustrated while R29+ was found not to bind 1gM in agreement with previous 
data(Rowe et al. 2002) (Figure 6.7). As frozen isolates of many of the PNG samples exist 
it should be possible to test these for 1gM binding in due course. No staining was 
observed in negative controls with an isotype control for the anti-IgM mAb. Heparin, a 
highly sulphated sugar molecule disrupted most of the rosettes efficiently, suggesting that 
a carbohydrate interaction might be important in the absence of CR1 mediated 
rosetting(Barragan et al. 2000; Barragan et al. 2000). Finally 6/8 of these isolates were of 
the A or B blood group type. When we examined the proportion of high rosetting isolates 
(>5 % rosettes) we found a significant excess of non-O blood groups among the strongly 
rosetting isolates (P = 0.017 by Fishers exact test, see also figure 6.8 a). 
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Strain 
Figure 6.7: 1gM binding of laboratory rosetting lines detected by indirect 
immunofluoresence assay (IFA). Results are expressed as % of infected erythrocytes 
binding 1gM. Results are means and standard errors of at least 2 experiments. 
6.3.5 Associations with rosetting ex vivo 
Our experiments with laboratory adapted rosetting P. falciparum clones (section 6.3.2) 
and others have shown that rosetting is reduced in RBC from 0 blood group(Carlson et 
al. 1992), low CR1 and ((Rowe et al. 1997)and f-thalassaemic individuals(Carlson et al. 
1994). We wished to examine if these associations still existed in ex vivo samples. There 
was a trend towards increased rosetting in A, B and AB blood group individuals as 
reported in other studies (Figure 6.8 a; P = 0.19, Mann Whitney U test)(al-Yaman et al. 
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1995; Rowe et al. 1995; Barragan et al. 2000). As in section 6.3.2 we were unable to find 
a correlation between CR1 expression and rosetting within our Papua New Guinean 
samples (Figure 6.8 b; P = 0.26, one-way ANOVA), however as almost all samples are 
deficient in CR! it may be impossible to identify a correlation. Nor was there any 
evidence for RH (Figure 6.8 c; P = 0.456, Kruskal Wallis test) or non-thalassaemic 
individuals (Figure 6.8 d; P = 0.782, Kruskal Wallis test) having higher levels of 
rosetting. However the sample size here is small and the numbers of individuals with 
higher CR1 expression genotypes smaller still. The other difficulty with such 
observations is that individuals may be infected with a variety of different strains of P. 
falciparum - thus a high CR1 individual is just as likely to be infected with a non-
rosetting strain as a low CR1 individual. We found no correlation between rosetting and 
haemoglobin (P = 0.70), age (P = 0.45) or parasitaemia (P = 0.94). Out of the isolates 
tested for rosetting we identified 1 Gerbich negative individual (XB27) whose parasites 
rosetted at high frequency (18%) despite a low CR1 expression (36 molecules per cell). 
There was also one individual with Southeast Asian ovalocytosis (XB1 15), the isolate 
showed 26% rosetting (Figure 6.6 c). These results suggest anecdotally that any 
protection afforded by these genotypes is not due to preventing rosetting. 
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Figure 6.8: The effect of blood group, CR1 expression, CR1 genotype and a -
thalassaemia on rosetting ex vivo. a. Relationship between bloods groups A, B and AB 
with rosetting.b. No correlation between CR1 expression and rosetting, CR1 expression 
in molecules per cell, rosetting in all figures is in % of mature stage parasites in rosettes. 
c. Relationship between rosetting and CR1 genotypes CR1 genotypes are defined as in 
figure 4.3. d. Relationship between rosetting and a-thalassaemia, thalassaemia 
genotypes are aa/aa: normal a-globin gene structure, -a/act, ct-thalassaemia trait and - 
ct/-ct for cC-thalassaemia. 
10 
Chapter 6: Rosetting in Papua New Guinea 
6.4 Results 2: Case-control study data 
Above we have given as full an analysis of the characteristics of rosetting in Papua New 
Guinea as is possible given the relatively small sample size available. The collection of 
community controls gave us an opportunity to expand our case-control study presented in 
the previous chapter and to gain information on CR1 expression itself and its effect on 
severe and uncomplicated malaria. 
6.4.1 Severe malaria in Papua New Guinea 
It is commonly asserted that severe malaria is rarer in Papua New Guinea than 
Africa(Moir et al. 1989) (and see section 1.1.5), though due to the difficulties of 
standardising studies in different locations it has not been possible to test this directly. 
Our study provides circumstantial evidence for this, as only 14 severe malaria cases were 
recorded in 4 months, though this excludes drug treated cases. Details of the cases are 
given in Table 6.2. Previous studies suggest that in Madang around half of all severe 
malaria patients have taken medication prior to admission(al-Yaman et al. 1995). Of the 
14 severe malaria cases none died of the disease. This accords with rigorous population 
surveys that find very low levels of malaria induced mortality in this population(Moir et 
al. 1989) and with the low case fatality for severe malaria(Allen et al. 1996; Genton et al. 
1997). Overall there were 3 children with cerebral malaria, with three others showing 
185 
Chapter 6: Rosetting in Papua New Guinea 
signs of impaired consciousness, 2 children with severe malarial anaemia, 3 with 
hypoglycaemia, 1 with hyperlactaemia, 5 in respiratory distress, 5 with a history of 
convulsions and 3 were prostrated (who were not also in coma). 3 children had only 1 
manifestation of severe malaria, 7 had 2, 3 had 3 and 1 child met 4 severe disease criteria. 
10 
Table 6.2: Severe malaria cases in this study 








XB10 2.1 2 YES 1 NO 3.99 5.1 ND ND 
XB14 3.9 5 NO 1 YES 0.26 9.9 4.7 4 
XB22 3 3 YES 0 NO 1.03 10.4 ND ND 
XB23 3.4 5 YES 0 NO 3.55 8.8 3.3 1.5 
XB24 0.8 5 NO 2 NO 2.89 7.2 3.8 4 
XB25 2.5 5 NO 0 NO 2.52 4.3 7.4 2 
XB27 1.9 4 NO 1 YES 2.83 8.7 3.7 7 
XB33 1.9 4 YES 0 NO 0.60 8.7 ND 4 
XB44 3.6 2 YES 0 NO 0.17 4.6 3 5 
XB58 1 5 NO 2 NO 0.34 7.8 3.2 2 
XB61 1 4* NO 2 YES 1.63 10.7 ND 11 
XB83 4.8 5 NO 2 NO 2.52 10.7 ND 3 
XB84 3.8 0* YES 2 YES 0.13 9.4 ND 10 
XB96 3 5 NO 1 YES 9.57 9.1 ND 4 
* CSF analysis negative for menigococcal bacteria (otherwise not done) 
Shading indicates severe malaria criteria met 
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We went on to compare the laboratory and population parameters between the severe and 
uncomplicated malaria cases. The results are summarised in table 6.3. The mean age of 
uncomplicated malaria cases was 4 years 0 months which was significantly more than the 
mean age of severe malaria cases 2 years 7 months(P = 0.007 Student's T test) perhaps 
reflecting the acquisition of immunity with age(Marsh 1992). 
Table 6.3 Indices of severity between severe and uncomplicated malaria 
cases 
Parameter 	 Severe malaria Uncomplicated Asymptomatic 	P 
malaria 	controls 
Haemoglobin*(gIdl) 
mean (sd) 8.24 (2.19) 8.80 (1.93) 10.43 (1.40) 	<0.001t 
n 14 28 36 
Lactate(mmol/L) 
mean (sd) 4.16 (1.54) 2.71 (0.85) ND 	0.0082 
n 7 16 
Glucose (mmol/L) 
mean (Sd) 4.79 (3.05) 6.78 (4.07) ND 	0.156 
n 12 20 
Pma(log 10(PIjJI)) 
mean (Sd) 5.04 (3.80-5.68) 4.87 (3.47-5.50) ND 	0.49 
n 14 28 
*Haemoglobin, lactate and glucose were found to be normally distributed. Analysis is by 
T test or one-way ANOVA for these variables. 
By one-way ANOVA across all three classes, however there is no significant difference 
between severe and uncomplicated malaria cases (P = 0.40) 
Parasitaemia had a skewed distribution data is given as median and range with number 
of observations in italics, analysis is by Mann Whitney U test. 
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Haemoglobin was not significantly different between severe and uncomplicated malaria 
cases, perhaps reflecting the small number of severe anaemia patients in this study. 
Lactate was significantly associated with disease severity even though only one patient 
met the criteria for hyperlactaemia (> 5 mmoIIL). This is in accordance with previous 
data showing that in Madang lactate levels are one of the most powerful predicates of 
disease severity(Allen et al. 1996). The lack of significant difference in parasitaemia 
between severe and uncomplicated malaria cases is not an original result but once again 
emphasises that parasite load is not a principal determinant of disease severity. 
6.4.2 Erythrocyte CR1 expression level may be reduced in malaria 
infections 
Having shown in the previous chapter and elsewhere(Allen et al. 1997) that genotypes 
associated with low CR! expression such as the L allele and cC-thalassaemia protect 
against severe malaria, we wanted to use our data to compare the actual CR1 expression 
between severe and uncomplicated malaria cases and their matched controls. To our 
initial surprise CR1 expression was slightly lower in individuals with both severe and 
uncomplicated malaria than on controls (Figure 6.9 a and b) though this was not 
significant by one-way ANOVA with just CR! expression in the statistical model (P> 
0.10 for both syndromes). 
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Figure 6.9 
a 	 b 
250 	 250 
• 	Control 	 • 	Controls 
200 	 Severe Malana 	 200 	 fl Mild Malaria 
	
C 	 C 
.2 0 
150 	 150 
0. 	 0. x 
100 	 100 
0 :1 50 5 	 IT 
n 	I-i 	0 1 	6 5 	8 8 	 ,, 	22 22 	0 4 	7 7 	15 1 
All 	1+1 HL LL 
All 1+1 HL LL 
CR1 genotype 	 CR1 genotype 
Figure 6.9: CR1 expression is dependent upon malaria infection and CR1 genotype. a. 
Severe malaria and b. uncomplicated malaria. Dark bars are the mean CR1 expression 
level of control individuals, while the light bars are the mean CR1 expression levels of 
infected individuals all subdivided by CR1 genotype. Error bars are standard errors. 
One possible explanation for this data is that malaria infection itself is directly affecting 
erythrocyte CR1 expression. This has been observed for severe anaemia patients in 
Kenya(Waitumbi et al. 2000; Stoute et al. 2003). We subdivided our malaria cases and 
controls by CR1 genotype. The data was then analysed by 2-way ANOVA with both CR! 
expression and case or control status in the model. We found that for any given genotype 
the malaria cases (severe or uncomplicated) had much lower CR! expression than 
genotype matched controls (P < 0.05 by 2-way ANOVA for both severe and 
uncomplicated malaria). We examined the distribution of CR! genotypes among severe 
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and uncomplicated malaria cases and controls. Despite the decreased CR1 expression 
overall among malaria cases, in accordance with the data in chapter 5 there we find a 
higher gene frequency of the H allele among the severe and mild cases compared to their 
controls. This is not statistically significant, presumably due to the small sample sizes 
(gene frequency (H) for severe malaria = 0.25, controls = 0.22, P> 0.2 by x2  test; gene 
frequency (H) for uncomplicated malaria = 0.34, controls = 0.16, P = 0.10 by x2  test). 
There was no difference between the mean erythrocyte CR1 expression of samples from 
severe and uncomplicated malaria patients (Figure 6.9 a and b, P > 0.2) suggesting that 
the severity of disease does not affect CR1 expression in this population. The sample 
sizes were too small to compute logisitic regression analyses to determine the odds ratios 
for risk of severe malaria among the different genotypes. 
Overall CR1 expression among these samples is dependent on CR1 genotype (P < 
0.0001) and infection (severe or mild) (P = 0.019) by multi-way ANOVA with 
thalassaemia also included in the model. There is also a trend for lower CR1 expression 
in thalassaemic individuals as reported in chapter 4 (P = 0.19). 
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6.5 Discussion 
In the work presented here I aimed to determine what the effects of CR1 deficiency in 
Papua New Guinea were on rosetting and severe disease. We confirmed the results of a 
previous study in showing that rosetting was not associated with severe disease(al-Yaman 
et al. 1995). Although in contrast to al-Yaman et al.(al-Yaman et al. 1995) we found a 
very low overall frequency of rosetting in this population. We also show that CR1 is 
rarely a receptor for rosetting and that rosetting in this population does not correlate with 
CR1 expression or genotypes associated with higher CR1 expression. Our study was 
hampered by difficulties in finding severe malaria cases, though we hypothesise that the 
low level of severe disease in Papua New Guinea might be in part a direct result of the 
rarity of CR1-mediated rosetting. 
Our in vitro data in which we measured the ability of erythrocytes from CR! deficient 
Papua New Guineans clearly demonstrates that these cells rosette poorly with rosetting 
laboratory strains. This was especially true with R29+ which is well documented as 
rosetting via CR1(Rowe et al. 1997; Rowe et al. 2000). Rosetting ability was found to be 
dependent on blood group (a result echoed in the ex-vivo data), and on thalassaemia. The 
thalassaemia effect was still present when CR1 expression was included in the model, 
showing reduced rosetting in these cells was not only mediated by low CR1 but by 
another factor too: possibly microcytosis. Though the effect of thalassaemia on rosetting 
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in vitro has been reported previously(Carlson et al. 1994) it has not been possible to 
replicate the result in other laboratories (David Roberts personal communication). 
Moreover in the study by Carison et al.(Carlson et al. 1994) the origin of the cells is not 
given, though it may have been Papua New Guinea, and the data might have been 
attributable to low CR1 expression caused mostly by the L allele as well as thalassaemia. 
These data accounting for all known factors affecting CR1 expression show that the 
effect of thalassaemia is probably real and dependent on both a reduction in CR1 
expression and a second factor too. 
A previous study on rosetting in Papua New Guinea found that rosetting was not 
associated with cerebral malaria(al-Yaman et al. 1995). This was counter to all African 
studies then published(Carlson et al. 1990; Ringwald et al. 1993; Rowe et al. 1995) and 
suggested that rosetting might not, after all, be a major parasite virulence factor. However 
our data showing that CR1 deficiency is almost universal in Papua New Guinea suggests 
another hypothesis: that CR1 is essential for disease-causing rosettes. This could be 
because rosettes formed without CR1 are too weak to withstand the sheer forces in the 
circulation - and therefore that the rosettes previously observed in in vitro culture from 
Papua New Guineans would not be able to cause severe disease in vivo. Though we too 
found no association between rosetting and severe disease our results differed from those 
of the previous study in finding many isolates without rosettes at all. This systematic 
difference may be explained by differences in counting protocols, we cultured parasites at 
2% haematocrit however al-Yaman et al., cultured at 5%. This does not affect rosette 
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formation (J. A. Rowe, DPhil Thesis) but may cause an overestimation of rosetting as 
many non-specific cell-cell contacts may be seen on a slide at 5% haematocrit. 
Nonetheless when our results from Papua New Guinea are compared to those from 
studies in Africa from our group(Rowe et al. 1995; Rowe et al. 2002) (which use 
identical methods) then it appears that rosetting frequencies in this population are lower 
than in Africa especially in the severe malaria group. In Kenya an association between 
parasitaemia and rosetting has been reported, this association is particularly strong in 
isolates from severe cases(Rowe et al. 2002). The authors suggest that this correlation is 
indicative of increased invasion or immune evasion by rosetting parasites. In Papua New 
Guinea we do not see such a correlation, which would be expected if there were no 
selective advantage to the rosette formation observed in this population. 
Initially we aimed to determine if there was a difference in receptor use in rosettes 
formed in culture from severe and uncomplicated parasite isolates. However this study 
was hampered by a lack of severe cases and a lack of highly rosetting isolates. We were, 
however, able to examine the receptor choice across all isolates. Strikingly an anti CR1 
antibody disrupted rosetting in only 3/8 isolates. The two isolates with greater than 50% 
rosette disruption had the highest rosette frequencies. Only 3 of the 8 isolates tested for 
rosette disruption had erythrocytes with CR1 expression >50 molecules per cell and two 
of those showed rosette disruption with an anti-CR 1 antibody, these two individuals also 
had at least one H allele. All other high rosetting isolates had very low CR1 expression so 
it was not unexpected that their rosettes were not disrupted with the anti-CR1 antibody. 
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The rarity of CR1 adhesion probably explains why we were unable to detect any 
associations between erythrocyte CR1 expression level or the genotypes controlling this 
phenotype and rosetting frequency. Another hindrance to trying to detect differences in 
rosetting frequency between the different genotypes in Papua New Guinea is the 
fractional difference in CR1 expression between them. As almost all individuals have low 
CR1 expression, a large sample size would be required to detect what are likely to be 
marginal differences between genotypes at a significant level. We have hypothesised that 
CR1 mediated rosettes are stronger than others, though this has not yet been tested 
experimentally. To test this we intend to study difference parasite isolates under 
conditions of sheer stress and to measure the detachment forces required to directly 
disrupt rosettes(Nash et al. 1992; Chu et al. 1997; Chotivanich et al. 2000). 
We must reconcile the fact that rosetting appears to have exerted selective pressure on the 
CR1 gene and yet is not apparently a cause of severe disease. We hypothesise that a 
proportion of rosettes formed in Papua New Guinea are formed via CR1 and that these 
are capable of causing severe disease. Rosetting studies may fail to detect an association 
because they do not distinguish between physiologically significant rosettes and in vitro 
artefacts. Moreover as rosetting is only rarely a cause of severe disease, most severe 
disease in this population is caused by other factors such as immunopathology and 
metabolic disturbances. Thus rosetting as a cause of severe disease is very difficult to 
detect on this background. It is as though we have arrived at the scene of the crime too 
late since CR! deficiency has almost reached fixation in this population and there is now 
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very little CR1 binding causing pathology in this population. Only large studies such as 
that presented in chapter 5 could have the power to detect the selective effect of rosetting 
parasites and severe disease on CR1, whereas smaller studies such as this one have little 
power to detect the rare cases where rosetting is a cause of severe disease. Finally we 
might consider if CR1 deficiency has affected the evolution of the parasite. If there is no 
CR! to bind to form rosettes, CR1 binding is unlikely to confer an advantage to the 
parasite. Therefore there may have been selection in the parasite population against CR1 
binding variants. There is a precedent for this in Papua New Guinea. The merozoite red 
cell binding ligand BAEBL has various alternative types, one of which mediates invasion 
via glycophorin C, while the other variants use an alternative receptor(Mayer et al. 2002). 
In Papua New Guinea most parasites express the alternative version of BAEBL are 
found(Mayer et al. 2002), perhaps because glycophorin C binding parasites have been 
selected against by the Gerbich mutation which is found in Papua New Guinea and 
prevents invasion via glycophorin C(Mayer et al. 2002; Maier et al. 2003). 
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Chapter 7: 
Conclusions, confusions and future work 
Pedants and philosophers of science point out that there is no such thing as a scientific 
conclusion; a scientist's work, it seems, is never done 7. But inasmuch as we have to agree 
on something to get anywhere I would regard the following as more-or-less settled. 
Most philosophers of science seem to have very little idea of what researchers actually 
do and are rightly ignored by scientists, but one good account of the scientific method is 
"The rationality of science" by W.H. Newton-Smith (Newton-Smith 1981) 
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We have been able to validate a method for the determination of erythrocyte CR1 for 
use on cells that have been fixed or frozen. This method is therefore usable for field 
settings and for analysing blood long after it has been taken. 
Individuals from Papua New Guinea have low erythrocyte CR1 expression, which is 
genetically determined by polymorphisms in the CR1 gene and cC-thalassaemia. We have 
not ruled out the involvement of other genetic and environmental factors such as 
infection having an effect on CR1 expression. 
The CR1 L allele confers protection against severe malaria. 
Erythrocytes from Papua New Guineans with low CR! expression show reduced 
rosetting compared to high CR1 Caucasian erythrocytes with rosetting laboratory P. 
falciparum clones. 
Rosetting is rare in Papua New Guinea, not mediated by CR! and not associated with 
disease severity. 
The data that leads us to these conclusions is in each of the results chapter and the 
reasons for accepting them are given in the corresponding discussion section. Thus far in 
my discussions I have tried to restrict myself to what is in the literature. But when 
thinking of future directions for work what is more interesting is to look at the things we 
do not know and to speculate on what we might want to know: 
1. We have not demonstrated formally that the CR1 L allele protects as a result of 
reduced erythrocyte CR! expression rather than some other functional effect. 
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We do not know if the protective effect of thalassaemia is a result of its effect on CR1 
expression or whether it acts by some other means. 
We do not know why low CR1 has been selected for in Papua New Guinea but not in 
African populations. 
We do not know if the mechanism of protection by the L allele is reduced rosetting (we 
have only hypothesised this). 
If reduced rosetting is the protective mechanism of this polymorphism we must 
reconcile that with the fact that rosetting is not apparently associated with severe disease 
in this population, so how can it exert the necessary selective pressure? 
Does low CR! expression explain the lower mortality due to malaria in Papua New 
Guinea compared to Africa? 
I shall try and examine each of these in order though many of the issues are overlapping. 
It shall be up to other scientists, or their funding councils, to decide if any of these leads 
are worth following. 
Our study shows that the L allele is protective against severe malaria, it does not show 
that the low CR! expression per se protects against severe malaria. The L allele is 
associated with two things: firstly it consists of a number of polymorphisms in the coding 
region of the CR1 molecule at least one of which lies in a binding site for CR1(Herrera et 
al. 1998; Xiang et al. 1999), secondly in populations outside Africa the L allele is 
associated with reduced erythrocyte CR! expression (Table 4.1 and references therein). 
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The strongest evidence that the L allele is acting through CR1 expression is the fact that 
the coding polymorphisms in the L allele exist in African populations but are not 
apparently selected for in this area(Rowe et al. 2002). Therefore we believe that the effect 
must be on CR1 expression. Sceptics could point out that there is in fact not much 
difference in the mean CR1 expression between HH and LL individuals CR! in Papua 
New Guinea as most individuals have low CR1. However a subset of individuals with H 
alleles will have high CR1 expression (the range in Madang goes up to 439 and in New 
Ireland to 839) and it is on individuals such as these that selection will act. So it does 
seem likely that the L allele is acting through CR! expression. 
We might legitimately ask how little CR1 is protective - do I simply need a bit less CR1 
than my neighbour, say 300 molecules per cell to his 400 to be protected against malaria 
relative to him or do I need to get my CR1 levels below a particular threshold, say 100 
molecules per cell before I see any benefit. If the mechanism of protection is indeed 
rosetting this is tied up with the amount of CR! required for stable rosette formation. The 
data in section 6.3.1 suggests that all the Papua New Guinea samples (with 0 blood) 
show reduced rosetting compared with Caucasian samples even those with intermediate 
CR1 expression. This suggests a threshold, i.e. above around 200 molecules per cell 
rosetting can be sustained, below this amount and you are protected. However these are 
static assays, under conditions of sheer stress such as in the circulation rosettes formed in 
static culture with red cells with 250 molecules/cell of CR1 may come apart whereas 
those formed with RBC expressing 900 molecules of CR1 may hold together. These 
200 
Chapter 7: Conclusions 
"dose response" experiments are some of the basic experiments in the rosetting field that 
have not been done. 
It is unclear if thalassaemia is acting through CR! expression or independently of this. 
There is no clear correlation between the risk a particular genotype combination confers 
to malaria and mean CR1 expression associated with it. We point out that HH; aa/acL 
individuals are the most at risk of severe malaria, but this could be result of simply 
having 4 risk loci, it does not mean that the loci are acting through the same mechanism. 
Far better evidence of genes acting in concert comes from linkage disequilibrium studies, 
which show if genes are selected together. As such we would expect the L allele and c-
thalassaemia to be found together, even despite the fact that they are not genetically 
linked (on the same chromosome). Evidence from our own small population survey finds 
no evidence of linkage disequilibrium occurring between these genes, though much larger 
surveys may be necessary to reveal this. On a global scale there is linkage disequilibrium 
in that the highest frequencies of a-thalassaemia occur where there is the highest level of 
the L allele i.e. in Southeast Asia and Papua New Guinea(Flint et al. 1993; Flint et al. 
1998). In Africa where there does not appear to be any genetically determined CR1 
deficiency cx-thalassaemia is much rarer(Flint et al. 1993; Flint et al. 1998). The 
discussion in the preceding paragraph about how much or little CR1 is protective 
suggests an explanation for this: these results could be rationalised if both a lesion in the 
CR1 gene and a-thalassaemia were required for CR1 levels to be low enough to be 
protective against severe malaria. If the threshold for rosetting were 200 molecules per 
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cell, having a couple of L chromosomes may not be sufficient to have low enough CR! 
levels (see Figure 4.2) but having a a-thalassaemia gene can lower the CR! sufficiently 
to be protective, thus the two genes may have been selected together in Papua New 
Guinea and perhaps parts of Southeast Asia. If this is true it seems that in our population 
thalassaemia is protecting through CR! deficiency. However thalassaemia does exist in 
Africa, so what is it doing there? Most probably ct-thalassaemia has a protective effect 
against malaria independent of erythrocyte CR1 deficiency. Many candidates have been 
put forward: impaired growth(Senok et al. 1997) (though cf.(Luzzi et al. 1990)), altered 
cytoadhesion(Udomsangpetch et al. 1993) and altered immune recognition(Luzzi et at. 
1991). All of these are controversial and hard to test in the field, but perhaps they all have 
some truth in them. Of course no one has yet checked that the populations in Africa 
(which contains more genetic diversity than the rest of the world) that do have a-
thalassaemia do not also have a CR! deficiency allele. 
So why has the L allele or erythrocyte CR! deficiency not been selected for in Africa? 
CR1 deficiency seems to be as rare in Africa as in Northern Europe. One reason may lie 
in the preceding paragraph - without a second allele like a-thalassaemia with which to act 
a lesion in the CR1 gene affecting its erythrocyte expression may not confer any selective 
advantage. An alternative explanation is that the genetic lesion that causes CR! 
deficiency (and is linked to the SNPs that constitute the L allele in non-African 
populations) never arose in African populations. We cannot know if this is the case until 
we know what that genetic lesion is. One hypothesis is that the H and L chromosome are 
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ancient and that the lesion arose on an L chromosome, possibly only after humans left 
Africa. Mapping the site of the genetic lesion would probably enable dating of the 
mutation by tracing the most recent common ancestor of populations that have the same 
mutation. Further support for the idea that the lesion has only arisen once come from the 
fact that it is probably seen on only one genetic background - the L allele. If the lesion 
had arisen many times the question of why it had not arisen in Africa would be even 
harder to skirt around. 
The final explanation for the lack of CR1 deficiency in malaria endemic populations in 
Africa might be the presence of alternative CR1 polymorphisms such as the Knops 
bloods groups types notably Sl:2 and McCb which may have been selected instead. Can 
several malaria resistance genes be selected together, or is one enough and so there is less 
pressure for more such genes to be selected for in a population? The presence of a-
thalassaemia, CR1 deficiency, ovalocytosis, Gerbich blood groups and glucose-6-
phosphate dehydrogenase polymorphisms in the same populations in Papua New Guinea 
suggests that they can be selected together. Our own data shows that the most protected 
people against severe malaria are those with two most beneficial genotypes: a-/a- and 
HL - in other words the protective effects appear to be additive. However all these 
polymorphisms are in different genes from each other, what happens when several 
different polymorphisms arise in a single gene such as CR!. If the polymorphisms arise 
on different backgrounds - if the Sl 2 allele arises on an H chromosome, while CR1 
deficiency arises on an L chromosome, those alleles are going to in direct competition 
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with each other. The usual outcome of such a head to head battle is that the least 
beneficial allele will disappear, or more likely fail to establish itself in the first place. 
Only in circumstances such as balancing selection do polymorphisms establish 
themselves at frequencies intermediate between 0 and 1. 
In the final chapter I attempt to test the hypothesis that the mechanism by which low CR1 
protects against severe malaria is reduced rosetting. To do this properly would require a 
large case-control study in which we were able to identify individuals with high CR1 
whose parasites rosetted well in their blood via CR1 and who developed severe disease. 
The work presented does not do this, but it does give some evidence in favour of this 
hypothesis and finds none that can rule it out. 
The evidence for reduced rosetting being the mechanism of protection is the following: 
rosetting appears to occur at a lower level in Papua New Guinea compared to what is 
seen in Africa. In particular comparison of African and Melanesian data shows that a 
pool a group of individuals are missing from the Melanesian study - severe malaria cases 
with high numbers of rosettes. Circumstantial evidence for reduced rosetting being the 
mechanism of protection by low CR1 comes from the observation that rosetting is not 
associated with severe disease in this population. This could be explained if the lack of 
CR1 in this population meant that rosetting simply was no longer an important 
determinant of disease severity - thus in Papua New Guinea severe disease is probably 
caused other parasite phenotypes such as ICAM1 adhesion(Newbold et al. 1997), TNF-a 
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release(Clark et al. 1991; Clark et al. 1993; Turner et al. 1998) and metabolic 
disturbances(Marsh et al. 1995). In 1999 trying to explain why rosetting was not 
associated with severe disease in a population in Malawi Rogerson et al. comment "It 
will be important to examine the prevalence of rosette formation receptors in different 
populations in relation to the frequency and intensity of rosette formation and in relation 
to the association between rosette formation and disease severity in these 
populations"(Rogerson et al. 1999). This certainly appears to be the case in Papua New 
Guinea. 
However, if this hypothesis is true we would expect to find individuals who are 
homozygous for the H allele, with high CR1 expression and a high frequency of rosette 
forming parasites among the severe cases. No such individuals were found. However 
individuals with high CR1 expression are few and far between in this population. These 
individuals would also have to suffer the misfortune to be infected with a parasite capable 
of taking advantage of the high levels of CR!. Such parasites may have been selected 
against as we discussed in the previous chapter. Nonetheless we did find two individuals 
with high rosetting frequencies and at least one H allele, the rosettes from these patients 
could be disrupted with an anti-CR! antibody (Figure 6.6). As stated in the discussion to 
chapter 6 it appears that we are looking at a selective process that is almost complete and 
so people unfortunate enough to have "risky" levels of CR! expression are rare. Only a 
large survey such as that in chapter 5 could have the power to detect the protective effect 
of the L allele relative to the rare H allele. 
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We set out to determine if rosetting was a cause or correlate of parasite virulence. By 
showing the crucial importance of CR1 polymorphisms in disease susceptibility and by 
studying their effect on rosetting we appear to have some strong evidence that rosetting is 
a cause of severe malaria. However can we rule out the possibility that CR1 adhesion 
rather than rosetting might be the true. In other words could rosetting via CR1 be a 
correlate of another adhesion process: parasite binding to macrophages and B cells via 
CR1 which is the true cause of severe disease. There is a small amount of evidence that 
rosetting lines can cause enhanced TNF-a release(O'Dea et al. 2003) perhaps by some 
interaction with macrophages. Nonetheless there is a certain amount of evidence against 
this - notably the fact that the polymorphisms we have discussed: the CR! L allele and 
ct+-thalassaemia are red cells specific( Wilson et al. 1986). 
The final and most controversial question I want to tackle is whether the low CR1 
expression seen in Papua New Guinea could explain the low malaria mortality in this 
population. Firstly as we saw in section 1.1.6 it is still controversial that there is actually 
lower mortality than would be expected around Madang, though three things convince 
me that it is - firstly the low mortality observed in a large population census around 
Madang(Moir et al. 1989), secondly the relatively low case fatality rates for cerebral 
malaria(Allen et al. 1996), and thirdly (the least scientific but for me the most 
compelling) the low number of cases of severe malaria that we saw in the study in 
Chapter 6 over a four month period. To explain low mortality in Papua New Guniea some 
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authors have suggested the prevalence of P. vivax, other protective polymorphisms and a 
limited range of parasites. However while some researchers have suggested that infection 
with P. vivax might provide some immunity to P. falciparum (based on epidemiological 
studies of (t-thalassaemia which enhances susceptibility to clinical infection with 
both( Williams et al. 1996)) there is no direct evidence of this. Moreover if P. vivax were 
beneficial then mutations in the Duffy blood group antigen should never have arisen in 
Papua New Guinea(Zinimerman et al. 1999). The presence of malaria resistance genes 
such as ovalocytosis and the Gerbich blood group are unlikely to have much effect on 
overall mortality as they rarely reach frequencies > 10 % in this population (Genton et 
al. 1995; Allen et al. 1999) and this study. Parasite diversity does indeed appear to be 
limited in neighbouring Vanuatu where there is virtually no malaria mortality(Maitland et 
al. 2000), however PNG is a much larger island, and studies find no shortage of diversity 
at either the AMA-i or MSP-1 loci(Felger et al. 1994; Cortes et al. 2003). The low level 
of CR! conferred by a 4 -thalassaemia and CR1 polymorphisms could however be 
responsible for reduced mortality: there is a hypothesised protective mechanism, which 
there is not for cross-protection with P. vivax. The polymorphisms are together present in 
virtually the entire population around Madang, but not in Africa whereas polymorphisms 
such as ovalocytosis, though absent from Africa are too rare in Papua New Guinea to 
have an overall effect on mortality. Finally low CR1 and its protective effect have been 
documented in this study, whereas no evidence exists for limited parasite diversity. 
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What, then, is the overall significance of these results? We have identified a new malaria 
resistance gene - the L allele of the CR1 gene. Secondly we have identified a novel 
mechanism by which a-tha1assaemia might protect against severe disease. Protective 
polymorphisms in erythrocyte CR1 are clear evidence that CR1 is an important rosetting 
ligand for many parasite strains in the wild and not merely an unusual adhesion 
phenotype of the R29+ parasite clone. Finally the fact that protective polymorphisms that 
reduce CR! binding and rosetting have been selected for is the strongest evidence yet that 
rosetting is a cause, and not a correlate of, parasite virulence and mortality. That means it 
is an important target for the development of drugs and vaccines against severe malaria. 
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Abstract 
The mean number of complement receptor 1 (CR1) molecules on erythrocytes differs between normal individuals within the 
range of 100-1000 molecules per cell. In some disease states such as systemic lupus erythematosus (SLE), acquired immune 
deficiency syndrome (AIDS), insulin-dependent diabetes mellitus and malaria, erythrocyte CR1 levels are reduced and CR1 
function may be impaired. Current methods for determining eiythrocyte CR1 levels by flow cytometry require the use of freshly 
drawn blood samples because CR1 is lost from eiythrocytes during storage. In order to facilitate field studies of associations 
between erythrocyte CR1 levels and disease, we have developed and validated an assay to quantify CR1 on both healthy and 
diseased erythrocytes that have been fixed in 5% formaldehyde or frozen in glycerol. These methods enable blood samples to be 
collected in areas lacking the facilities for flow cytometty and stored for later accurate quantification of CR1. Such procedures 
will be of particular benefit for future investigations of erythrocyte CR1 expression level and malaria susceptibility. 
© 2002 Elsevier Science By. All rights reserved. 
Keywords: Complement receptor I; Erythrocyte; Flow cytometry; Formaldehyde; Glycerol; Malaria 
1. Introduction 
Abbreviations: ABS, AR Serum; AIDS, acquired immune 
deficiency syndrome; BSA, bovine serum albumin; CR1, comple-
ment receptor I; EDTA, ethylenediaminetetraacetic acid; ELISA, 
enzyme-linked immunosorbent assay; HEPES, N-2-hydroxy-ethyl-
piperazine-N-2-ethanesulphonic acid; PBS, phosphate-buffered 
saline; SLE, systemic, lupus erythematosus; Iris, 2-amino-2-
(hydroxymethyl)-1 ,3-propanediol. 
* Corresponding author. Tel.: +44-131-650-5492; fax: +44-131-
650-6564. 
E-mail address: Alex.Rowe@ed.ac.uk (iA. Rowe). 
EA3309; 1FR53. Pole biomolecule. 
The level of complement receptor 1 (CR1) on 
erythrocytes is important in a variety of disease pro-
cesses. Reduced levels of erythrocyte CR1 correlate 
with disease severity in acquired immune deficiency 
syndrome (AIDS), systemic lupus erythematosus 
(SLE) (Kazatchkine et al., 1987) and insulin-dependent 
diabetes mellitus (Ruuska et al., 1992). In the case of 
SLE, low CR1 levels may cause pathology because the 
normal function of CR1 in regulating complement 
activation and removing immune complexes from the 
circulation is impaired (Gibson and Waxman, 1994). In 
malaria infection, reduced levels of erythrocyte CR1 
0022-1 759/02/$ - see front matter © 2002 Elsevier Science B.V. All rights reserved. 
PIT: S0022-1759(02)00368-X 
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have, been implicated in the pathogenesis of severe 
malarial anaemia (Waitumbi et al., 2000). Conversely, 
we have suggested (Rowe et al., 1997) that low 
erythrocyte CR1 may protect against severe malaria 
by reducing the virulence-associated rosetting phe-
nomenon whereby Plasmodium falciparum-infected 
erythrocytes bind to uninfected erythrocytes to form 
clumps of cells that may block microvascular blood 
flow and contribute to severe disease (Kaul et al., 
1990). Further elucidation of the role of erythrocyte 
CR! in malaria and other diseases requires the inves-
tigation of CR1 expression levels and disease associa-
tions in a variety of populations and patient sets. 
Several methods currently exist to quantif' the 
mean number of CR1 molecules per erythrocyte, 
including an ELISA technique and a flow cytometry 
method (Cohen et al., 1999). Both methods give 
equivalent results, although flow cytometry is pref-
erable in many circumstances because it can be 
performed on very small quantities of blood. This is 
a particular advantage when studying young children 
or when multiple investigations are to be carried out 
on a single blood sample. One drawback, however, is 
that the flow cytometty method can only be used to 
determine CR1 numbers on fresh blood samples, 
because CR1 is lost from erythrocytes during storage 
(Pascual et al., 1993). This is a particular problem 
when working on malaria and AIDS in some field 
study areas in developing countries where facilities for 
flow cytometry may not always be available. We 
therefore set out to test a variety of methods of 
erythrocyte preservation in order to develop an assay 
to determine accurately by flow cytometry the CR! 
expression level on erythrocytes after storage. 
2. Methods and study design 
2.1. Determination of CR] expression by flow 
cytometiy 
The mean erythrocyte CR! expression level on 
freshly drawn blood samples was determined using a 
modification of a previously published method 
(Cohen et al., 1987). Whole blood (50 j.tl) was washed 
three times in PBS (all reagents from Sigma, Poole, 
Dorset, UK unless otherwise stated) supplemented 
with 4% RPMI 1640 (Gibco Life Technologies, Rock- 
yule, MD) and 1% AB serum (Blood Transfusion 
Service, Edinburgh, UK) (PBS-RPMI-ABS). The 
cells were resuspended in 1 ml of PBS-RPMT-ABS 
and 100 tl of this suspension (i.e. approximately 2.5 
j.il of cells) was placed in a 96-well plate, spun at 1500 
rpm for 1 min and the supematant removed. The cells 
were then incubated at 4 °C with 40 tl of 0.5 tg/m1 of 
the CR1 monoclonal antibody J3133 (Immunotech, 
Marseille, France) in PBS-RPMI for 1 h with occa-
sional agitation. The cells were washed three times in 
PBS-RPMI-ABS and resuspended in 10 .tg/ml of 
Alexa F1uor 488-conjugated goat anti-mouse IgG 
(Molecular Probes, Leiden, the Netherlands) followed 
by incubation at 4 °C for 1 h with occasional 
agitation. Alexa FluorTM  488 is equivalent to fluores-
cein isothiocyanate but is more stable and sensitive 
and less prone to photo bleaching. Negative control 
samples were treated as above but without the primary 
antibody. After the secondary incubation, cells were 
washed three times in PBS-RPMI-ABS and resus-
pended in PBS-RPMI-ABS supplemented with 0.37% 
formaldehyde (BDH, Poole), and analysed on a 
FacSCAN flow cytometer (Becton Dickinson, San 
Jose, CA). The mean fluorescence intensity of each 
sample, minus the mean fluorescence intensity of the 
negative control was determined. A standard curve 
was obtained by plotting the fluorescence intensities 
of blood samples from donors of previously deter-
mined CR! numbers (standards, initially determined 
by Scatchard analysis using 1251  labelled mAb (Cohen 
et al., 1987)) ranging from 200 to 1000 molecules per 
cell. The standard curve was used to read off the CR1 
expression level of unknown samples. 
2.2. Preservation of blood samples 
After obtaining informed consent, 5 ml of blood 
was drawn from 11 donors (five standards and six 
unknown samples) into Vacutainers containing 0.12 
ml of 15% EDTA (BD Vacutainer systems, Plymouth, 
UK). We then preserved or fixed aliquots of all 11 
blood samples in four different ways. The first was 
simply left in the EDTA Vacutainer into which the 
blood had been drawn. The second aliquot was fixed 
in 0.25% glutaraldehyde according to the method of 
Pattanapanyasat et al. (1993), in which washed cells 
are resuspended in 0.25% (vlv) glutaraldehyde in PBS 
at 2% haematocrit for 20 min before being washed in 
IA. Cockburn et al. /Journal of Immunological Methods 271 (2002) 59-64 
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PBS and resuspended at 50% haematocrit in PBS 
supplemented with 1% BSA. The third aliquot was 
fixed in formaldehyde as outlined by Bianco et al. 
(1986). These cells were first washed three times in 
incomplete RPMI (RPMI 1640 medium with sodium 
bicarbonate (Gibco Life Technologies), supplemented 
with 2 mM L-glutamine, 25 mM HEPES, 20 mM 1)-
glucose and 25 tg/ml gentamicin). Whole blood (50 
jil) was resuspended at 4% haematocrit in complete 
RPMI (as for incomplete RPMI but with the addition 
of 10% ABS) and an equal volume of fixative solution 
(10% w/v formaldehyde, 4% w/v glucose in Tris-
saline (10 mM Iris, 150 mM NaCl, 10 mM sodium 
azide adjusted to pH 7.3) was added. The fixed 
samples and the EDTA-preserved samples were stored 
at 4 °C for the remainder of the experiment. The final 
aliquot of blood was frozen in glycerol by adding 
drop-wise five volumes of freezing solution (42.25% 
w/v glycerol, 0.1 M sodium lactate, 4 mM potassium 
chloride, 0.1 M sodium dihydrogen phosphate 
adjusted to pH 6.8) to three volumes of erythrocytes 
and then freezing overnight at - 70 °C before cry -
opreservation in liquid nitrogen. At the appropriate 
time (see below), cryopreserved cells were thawed at 
37 °C and 200 tl of 12% NaCl solution was added 
slowly and drop-wise to each sample, followed by a 
further slow drop-wise addition of 10 ml of 1.8% 
NaCl followed by 10 ml of 0.9% NaCl, 0.2% glucose 
solution. The cells were washed in incomplete RPMI 
1640 and were then ready for flow cytometry. 
2.3. Study design 
To determine whether the flow cytometry could be 
used to quantif' CR1 expression level using preserved 
erythrocytes from healthy donors we performed the 
following experiment. We drew blood from five 
individuals with known CR! expression who were 
then used as standard donors for CR1 quantification 
as described above. We also drew blood from six test 
subjects who had unknown erythrocyte CR! levels. 
We determined the mean number of CR1 molecules 
per cell from the fresh blood samples of the six 
unknowns according to the flow cytometry protocol. 
We then preserved or fixed aliquots of all 11 blood 
samples according to the methods outlined above. 
After 1, 2, 4, 6 and 8 weeks, the EDTA preserved, 
fixed and frozen samples underwent flow cytometry  
to assess erythrocyte CR! level. In order to determine 
the optimum method of measuring CR1 levels on the 
stored cells, we assessed them in two ways. Firstly, we 
used a standard curve derived from freshly drawn 
standards at each time point (absolute standards) and, 
secondly, we derived a standard curve from the stand-
ards that had been drawn and preserved in an identical 
way to the test samples at the start of the experiment 
(relative standards). 
Having determined the most promising techniques 
for the preservation of healthy erythrocytes (fixing in 
5% formaldehyde and freezing—see Results and dis-
cussion) we then proceeded to determine whether 
these techniques were reliable with diseased erythro-
cytes which may have reduced CR1 levels. Accord-
ingly, we repeated the experiment using the same CR! 
standard donors and unknown samples from seven 
individuals with SLE whose symptoms met the Amer -
ican Rheumatism Association criteria for the disease. 
The erythrocytes were preserved by fixing in 5% 
formaldehyde and freezing in glycerol as described 
above, and the CR! expression levels assessed with 
relative and absolute standards at 4 and 8 weeks. 
3. Results and discussion 
Mean erythrocyte CR1 levels were measured on six 
fresh blood samples from healthy donors (unknown 
samples) by flow cytometry using a standard curve 
derived from five donors with known CR1 levels 
(standards) as shown in Fig. !. Erythrocytes from the 
six healthy test samples and the five standard donors 
were tlten preserved by fixing or freezing as described 
under Methods and study design. For each of the six 
test samples, the CR1 levels were then measured on 
the preserved cells at various time points (1, 2, 4, 6 and 
8 weeks after the blood was drawn) using both 
absolute (freshly drawn) and relative (preserved) 
standards as described in Methods and study design. 
At each time point, the CR1 levels of the preserved 
cells were compared to the CR1 levels of the samples 
when freshly drawn, and the data were analysed by 
linear regression. The best results were obtained with 
erythrocytes preserved by fixation in 5% formalde-
hyde. Comparison with the relative standards gave 
accurate results throughout the 8 weeks of the experi-
ment (Table 1 and Fig. 2A, open squares), whereas 
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a)  10 
0 
Erythrocyte CR1 expression 
(molecules per cell) 
Fig. 1. A standard curve used to determine the mean eiythrocyte 
CR! expression level of unknown samples. The standard curve was 
p!otted with data from five standards with previously determined 
CR1 expression levels (s), with the point at the origin representing 
the negative control sample with no primary antibody. The mean 
fluorescence intensity of six unknown samp!es was read off the 
standard curve to determine the number of CR1 molecules per cc!! 
(dotted !ines). The mean CR! expression levels of the six unknown 
samples were determined as 448, 727, 796, 814, 894 and 967 
mo!ecules per cell. 
comparison to absolute standards was accurate up to 4 
weeks after the blood was drawn, but thereafter gave 
an underestimate of true CR1 numbers (Table 1 and 
Fig. 2A, filled squares). Preservation in EDTA also 
gave good results providing the test samples were 
compared to relative standards (Fig. 213, open squares). 
This was true up to 6 weeks from the date of blood 
Fig. 2. CR! expression leve!s determined after the preservation of 
hea!thy erythrocytes compared to CR1 !evels determined on fresh 
etythrocytes. (A) Etythrocytes stored in 5% formaldehyde at 4 C 
for 8 weeks. (B) Erythrocytes stored in EDTA at 4 ° C for 6 weeks. 
(C) Eiythrocytes cryopreserved in liquid nitrogen for 8 weeks. The 
CR! expression levels of the six test samp!es determined by com-
parison to freshly drawn (abso!ute) standards are shown as filled 
squares (U), whereas the CR! expression !evels of the six test sam-
p!es determined by comparison to preserved (relative) standards are 
shown as open squares (0). The re!ationship between the CR! le-
vels measured on preserved ce!!s compared to fresh cells was ana-
lysed by linear regression. The regression equation for the data deter-
mined using re!ative standards is shown at the top of each graph, and 
the regression equation for the data determined using absolute stan-
dards is shown at the bottom of each graph. RBC, red blood cell. 
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Table I 
Assessment of CR! expression level over the course of 8 weeks on 
eiythrocytes fixed with 5% formaldehyde 
No. of CR1 molecules per cell when fresh 
448 727 796 814 894 967 
CR] measured using absolute standards 
Week 1 425 719 816 826 929 1072 
Week 2 421 860 886 1064 1308 1173 
Week 4 436 740 804 833 889 1014 
Week 6 294 529 585 606 632 746 
Week 8 350 575 645 690 760 788 
CR] measured using relative standards 
Week 1 427 757 865 877 993 1152 
Week 2 355 732 754 907 1117 1001 
Week 4 442 760 826 856 915 1045 
Week 6 408 753 835 866 904 1071 
Week 8 406 682 769 824 909 944 
withdrawal (Fig. 2B), after which time, the extent of 
haemolysis of the samples became too great for further 
use. When absolute standards were used to assess the 
CR! level of EDTA-preserved cells, this was accurate 
up to 2 weeks after the blood was drawn, and thereafter 
resulted in an underestimation of the number of CR! 
molecules per cell (Fig. 2B, filled squares). Fixation of 
erythrocytes in 0.25% glutaraldehyde resulted in high 
background fluorescence of all samples and it impos-
sible to generate a standard curve (data not shown). 
Therefore, it was concluded that this method was not 
Table 2 




Maximum time of storage for 
accurate CR! determination 
Using absolute standards 
EDTA Up to 2 weeks after blood drawn 
5% formaldehyde Up to 4 weeks after blood drawn 
Freezing in glycerol Inconsistent results - not 
recommended 
Using relative standards 
EDTA 	 Up to 6 weeks after blood drawn 
5% formaldehyde 	 Up to 8 weeks after blood drawnt 
Freezing in glycerol Up to 8 weeks after blood draw&' 
"Fixation in 0.25% glutaraldehyde was also tested but was not 
acceptable at any time point due to high background fluorescence. 
b Longer periods of storage may be acceptable, but, this would 
require validation. The samples were only tested up to 8 weeks in 
these experiments.  
suitable for CR1 quantification. Preservation of etyth-
rocytes by freezing in glycerol gave accurate results at 
all time points when relative standards were used (Fig. 
2C, open squares, data from week 8). The use of abso-
lute standards gave good results at some time points 
5% formaldehyde 
y=0.886x r 2 =0.877 
/0. 
- 	 5 xr2 = 0.670 
I 	 I 	 I 
Mean CR1 number 
on fresh RBC 
Cryopreservation 
	
- y=0.797x r2=0.903 	• 
- 
y = 0.855x r 2 = 0.878 
I 	 I 	 I 
Mean CR1 number 
on fresh RBC 
Fig. 3. CR1 expression levels determined after preservation of 
eiythrocytes from seven donors with SLE compared to CR1 levels 
determined on fresh SLE eiythrocytes. The mean CR1 levels when 
fresh were 104, 218, 275, 493, 794, 867 and 896 molecules per cell. 
Erythrocytes stored in 5% formaldehyde at 4 "C for 8 weeks. 
Eiythrocytes cryopreserved in liquid nitrogen for 8 weeks. 
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(e.g. week 8, Fig. 2C, filled squares), although, at two 
earlier time points the use of absolute standards gave 
widely differing estimates of CR1 numbers (data not 
shown), and we would not recommend the use of 
absolute standards with frozen cells. A summary of 
the results from each method of preservation is given 
in Table 2. 
Our results indicate that CR1 levels can be accu-
rately measured on erythrocytes from healthy donors 
preserved by formaldehyde fixation or freezing, as 
long as similarly preserved erythrocytes are used to 
generate the standard curve. To determine whether 
these methods are also reliable using erythrocytes 
from donors with disease states that may reduce 
CR1 numbers, we repeated the experiment using 
samples from seven donors with SLE. Once again 
we found that fixing in 5% formaldehyde and freezing 
in glycerol both gave good results over 8 weeks when 
relative standards were used (Fig. 3A and B, open 
squares). As previously, an underestimation of CR1 
expression was observed when fixed samples were 
used with absolute standards (Fig. 3A, filled squares), 
while frozen cells with absolute standards gave good 
results in some cases (Fig. 3B, filled squares; data 
from week 8) but was not reliable at all time points. 
Crucially, both the fixing and freezing techniques 
worked well with samples showing low CR1 expres-
sion (<250 molecules per cell). 
We conclude that accurate CR1 quantification may 
be performed after preservation of either diseased or 
healthy erythrocytes using either a freezing teclmique 
or fixation in 5% formaldehyde, providing that the 
CR1 expression level standards are collected and 
fixed in an identical fashion. Cryopreservation of 
erythrocytes in glycerol is reliable and permits poten-
tially long-term storage of samples, but does require 
liquid nitrogen for freezing and transportation of cells, 
which may not always be available during field 
studies. Fixation of eiythrocytes in 5% formaldehyde 
is quick and economical and gives an accurate deter-
mination of CR1 level for at least 2 months after 
sample collection. These methods will facilitate fur-
ther studies of CR1 expression level and disease 
susceptibility in areas lacking facilities for flow 
cytometry. 
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Parasitized red blood cells (RBCs) from children suffering from 
severe malaria often adhere to complement receptor 1 (CR1) on 
uninfected RBC5 to form clumps of cells known as "rosettes." 
Despite a well documented association between rosetting and 
severe malaria, it is controversial whether rosetting is a cause or a 
correlate of parasite virulence. CR1-deficient RBC show greatly 
reduced rosetting; therefore, we hypothesized that, if rosetting is 
a direct cause of malaria pathology. CR1-deficient individuals 
should be protected against severe disease. In this study, we show 
that RBC CR1 deficiency occurs in up to 80% of healthy individuals 
from the malaria-endemic regions of Papua New Guinea. This RBC 
CR1 deficiency is associated with polymorphisms in the CR1 gene 
and, unexpectedly, with a-thalassemia, a common genetic disorder 
in Melanesian populations. Analysis of a case-control study dem-
onstrated that the CR1 polymorphisms and a-thalassemia inde-
pendently confer protection against severe malaria. We have 
therefore identified CR1 as a new malaria resistance gene and 
provided compelling evidence that rosetting is an important par -
asite virulence phenotype that should be a target for drug and 
vaccine development. 
S evere malaria remains one of the largest causes of childhood mortality inthe world. The number of deaths is high at "'1-2 
million per year; however, this number, represents a small 
fraction of the total number of clinical malaria episodes that 
occur worldwide, estimated to be "400-900 million (1). Much 
work has been done to determine the factors that lead to the 
development of severe malaria, with parasite virulence pheno-
types and host genetic factors being two major foci of research. 
One such Plasmodium fakiparum virulence phenotype is roset-
ting, an adhesion property in which parasitized red blood cells 
(RBCs) bind to unparasitized RBCs to form clumps of cells (2). 
Rosetting is thought to contribute to malaria pathology by 
cauing microvascular obstruction and impaired tissue perfusion 
(3, 4). Rosetting has been associated with severe malaria in many 
studies in Africa (e.g., refs. 5-7), although no association with 
severe disease was seen in Southeast Asia (8) or Papua New 
Guinea (PNG) (9). This inconsistency in the association of 
rosetting with severe disease has led some investigators to 
question the role of rosetting in malaria pathogenesis (10). 
Rosetting is mediated by the parasite ligand PfEMP1 on the 
surface of infected RBCs (11, 12), binding to a variety of 
uninfected RBC receptors, including complement receptor 1 
(CR1) (11, 13). CR1 is an immune-regulatory protein found on 
RBCs and a variety of leukocytes, and its functions include 
control of complement activation and the clearance of immune 
complexes (14). On RBCs, CR1 levels vary between individuals 
in the range of 50-1,200 molecules per cell (15-21). In Cauca-
sians, RBC CR1 levels are genetically determined and are 
associated with at least three single-nucleotide polymorphisms  
(SNP5) in the CR1 gene (in exon 22, intron 27, and exon 33; ref. 
22). These SNPs comprise high (H) and low (L) CR1 expression 
haplotypes that are codominant and are associated with CR1 
level on RBC, but not on other cell types, such as B cells and 
macrophages (15). We have shown previously that CR1-deficient 
RBCs from LL homozygotes with <200 CR1 molecules per cell 
show greatly reduced rosetting with P. falciparum-infected RBCs 
(ref. 11 and J.A.R., unpublished data). We reasoned that if 
rosetting is important in malaria pathology, then CR1 deficiency 
should protect against severe disease by reducing rosette-
mediated microvascular obstruction. CR1 deficiency is thought 
to be rare in most populations; however, a review article (23) 
stated that 28 of 67 Melanesians had CR1-deficient RBCs. No 
experimental details were given, and no further information was 
published to validate this claim. This tantalizing suggestion that 
CR1 deficiency could be very common in Melanesians led us to 
examine the prevalence and genetic basis of CR1 deficiency in 
PNG and to determine whether RBC CR1 deficiency protects 
against severe malaria. 
Methods 
Study Sites and Sample Collection. We collected fresh blood samples 
into EDTA from healthy adult volunteers at two malaria-endemic 
sites within PNG (New Ireland and Madang) and from Edinburgh, 
UnitedKingdom. Informed consent was given by all donors after 
the aims of the project were explained, and the PNG Medical 
Research Advisory Committee approved all protocols. In Edin-
burgh and New Ireland the blood samples were analyzed fresh, 
whereas in Madang, buffy coats were removed for DNA extraction 
and the RBCs were fixed in 5% formaldehyde (24) before shipping 
to the United Kingdom. Buffy-coat samples from the Eastern 
Highlands Province (PNG) were kindly made available to us by the 
PNG Institute of Medical Research and came from a village 2,000 
in above sea level, where no regular malaria transmission exists. 
New Ireland and Madang both have intense year-round malaria 
transmission with a spleen enlargement rate of >70% (25, 26). 
Determination of RBC CR1 Level. The mean RBC CR1 level on both 
fresh and fixed blood samples was determined as described (24). 
In brief, the CR1 level was determined by flow cytometry using 
the anti-CR1 monoclonal antibody J3D3, with comparison to a 
standard curve derived from a set of reference RBCs with known 
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CR1 levels. The reference RBCs used to establish the assay had 
their CR1 expression initially determined by the use of 125 1 
labeled antibody and Scatchard analysis to determine the num-
ber of antigenic sites per cell, controlling for the number of 
antibody-binding sites per CR1 molecule (24). We have shown 
that fresh and fixed RBC samples are similar and that CR1 level 
can be assessed accurately on fixed RBCs provided that the 
reference RBCs used to generate the standard curve are fixed in 
the same manner (24). 
DNA Extraction and Genotyping. DNA was extracted from buffy 
coats by using the Nucleon BACC I kit (Amersham Pharmacia 
Life Science). Samples were genotyped for three SNPs in the 
CR1 gene at nucleotide 3650 in exon 22, a Hindill restriction 
fragment length polymorphism in intron 27, and at nucleotide 
5507 in exon 33 by PCR and restriction digest as described (22). 
a-Thalassemia genotyping for the —a 3 - 7 and —a 4 -2 deletions was 
done by multiplex PCR according to the method of Chong et al. 
(27). Southeast Asian ovalocytosis genotype was determined by 
PCR as described (28). DNA samples for the case-control study 
were as described (29, 30) and were amplified by primer-
extension preamplification (31) before CR1 genotyping. 
a-Thalassemia genotyping for the case-control study was carried 
out by Southern blotting (29). 
Determination of Glucose-6-phosphate Dehydrogenase (G6PD) Defi-
ciency. Whole-blood samples from Madang and New Ireland 
were screened for G6PD deficiency by using Sigma Procedure 
no. 400 (Sigma). 
Statistical Analysis. Statistical tests for differences in RBC CR1 
levels between populations, between CR1 genotypes, and between 
a-thalassemia genotypes were performed by using multiway 
ANOVA and F tests in the statistical package SAS (SAS Institute, 
Cary, NC). Further analyses were performed to test for population 
differences in the frequencies of the CR1 alleles and a-thalassemia 
genotype by using the X 1 test or Fisher's exact test when the numbers 
of observations per cell were small. Odds ratios for the protective 
effects of genotypes in the case-control study were derived by 
logistic regression analysis in SAS. Data were analyzed by using both 
conditional and unconditional logistic regression; conditional lo-
gistic regression allows for matching of case-control pairs and 
maximizes power. However, because CR1 genotyping was not 
carried out in pairs, information was unnecessarily lost by using 
conditional logistic regression, and so results from unconditional 
analyses were used. This choice made no difference in the outcome 
of the analysis, nor did the fitting of ethnic groups in the model 
make a difference in the outcome. 
Results 
We measured the RBC CR1 levels of healthy adult volunteers 
from two highly malarious regions of PNG (Madang and New 
Ireland) and from a control-Caucasian population from Ed-
inburgh, United Kingdom. CR1 levels in Edinburgh varied 
between individuals in the range of 235-1,181 molecules per 
cell, with a mean of 786 (Fig. la). These results are similar to 
CR1 levels described in other Caucasian populations (Table 1), 
showing that our assay for CR1 (24) is similar to those used 
previously. In PNG, CR1 levels were significantly lower than 
in Edinburgh (Fig. la, P < 0.001), with 79% of individuals in 
Madang and 55% of individuals in New Ireland having fewer 
than 200 CR1 molecules per cell. The mean RBC CR1 levels 
in Madang and New Ireland are the lowest in the world (Table 
1). These results indicate that, in malarious regions of PNG, 
CR1 deficiency is extremely common and could therefore play 
a major role in influencing susceptibility to severe malaria. 
To ascertain whether RBC CR1 levels in Melanesians are 
genetically determined, we studied the three SNPs in the CR1  
gene that have been associated with CR1 expression levels in 
Caucasians (22). The CR1 exon 22 SNP (A/G at nucleotide 
3650) showed the strongest association with RBC CR1 level in 
all three populations; therefore, only exon 22 data are shown. At 
all three study sites the exon 22 genotype had a highly significant 
effect on RBC CR1 level, with carriers of the G3650 low (L) 
expression allele having significantly lower CR1 levels than HH 
individuals (Fig. 1 b—d, F2 ,96 = 50, P < 0.001). The RBC CR1 
levels of HL individuals were intermediate between those of HH 
and LL individuals, as expected for codominant alleles. The 
frequency of the CR1 L allele in the malarious regions of PNG 
is the highest described in the world to date (Table 1, significantly 
different to Edinburgh, X 2 >6, P < 0.01). DNA samples were also 
studied from the nonmalarious Eastern Highlands Province of 
PNG, and the frequency of the L allele was found to be 
significantly lower than in the malarious regions (Table 1, x2 = 
8.1, P < 0.01). This may indicate selection for the L allele in areas 
with high malaria mortality, although other explanations cannot 
be excluded. The data above indicate that RBC CR1 levels in 
Melanesians are associated with polymorphisms in the CR1 
gene. However, even when matched for exon 22 genotype, CR1 
expression levels in Edinburgh, Madang, and New Ireland 
remained significantly different from each other (F2 , 96 = 66.0, 
P < 0.001). For example, the CR1 levels of HH individuals from 
PNG are lower than those of HH individuals from Edinburgh 
(Fig. 1 b—d), suggesting that additional factors influence CR1 
levels in Melanesians. 
We investigated whether other RBC polymorphisms that 
occur commonly in PNG such as ovalocytosis (30), G6PD 
deficiency (32), and a-thalassemia (32) could affect RBC CR1 
levels. a-Thalassemia occurred in 89% of individuals in 
Madang and in 23% of individuals in New Ireland. At both 
sites, individuals with one or more a-thalassemia mutations 
had RBC CR! levels significantly lower than those of non-
thalassemic individuals (Fig. 2 a and b, F1 , 111 = 12.4, P < 
0.001). The effect of a-thalassemia genotype on RBC CR1 
level was independent of the CR1 exon 22 polymorphism, 
because both genotypes were statistically significant when 
simultaneously included in the analysis (F2 , 110 = 10, P < 0.001 
for a-thalassemia genotype; F2 , 110 = 44, P < 0.001 for exon 22 
genotype). Thus, an individual's RBC CR1 level depends on 
both their CR1 exon 22 genotype and their a-globin genotype 
(Fig. 2c). Significant population differences still remained 
after including a-thalassemia and CR1 exon 22 genotype in the 
statistical model, suggesting that additional factors that influ-
ence RBC CR1 levels in Melanesians are undetected. Ovalo-
cytosis and G6PD deficiency occurred in up to 15% of 
individuals in Madang and New Ireland and were not associ-
ated with RBC CR1 level (ovalocytosis, F1 , 115 = 0.2, P > 0.10; 
G6PD deficiency, F1 , 115 = 1.8, P > 0.10). 
To determine whether the low CR1 levels in PNG influence 
susceptibility to severe malaria, we studied DNA samples from a 
case-control study carried out in Madang. These samples have been 
used previously to show that a-thalassemia and ovalocytosis confer 
protection against severe malaria (29, 30). One hundred eighty 
severe malaria cases and 179 community controls (matched for age, 
sex, ethnicity, season, and residential location) were genotyped for 
the CR1 exon 22 polymorphism. The data were analyzed by logistic 
regression, incorporating the previously identified protective fac-
tors of ovalocytosis (30) and a-thalassemia (29) into the model. We 
found that HL individuals for the CR1 exon 22 polymorphism were 
significantly protected against severe malaria (odds ratio, 0.33; P = 
0.01; Table 2). The protective effect of the HL genotype was most 
prominent when present on a homozygous a-thalassemia back-
ground (odds ratio, 0.13; 95% confidence intervals, 0.02-0.67; P 
0.005). In contrast, RH/normal a-globin individuals, who would be 
expected to have the highest CR1 levels (Figs. 1 and 2), were most 
at risk of severe malaria, with this genotype being found in seven 
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Fig. 2. RBC CR1 deficiency in Melanesians is associated with a-thalassemia. (a and b) RBC CR1 level in relation to a-thalassemia genotype. Thalassemia genotypes 
arethe following: -a/au, heterozygotes for the - (x - deletion (32); - u/ - a, homozygotes forthe - a42 deletion; and au/au, normal a-globin gene structure. 
Only one individual carried the - u s 'deletion(32); therefore, this case was excluded from the analysis. (c) The effect of is-thalassemia and CR1 exon 22 genotype 
on RBC CR1 level are independent of each other. The mean CR1 level for the Madang population subdivided by CR1 genotype (n3650 polymorphism) and 
a-thalassemia ( - tr4-2 deletion) is shown, and standard errors are indicated. The HH/normal a-globin genotype was not represented. 
Discussion 
This study shows that RBC CR! deficiency is extremely common 
in malaria-endemic regions of PNG and that polymorphisms 
associated with CR1 deficiency confer protection against severe 
malaria. As parasites invade and grow normally in both CR!-
deficient normal (33) and thalassemic RBCs (34), the simplest 
interpretation of our findings is that these polymorphisms pro-
tect against severe malaria through CR1 deficiency bringing 
about reduced rosetting (II, 35). Positive selection of rosette-
reducing polymorphisms in a human population with high 
malaria mortality is strong evidence that CR1-mediated roset-
ting plays a causal role in the pathogenesis of severe malaria. 
The case-control study results shown here indicate that het-
crozygotes for the CR1 low-expression allele (HL) are signifi-
cantly protected from severe malaria, whereas homozygotes 
(LL) have a reduced odds ratio, but this reduction does not reach 
statistical significance. It is unclear whether the difference 
between the levels of protection provided by the HL and LL 
genotypes is genuine, and a larger sample size would be required 
to resolve this issue. The only previous small study of CR! 
polymorphisms and malaria suggested that the LL genotype is a 
risk factor for severe malaria in Thai adults (36). In Southeast 
Asia, severe malaria in characterized mainly by metabolic dis-
turbances and multiorgan failure (37) rather than by severe 
anemia and cerebral malaria, which occur commonly in children 
Table 2. The effect of the L allele on susceptibility to severe malaria 
Genotype 




Adjusted odds ratio 
(95% Cl)* P value 
All severe cases 
n=180 n=178 
NH 21(12) 9(5) 1 
HL 57 (32) 81(46) 0.33 (0.14-0.77) 0.01 
LL 102 (56) 88(49) 0.55 (0.24-1.28) 0.16 
Severe anemia 
n=113 n=109 
HH 15(13) 5(5) 1 
HL 34 (30) 45 (41) 0.30 (0.10-0.93) 0.04 
LL 64(57) 59(54) 0.46 (0.15-1.40) 0.17 
Cerebral malaria 
n=45 n=46 
NH 4(9) 2(4) 1 
HL 15 (33) 21(46) 0.40 (0.06-2.50) 0.33 
LL 26 (58) 23 (50) 0.60 (0.10-3.69) 0.55 
Other severe maIaria 
n=58 n=58 
HH 5(9) 6(10) 1 
HL 18(31) 25(43) 1.18 (0.29-4.79) 0.82 
LL 35 (60) 27 (47) 2.23 (0.56-8.87) 0.26 
*Odds ratios for the IlL and LL genotypes are calculated in relation to the HH genotype after adjusting for the 
potential confounding factors ovalocytosis and u-thalassemia. Cl, confidence intervals. 
tH y poglycemia, acidosis (low plasma bicarbonate), and hyperlactatemia; the odds ratios were similar for all three 
syndromes when analyzed separately. 




















I i. e 
S. S 
Edinburgh New Ireland Maclang 
n 	 31 	47 	96 


















HH 	HL 	LL 
n 	 18 12 1 
mean(SD) 915(136) 639(159) 	235(na) 










































HH 	HL 	LL 	 Hf-I 	HL 	LL 
n 	 4 17 26 n 	 19 39 38 
mean(SD) 589(180) 332(169) 	142(72) 	mean(SD) 178(88) 	154(89) 	65(53) 
Fig. 1. RBC CR1 deficiency is common in Melanesians and is associated with SNPs in the CR1 gene. (a) RBC CR1 levels in Edinburgh (United Kingdom), Madang 
(PNG), and New Ireland (PNG). Each point represents the mean RBC CR1 level of a single individual in molecules per cell. SD, standard deviation. (b-d) RBC CR1 
levels in relation to CR1 genotype based on typing at the n3650 polymorphism in exon 22. H, high-expression allele; L low-expression allele; na, not applicable. 
severe cases but no controls (P = 0.015 by Fisher's exact test). When 	(a pool of metabolic complications. Table 2). The odds ratios for the 
the cases were subdivided into different severe malaria syndromes. LL genotype were also reduced for all severe malaria cases, severe 
the odds ratios for the HLgenotype were reduced for severe anemia 	anemia, and cerebral malaria but did not reach statistical signifi- 
and cerebral malaria but not for other forms of severe malaria cance (Table 2). 
Table 1. RBC CR1 levels and frequency of the CR1 low-expression (L) allele in different populations 
Mean RBC CR1 in molecules Gene frequency of 
Population No. tested per cell (range) the CR1 L allele Ref. 
Edinburgh, U.K. 31 786 (235-1181) 0.23 This study 
New Ireland (PNG)* 47 253 (40-839) 0.73 This study 
Madang (PNG)* 96 124 (0-439) 0.60 This study 
Eastern 1-lighiands Province (PNG)t 17 ND 0.41 This study 
United Kingdom 60 624 (119-1220) 0.27 16 
France 84 613 (161-712) 0.21 17 
African Americans 54 635 (158-1023) 0.25 19 
Caucasian Americans 53 547 (89-1166) 0.25 19 
India 48 648 (140-1294) 0.23 18 
Mali 149 415 (58-1032) 0.14 21 
China 100 446 (27-1039) 0.28 20 
Thailand 30 ND 0.52 36 
The L allele is associated with low RBC CR1 levels in all populations studied to date, except for Africans or African Americans (19,21) 
ND, not determined. 
*S.fes in PNG with intense malaria transmission. 
tsite in PNG with no regular malaria transmission. 
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in PNG (38). Our data for the small subgroup of children with 
metabolic forms of severe malaria indicated a trend toward 
increased risk for LL individuals. It is possible that the L allele 
protects against the forms of severe malaria caused by micro-
vascular obstruction and RBC damage (by means of reduced 
rosetting), but it increases risk for other syndromes with different 
pathological mechanisms, such as multiorgan failure and meta-
bolic disturbances (39). 
The results shown here linking RBC CR1 expression to 
a-thalassemia are striking. Although the protective effect of this 
disorder is well known (25, 29), the mechanism is debated (40). 
Parasite growth is unimpaired in thalassemic cells (34), so 
investigators have sought explanations based on reduced cytoad-
herence (41) or enhanced immune recognition (42). Carlson et 
al. (35) showed a large reduction in rosetting with thalassemic 
RBCs. They argued that this could be a result of microcytosis, 
because thalassemic cells have '15% less surface area than 
normal RBCs (42). However, thalassemic RBCs formed rosettes 
less well than microcytic RBCs with normal hemoglobin (35). 
Microcytosis is insufficient to explain the reduction in RBC CR1, 
which is '50% lower in thalassemic individuals than in those 
with normal a-globin (Fig. 2c). The mechanism responsible for 
low CR1 on thalassemic RBCs is unclear. CR1 is preferentially 
lost in vesicles from the cell surface as RBCs age or become 
ATP-depleted (43, 44). It is possible that biochemical abnor-
malities in thalassemic RBCs promote a similar process that 
would reduce their CR1 level. 
The high prevalence of CR1 deficiency in Southeast Asia and 
PNG could explain wh'y rosetting is not associated with malaria 
severity in this region (8, 9). Rosetting is greatly reduced in 
CR1-deficient RBCs, but some small rosettes still form in in vitro 
cultures, presumably by using other RBC receptors such as the 
A or B blood group sugars (45). These small and weak rosettes 
are unlikely to withstand the sheer forces encountered in the 
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circulation in vivo. Therefore, many of the rosettes observed in 
vitro in Southeast Asia and PNG may not be physiologically 
relevant. In Africa, on the other hand, RBC CR1 deficiency does 
not appear to have been selected to high frequencies (19, 21). 
Instead, African populations possess other CR1 polymorphisms, 
such as the Knops blood group antigens that reach high fre-
quencies in East and West Africa (ref. 46 and J.A.R. and J.M.M., 
unpublished data). Our initial DNA-based studies of these 
African CR1 polymorphisms have been complicated by a high 
level of genotype/phenotype mismatch (47); therefore, a pro-
spective case-control study is underway to examine the effect of 
RBC CR1 phenotype on severe malaria in Africans. Clearly, the 
selective pressure of malaria has acted in different ways on the 
CR1 gene in diverse populations. 
The results of this study have therapeutic implications. Case 
fatality rates for severe malaria are high, even in areas with 
intensive care facilities, so new approaches to treatment are 
urgently needed (48). Our findings indicate that therapies aimed 
at inhibiting CR1-mediated rosetting, such as soluble recombi-
nant CR1 (49), could be of benefit in treating severe malaria. 
Alternatively, development of a vaccine against the parasite 
rosette-mediating ligand PfEMP1 (11) may prevent some cases 
of severe disease. The selective pressure of malaria on a major 
rosetting receptor indicated by our results strongly supports a 
direct role for CR1-mediated rosetting in the pathogenesis of 
severe disease and emphasizes that further research to develop 
rosette-inhibiting interventions should be a high priority. 
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